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Abstract 
B cell lymphoma 6 (Bcl6) is a proto-oncogene functioning as a transcriptional 
repressor at the germinal centre (GC) stage of B cell development, regulating 
proliferation, differentiation and survival. Bcl6 is commonly dysregulated in GC-
derived lymphomas and hence a promising therapeutic target. Although a 
number of agents targeting Bcl6 are being developed, there is currently no 
good model available for functional analysis and hence drug target validation. 
To address this issue, I have established a conditional BCL6 knockout cell line 
for in-depth functional analyses of Bcl6. I have used homologous recombination 
to disrupt one BCL6 allele in the human Burkitt’s lymphoma cell line DG75 with 
a zeocin resistance cassette and have shown this line to be capable of 
supporting tetracycline (tet)-regulated Bcl6 expression from an integrated 
expression construct. The zeocin cassette used to disrupt the first BCL6 allele 
was subsequently deleted by Cre recombination. This allowed me to reuse the 
same targeting construct to disrupt the second BCL6allele. I subsequently set 
out to characterise the resulting conditional knockout cell line and found that 
depletion of Bcl6 leads to less proliferation, characterised by a prolonged 
G0/G1cell cycle phase. I went on to further characterise the effect of Bcl6 
depletion in my system by cDNA microarray analysis, which revealed 
interesting insights into functions of Bcl6 such as the modulation of B cell 
receptor signalling and calcium signalling. The system I have developed is the 
first precisely regulated genetic model for studying Bcl6 function and will be of 
great benefit for research aiming to develop Bcl6 targeted drug therapy.   
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CHAPTER 1 – Introduction 
The focus of this thesis is the functional analysis of the B cell lymphoma 6 
(Bcl6) protein. Bcl6 is a master transcription factor and potent oncogene 
involved in normal immune responses and germinal centre-derived B cell 
lymphomas (Jardin et al., 2007). I will therefore commence with an overview of 
the role of B cells in the adaptive immune response and particularly the 
germinal centre (GC) reaction. I will then describe what is known about the role 
of Bcl6 in lymphomas and outline the regulation of Bcl6, its interactions with co-
repressors via its various domains and the potential of Bcl6 as therapeutic 
target. Following this literature review, I will discuss the limitations of models 
currently available to study the function of Bcl6 and propose a novel cell line-
based BCL6 knockout model that will greatly facilitate functional analysis of the 
Bcl6 protein.  
1.1 Human immune response and B cell development 
The human immune system is a multi-layered defence mechanism, aiming to 
prevent and fight infection by microorganisms. The first layer of protection 
prevents the infectious agent from entering the human body. The innate 
immune system is the first barrier to infectious agents. Macrophages and 
neutrophils recognise a variety of microbial constituents and mount an 
immediate innate immune response (Janeway and Medzhitov, 2002). They can 
engulf and degrade invading pathogens and trigger local inflammation leading 
to the recruitment of additional cells and molecules of the adaptive immune 
response that help clear the infection. Local inflammation eventually also 
recruits cells of the adaptive immune system, which then trigger a more specific 
response and establish immunologic memory (Carroll, 2004, Fearon and 
Carter, 1995, Fearon and Locksley, 1996). B and T lymphocytes mediate the 
adaptive immune response. B cells are responsible for antibody production to 
defend against extracellular pathogens. T cells in turn, have roles in fighting 
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intracellular pathogens and regulation of the B cell response. As the current 
thesis focuses on Bcl6, a master transcriptional regulator in B cell development, 
it is essential to draw special attention to the development of B lymphocytes. 
1.1.1 B cell development in the bone marrow 
The earliest B cell (pro-B cell) develops from the common lymphoid progenitor 
(CLP) and this differentiation step is dependent on the specialised 
microenvironment of the bone marrow (Nagasawa, 2006). Signals supplied by 
specialised stromal cells in the bone marrow trigger somatic rearrangement of 
the immunoglobulin receptor genes. The human heavy chain gene on 
chromosome 14 contains three groups of gene segments that require genetic 
recombination in order to produce a functional pre-B cell receptor (Matsuda and 
Honjo, 1996). Figure 1.1 shows a schematic representation of the steps 
involved in V(D)J recombination i.e. the generation of a functional pre-B cell, 
and mature B cell receptor (BCR) gene. On a molecular basis, V(D)J 
recombination requires the recombination activating genes 1 and 2 (RAG1 and 
RAG2) (Mombaerts et al., 1992, Shinkai et al., 1992). RAG1 and RAG2 form a 
complex with the recombining genomic region and introduce a nick in the DNA 
(deoxyribonucleic acid) strand. These nicks then get processed resulting in 
double strand breaks that are subsequently joined by non-homologous end-
joining (NHEJ) (Puebla-Osorio and Zhu, 2008). Due to the fact that NHEJ often 
results in the loss of nucleotides (nt) at the break region, two out of three 
recombinations between these protein coding sequences will be out of frame 
and thus non-functional. If recombination does not achieve a functional open 
reading frame, recombination will be re-attempted using the second allele of the 
heavy chain locus. If recombination of the second allele repeatedly yields a 
non-functional reading frame, the cell will undergo apoptosis (Mostoslavsky et 
al., 2004). In case of a successful in-frame recombination of the first or second 
allele, transcription through the newly recombined VDJ segments and the 
downstream constant (C) gene segment produces a messenger ribonucleic 
acid (mRNA) coding for a functional heavy chain of the immunoglobulin (Jung et 
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al., 2006). Subsequently, the heavy chain of the receptor binds to a transiently 
expressed surrogate light chain, forming the pre-B cell receptor (Nishimoto et 
al., 1991). The mature BCR is created when the final light chain replaces the 
surrogate light chain after rearrangement of the light chain locus (Figure 1.1). 
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Figure 1.1: Gene rearrangement at the heavy and light chain loci 
Left: Heavy chain rearrangement follows the somatic and sequential joining of D-J and V-DJ. 
In this process, a diversity (D) gene segment (yellow box) is initially recombined with a joining 
(J) segment (blue box), deleting all genomic sequences in between (D-J recombination). This 
DJ segment is then joined to a variable (V) gene segment (red box) to complete 
rearrangement of the heavy gene locus, again leading to the loss of all DNA between the two 
segments that are being joined (V-DJ recombination). Transcription through the recombined 
heavy chain locus and mRNA processing generates a transcript encoding a complete 
immunoglobulin heavy chain. The heavy chain then associates with a transient, surrogate light 
chain (white) that completes the pre-B receptor. Right: Rearrangement of the light chain locus 
does not include a diversity segment and hence V-J recombination (pale red and pale blue 
boxes), followed by transcription and mRNA processing results in the formation of a functional 
light chain that replaces the transient light chain of the pre-B cell receptor, thereby generating 
the final B cell receptor. 
 
CHAPTER 1 – Introduction 
21 
1.1.2 B cell activation in the periphery 
The contact of a B cell with its antigen in the periphery is usually mediated 
through the interaction of the B cell with an antigen-presenting cell (APC) that 
has taken up and processed antigen at a site of infection. When a mature B cell 
recognises its cognate antigen displayed by an APC, the B cell upregulates its 
chemokine receptors and this will help it to find its way to T-cell rich areas within 
secondary lymphoid organs (Batista and Harwood, 2009). Once the activated B 
cell arrives in T cell zones, it becomes fully activated in response to the 
interaction with additional APCs and CD4+ T cells. These fully activated B cells 
then follow one of the two distinct routes to antibody production. They can either 
proliferate as plasmablasts (MacLennan et al., 2003) or alternatively enter the 
germinal centre reaction which will enable them to improve the affinity of their 
BCRs for their corresponding antigen and also enable them to produce 
antibodies with diverse effector functions. 
1.2 Germinal centres and affinity maturation of 
immunoglobulin receptors 
1.2.1 Germinal centres 
GCs constitute a complex microenvironment that supports affinity maturation of 
rapidly proliferating B cells. They can form in secondary follicles of antigen-
stimulated lymph nodes, B cell areas of the white pulp of the spleen and the 
mucosa-associated lymphoid tissue (MALT). Figure 1.2 displays a graphic 
overview of GC B cell development. The developmental stages and selection 
processes involved will be described in more detail in the following sections. 
  
  
Figure 1.2: Schematic organisation of the germinal centre reaction 
Following rearrangement of the immunoglobulin genes in the bone marrow (V
recombination), naïve B cells are activated in the periphery when they encounter an antigen that 
their BCR can recognise. These activated B cells migrate into B cell follicles in secondary 
lymphoid organs where they proliferate extensively, thereby establ
can be divided into three separate areas: the dark zone, the light zone and the mantle zone (dark 
yellow). The dark zone (left half of pale yellow area) is the site of rapid proliferation of B cells 
(clonal expansion) and the s
hypermutation (SHM). The binding affinity of the mutated BCR is tested in the light zone of the 
germinal centre (right half of pale yellow area). If a BCR has acquired disadvantageous 
mutations in the process of SHM, the B cell is destined to undergo apoptosis. Only if SHM 
improves the affinity of the BCR for antigen binding will the B cell survive in the GC light zone 
through interaction with follicular dendritic cells (FDCs) and T cells. Selected GC 
remodel the effector function of their BCR by class switching and finally differentiate into memory 
B cells or plasma cells that leave the GC.
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1.2.2 Initiating the GC reaction - Centroblasts and somatic 
hypermutation 
The GC reaction is initiated when GC-precursor B cells migrate to primary 
follicles in secondary lymphoid organs. Within the primary follicles, the B cells 
interact with a network of follicular dendritic cells (FDCs) and differentiate into 
highly proliferative centroblasts. Centroblasts can complete a cell cycle within 6-
8 hours, the shortest known for eukaryotic cells (MacLennan, 1994).The 
dramatic proliferative capacity of centroblasts is an effect of the strong 
upregulation of genes that promote cell proliferation and the downregulation of 
genes that impose a negative effect on cell cycle progression (Klein et al., 
2003). Furthermore, centroblasts express telomerase, thereby securing limitless 
replicative potential (Hu et al., 1997). Thus, within only a few days, centroblasts 
generate a pool of rapidly proliferating, densely packed cells forming the dark 
zone of the GC.  
The rapidly expanding centroblast pool is used as substrate for diversification of 
antigen receptor by somatic mutation of the immunoglobulin variable regions. 
This process is termed somatic hypermutation (SHM) and relies on the enzyme 
activation-induced deaminase (AID). AID can transform cytidine (C) into uracil 
(U) within both ribonucleic acid (RNA) and DNA (Petersen-Mahrt et al., 2002). 
The resulting U:G lesion in the sequence of the variable region of the 
immunoglobulin gene is processed by one of several pathways and the 
pathway chosen will determine the type of base substitution generated (Di Noia 
and Neuberger, 2007). If DNA replication across the U:G lesion occurs, this will 
result in C to T (thymine) and G (guanine) to A (adenine) transition 
substitutions. Alternatively, the U:G lesion can be processed by the base 
excision repair (BER) or mismatch repair (MMR) machinery, both generating a 
gap lesion. In both cases, the resulting lesion will be filled in by error-prone 
DNA polymerases, which will potentially create transition (A:T) as well as 
transversion (C:G) mutations (Di Noia and Neuberger, 2007). In order to 
tolerate the high degree of DNA damage generated by SHM, centroblasts have 
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a suppressed DNA damage response (Phan and Dalla-Favera, 2004). This high 
tolerance of centroblasts towards DNA damage is counterbalanced by their 
increased sensitivity to undergoing apoptosis. This sensitivity is the result of the 
expression of several pro-apoptotic genes such as p53, Fas, Bax and c-Myc 
(cellular myelocytomatosis) (Martinez-Valdez et al., 1996). Moreover, 
centroblasts lack expression of common anti-apoptotic factors such as Bcl-2 
and its family members (Liu et al., 1991a). The pro-apoptotic nature of 
centroblasts imposes a strong selective pressure on the cell population to 
diversify and improve their antigen receptors. After diversification of the BCR, 
centroblasts move to the light zone of the GC. 
1.2.3 Centrocytes 
Centroblasts that have ceased to proliferate rapidly and have moved to the GC 
light zone are termed centrocytes. Centrocytes test their freshly diversified and 
mutated antigen receptor for improved antigen binding, likely through interaction 
with antigen presented on the membrane of dendritic cells (Meyer-Hermann et 
al., 2006). Failure to establish a strong interaction with antigen and helper T 
cells induces Fas-mediated cell death (Choe et al., 1996, Koopman et al., 
1997). Because the majority of random somatic mutations in the BCR are 
deleterious to binding of antigen, most centrocytes will undergo apoptosis in the 
light zone of the GC. If SHM has improved the antigen binding affinity, a strong 
interaction of the BCR with antigen in conjunction with CD40 signalling (T cell 
help) will allow the centrocyte to activate anti-apoptotic factors such as Bcl-2 
and Bcl-XL (Smith et al., 2000, Takahashi et al., 1999). CD40 signalling also 
induces the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB), which is viewed as an important contributor that keeps the pro-apoptotic 
tendency of centrocytes at bay. Moreover, CD40 signalling upregulates the 
interferon-regulatory factor 4 (IRF4), which seems to upregulate AID expression 
and thereby initiates class switch recombination (CSR) (Klein et al., 2006, 
Sciammas et al., 2006).  
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1.2.4 Class switch recombination 
CSR allows centrocytes to diversify their antibody’s effector functions without 
altering its antigen-binding affinity (Stavnezer, 1996). Prior to CSR, activated B 
cells express immunoglobulin (Ig) M and D (IgM and IgD) isotypes on their 
surface, which are generated by alternative splicing of a primary transcript(Early 
et al., 1980).Certain cytokines stimulate the initiation of CSR. In a first step 
transcription of so-called switch (S) regions leads to the generation of DNA-
RNA hybrid structures termed R-loops. These R-loop structures are a preferred 
substrate for AID and are subjected to deamination as described for SHM (in 
section 1.2.2 p. 23) (Chaudhuri and Alt, 2004). As for SHM, the mismatch is 
then processed by BER or MMR thus generating a nick in the DNA strand. If 
two nicks are generated in close proximity on both DNA strands, this will create 
a double strand break in the S region which is repaired by the NHEJ machinery 
(Wuerffel et al., 1997). In this process the V(D)J segment is ligated to an 
alternative downstream constant heavy chain region, deleting all intervening 
DNA sequence. This somatic gene rearrangement confers a distinct biological 
function to the antibody without altering its affinity for antigen recognition. 
1.2.5 Exit from the GC reaction 
The GC reaction is terminated once testing of the antigen receptor and CSR is 
completed in the GC light zone, leading to terminal differentiation of GC B cells 
into either plasma cells or memory B cells. Plasma cells are non-dividing, 
terminally differentiated Ig-secreting cells which reside in the bone marrow 
(Shapiro-Shelef and Calame, 2005). Plasma cells can either differentiate 
directly from GC cells or memory B cells. Memory B cells are quiescent antigen-
experienced B cells (Tarlinton, 2006) which can respond to secondary antigen 
encounter much more rapidly than naïve B cells (Tangye et al., 2003). Although 
it is currently unclear what causes the decision between differentiation into a 
plasma or memory B cell of a centrocyte at the end of the GC reaction, it is 
generally accepted that plasma cell differentiation is preceded by 
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downregulation of the transcriptional suppressor Bcl6 (see section 1.3 below for 
more detail). The factors required for memory B cell differentiation are less 
clear. It has been suggested that activation of the signal transducer and 
activator of transcription (STAT)-5 (Scheeren et al., 2005) and continued CD40 
signalling (Arpin et al., 1995) can drive GC cells towards the memory B cell fate 
in vitro.  
1.3 Regulation of normal B cell development by Bcl6 
Bcl6 is a master transcription factor playing a crucial role at the affinity 
maturation stage of B cell development. Bcl6 protein is expressed in germinal 
centre cells but not in most other B cells within human lymphoid tissues 
(Cattoretti et al., 1995, Flenghi et al., 1995, Onizuka et al., 1995). At the GC 
stage of B cell differentiation, Bcl6 collaborates with other key transcription 
factors and thereby regulates late stages of B cell development (Figure 1.3). 
  
  
 
 
Figure 1.3: Role of Bcl6 in terminal B cell differentiation
In germinal centre (GC) cells, 
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Bcl6 plays two important roles in the GC reaction. Firstly, Bcl6 secures 
proliferation of GC cells through suppression of genes involved in negative 
regulation of the cell cycle. Secondly, Bcl6 inhibits terminal plasma cell 
differentiation by repressing transcription of the master transcription factor of 
plasma cell differentiation i.e. B lymphocyte-induced maturation protein-1 
(Blimp-1) which is encoded by the PRDM1 (PR domain containing) gene 
(Shaffer et al., 2000). In order to terminally differentiate, a GC cell must 
downregulate Bcl6 activity and a T cell signal is thought to trigger this process.  
When the CD40 ligand (CD40L) on a T cell engages the B cell CD40 receptor, 
Bcl6 activity is downregulated via two different routes. Firstly, CD40 signalling 
activates the NF-κB pathway, which can disrupt the interaction of Bcl6 with the 
nuclear hormone receptor co-repressor (NCoR) (Espinosa et al., 2003, 
Espinosa et al., 2002) and relieves repression of some of the Bcl6 target genes 
such as ATR (ataxia telangiectasia and Rad3 related) (Ranuncolo et al., 2007). 
Secondly, strong CD40 signalling activates transcription of IRF4. IRF4 in turn 
binds to the BCL6 promoter and downregulates its transcription (Saito et al., 
2007). Bcl6 downregulation allows for Blimp-1 expression, which in turn 
downregulates a broad range of genes involved in cell growth and proliferation 
(Shaffer et al., 2002) and thereby guides GC cells towards the plasma cell fate.  
Moreover, Blimp-1 activates a second key transcription factor in B cell terminal 
differentiation, Xbp-1 (X-box binding protein-1) (Reimold et al., 2001), through 
transcriptional repression of the GC transcription factor Pax5 (paired box 
protein 5) (Lin et al., 2002). Together, Blimp-1 and Xbp-1 drive GC B cells 
towards the plasma cell fate. Blimp-1 is thought to mostly contribute to 
suppression of proliferation (Shaffer et al., 2002), while Xbp-1 plays a vital role 
in the regulation of immunoglobulin secretion (Liou et al., 1990). 
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1.4 Bcl6 expression outside of B cell development 
Bcl6 protein is expressed at the GC stage of B cell development and hence 
most of the research has focused on this cell type, however, there is a 
constantly expanding literature exploring additional functions of Bcl6 in different 
cell types (Albagli-Curiel, 2003). It is interesting to note that Bcl6 mRNA is 
expressed in almost all developing tissues of postnatal mice (Bajalica-
Lagercrantz et al., 1998), emphasising a bigger role for Bcl6. 
 Pro-survival function of Bcl6 outside of B cell development 
One of the main functions of Bcl6 in the GC reaction is that of a pro-survival 
factor and it is perhaps not surprising that Bcl6 can fulfil the same role in other 
tissues. It has been demonstrated in various cell lines and in vivo that Bcl6 can 
protect cells from certain stress stimuli, which would, under normal 
circumstances trigger an apoptotic response. When Bcl6 was knocked down in 
mouse skeletal myocytes by RNA interference (RNAi), cells no longer terminally 
differentiated but died in response to serum starvation (Kumagai et al., 1999). In 
accordance with this finding, cardiac myocytes of BCL6 knockout mice are very 
prone to degeneration after 4 weeks of age (Yoshida et al., 1999) and 
spermatocytes from BCL6 knockout mice are more sensitive to apoptosis 
induced by hyperthermia in comparison to their wild-type counterparts (Kojima 
et al., 2001). 
 Regulation of differentiation by Bcl6 outside of B cell development 
Bcl6 blocks terminal differentiation in the B cell lineage and also seems to play 
a role in stabilising terminal differentiation of other cell types (Albagli-Curiel, 
2003). Evidence for a role of Bcl6 in differentiation of other cell types has been 
demonstrated in monocytic cells (Yamochi et al., 1997), memory T cells (Ichii et 
al., 2002), keratinocytes (Yoshida et al., 1996), skeletal myocytes (Albagli-
Curiel et al., 1998) and male germ cells (Yoshida 1996). 
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 Pro-apoptotic function of Bcl6 outside of B cell development 
In contrast to the well-established role of Bcl6 as a pro-survival factor, Bcl6 also 
appears to function as a pro-apoptotic factor under certain circumstances. 
Earlier studies demonstrated that enforced Bcl6 expression causes apoptosis of 
cell lines that do not naturally express Bcl6 (Albagli et al., 1999, Yamochi et al., 
1999). These cell line-based observations were later supported by the finding 
that macrophages isolated from BCL6 knockout mice display a better survival in 
vitro when compared to macrophages derived from wildtype mice (Tang et al., 
2002). Taken together, these observations led to the suggestion that Bcl6 
expression can potentially kill all cells that do not normally express Bcl6 (Dent 
et al., 2002). 
1.5 Regulation of Bcl6 expression 
1.5.1 Regulation of Bcl6 transcription 
Bcl6 mRNA is abundant in resting B and T cells and also in GC B cells (Allman 
et al., 1996), however, only little is known about the factors involved in 
activating Bcl6 transcription. It has been suggested that certain STATs 
(Scheeren et al., 2005, Zhou and Ono, 2005) and the activator protein 1 (AP-1) 
(Arguni et al., 2006) have a potential function in this process. It remains to be 
demonstrated, however, how these pathways perform and interact in vivo. 
Although not entirely clear, the transcriptional downregulation of Bcl6 is slightly 
better understood. It is now generally accepted, that negative autoregulation 
plays an important part. The observation that BCL6 knockout mice expressed 
numerous truncated Bcl6 transcripts led to the suggestion that the Bcl6 protein 
negatively regulates transcription of its own gene, and in fact, two Bcl6 binding 
sites were discovered in the BCL6 promoter region (Wang et al., 2002). It was 
later shown that the C-terminal (carboxy-terminal) binding protein 1 (CtBP1) 
functions as an important co-repressor in this process (Mendez et al., 2008). 
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The Bcl6 binding sites in the BCL6 promoter region were often found mutated in 
patients suffering from diffuse large B cell lymphoma (DLBCL) (see section 1.9 
below for more information on Bcl6-expressing B cell lymphomas), emphasising 
the biological significance of these sites for regulation of Bcl6 expression 
(Pasqualucci et al., 2003). Another factor that can downregulate BCL6 
transcription is CD40 stimulation as already described in section 1.3 (p.26). 
1.5.2 Regulation of Bcl6 protein stability 
Although Bcl6 mRNA is abundant in resting B and T cells and in GC B cells, 
only GC cells express high amounts of Bcl6 protein (Allman et al., 1996). This 
observation led to the conclusion that Bcl6 protein expression is strongly 
controlled by post-translational mechanisms. Bcl6 protein is detected by 
Western blotting as a broad band of an apparent molecular weight of 92-98 kilo 
Dalton (kDa) due to heavy phosphorylation (Onizuka et al., 1995) (predicted 
molecular weight 79 kDa (Kerckaert et al., 1993)). The site of this weighty 
phosphorylation maps to a sequence of the Bcl6 protein that is rich in proline, 
glutamic acid, serine and threonine (PEST domain) (see also section 1.6.2) and 
that contains several phosphorylation sites for mitogen-activated protein 
kinases (MAPKs) (Moriyama et al., 1997). Phosphorylation of Bcl6 at these 
residues in response to BCR signalling leads on to degradation of Bcl6 by the 
ubiquitin-proteasome pathway (Niu et al., 1998). As BCR signalling is also 
active upon initiation of the GC reaction, Bcl6 degradation must be suppressed 
in centroblasts. Three mechanisms have been proposed to aid Bcl6 protein 
stabilisation (Niu et al., 1998), the first two of which modulate the intensity of the 
BCR signal. Reducing BCR signalling will at the same time reduce MAPK 
activity and thereby protect Bcl6 from phosphorylation, subsequent 
ubiquitination and degradation. Firstly, downregulation of BCR expression itself 
at the centroblast stage has been observed in rats and might also function to 
reduce the amplitude of BCR signalling in humans (Liu et al., 1991b, 
MacLennan, 1994). Secondly, BCR signalling can be modulated by signals 
received from CD22 or Fc (fragment, crystallisable) γ receptor (Cambier, 1997, 
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Tedder et al., 1997). Thirdly, Bcl6 that has been targeted by ubiquitination in 
response to BCR signalling can be de-ubiquitinated by deubiquitinases (DUB) 
specifically expressed in GCs (Zhu et al., 1996).  
1.6 Bcl6 functional domains and interaction sites 
Bcl6 is a transcriptional repressor with three main functional protein domains. 
DNA binding is mediated via its C-terminal DNA binding domain consisting of 
six zinc finger (ZF) motifs. Transcriptional repression of Bcl6 is achieved mainly 
through recruitment of various co-repressors, most of which interact with Bcl6’s 
most studied domain, i.e. its amino-terminal (N-terminal) BTB/POZ (broad 
complex, tramtrack and bric-à-brac / poxviruses and zinc finger) domain. It 
seems generally accepted that Bcl6 co-repressor availability varies between cell 
types and differentiation stages, and that this greatly modulates the target gene 
programmes repressed by Bcl6 in a given situation (Cimmino et al., 2008). The 
middle portion of Bcl6 has a central role in regulating Bcl6 protein degradation. 
As described above (section 1.5.2), the PEST domains in the central portion of 
the Bcl6 molecule are subjected to phosphorylation and consequent 
ubiquitination, which targets Bcl6 for proteosomal degradation. Figure 1.4 
summarises various physical contacts that the Bcl6 protein makes with its 
interaction partners. 
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Figure 1.4: Bcl6-interacting proteins and target genes (Jardin et al., 2007) 
This diagram shows the three functional domains of Bcl6 (middle), proteins that 
interact with these domains (top) and selected Bcl6 target genes summarised in three 
groups (bottom). Bcl6 has three functional domains, an N-terminal BTB/POZ domain 
mainly responsible for protein interactions, a central PEST domain that regulates Bcl6 
half-life and some protein interactions, as well as six C-terminal zinc fingers, which are 
capable of interacting with DNA and various proteins. The zinc fingers bind to 
consensus sequences in promoter regions of Bcl6 target genes, thereby mediating 
repression.  
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1.6.1 Bcl6 N-terminal POZ domain 
Bcl6 has an N-terminal BTB/POZ domain (amino acid (aa) residues 1-121) 
(Dhordain et al., 1995). BTB/POZ domains are found in many zinc finger 
transcription factors and can facilitate gene regulation by modifying local 
chromosome conformation (Ahmad et al., 2003). The Bcl6 BTB/POZ domain 
mediates homodimerisation with itself and heterodimerisation with other POZ 
domain containing proteins, such as the promyelocytic leukaemia zinc finger 
protein (PLZF) (Dhordain et al., 2000). Known partners that interact with the 
POZ domain of Bcl6 are the silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT) and NCoR (Dhordain et al., 1997, Dhordain et al., 
1998), Bcl6-interacting co-repressor (BCoR) (Ghetu et al., 2008, Huynh et al., 
2000), CtBP (Mendez et al., 2008), Bcl6-associated zinc finger protein (BAZF) 
(Okabe et al., 1998), Myc-interacting zinc finger protein-1 (Miz-1) (Phan et al., 
2005) and another zinc finger protein named ecotropic viral integration site 9 
(Evi9) (Nakamura et al., 2000) (Figure 1.4). 
The interaction of Bcl6 with SMRT, NCoR and BCoR depends on a charged 
pocket in the Bcl6 POZ domain, also referred to as lateral groove involving aa 
residues 25-54. This interaction site is thought to be the most crucial for Bcl6 
function, as inhibitors interfering with this part of the Bcl6 molecule seem to 
completely abolish its function (see section 1.10 for below for details). The 
interaction of Bcl6 with CtBP seems to play a role in negative autoregulation of 
Bcl6 (Mendez et al., 2008) (see section 1.5.1 p.30).  
Although many of the proteins that interact with the Bcl6 POZ domain have 
been identified and validated using experimental approaches such as 
mammalian two-hybrid, co-localisation, co-immunoprecipitation and reporter 
assays (Ahmad et al., 2003), the functional significance of the various 
interactions remains poorly understood. This area of Bcl6 research deserves 
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special attention, as it will provide a solid base for the development of Bcl6-
targeting therapy (see section 1.10 below for details).  
1.6.2 Central Bcl6 domain 
The central part of the Bcl6 protein functions in transcriptional repression and 
regulation of protein stability. Although transcriptional repression is mostly 
attributed to the Bcl6’s N-terminal POZ domain, the central portion of Bcl6 
contributes to this function. Residues 191-383 of Bcl6 interact with the 
mammalian orthologue of the yeast SIN3 co-repressor (mSIN3A, component of 
a histone deacetylase (HDAC) complex) (Dhordain et al., 1998). Additionally, 
residues 370-386 of Bcl6 appear to be of functional significance in 
transcriptional repression too, although not through interaction with mSIN3A 
(Zhang et al., 2001). Furthermore, the central Bcl6 domain mediates the 
interaction with the metastasis-associated protein 3 (MTA3), a component of 
the Mi2-NuRD (HDAC) co-repressor complex (Fujita et al., 2004). The 
interaction of MTA3 with Bcl6 can be impaired by acetylation of the KKYK 
(lysine (K), tyrosine (Y)) motif of Bcl6 (aa 376-379) by the histone acetyl 
transferase (HAT) p300/CBP (CREB-binding protein) (Bereshchenko et al., 
2002). Acetylation of this motif leads to upregulation of Bcl6 target genes 
involved in B cell terminal differentiation (Fujita et al., 2004, Jaye et al., 2007). 
In addition to its role in co-repressor interactions, the central Bcl6 domain 
regulates protein stability. The PEST motifs in the central region of the Bcl6 
molecule (aa 336-430)become phosphorylated by MAPK, inducing degradation 
of Bcl6 via the ubiquitin proteasome pathway (Moriyama et al., 1997, Niu et al., 
1998) (see also section 1.5.2 p.31 for more information on the regulation of Bcl6 
protein stability). 
CHAPTER 1 – Introduction 
36 
1.6.3 Bcl6 C-terminal zinc finger domain 
The C-terminal portion of Bcl6 (aa 520-681) contains six zinc fingers. In addition 
to DNA binding, these zinc fingers interact with other proteins such as eight-
twenty-one (ETO) (Chevallier et al., 2004), Evi9 (Nakamura et al., 2000) and 
members of class II HDACs (Lemercier et al., 2002). 
Interestingly, a mutagenesis study demonstrated, that only the four C-terminal 
zinc fingers of Bcl6 participate in DNA binding and transcriptional repression, 
whereas the function of the two N-terminal zinc fingers remains to be 
determined (Mascle et al., 2003). Following this study, another group detected a 
new Bcl6 transcript variant that lacks exon 7 of Bcl6 and with it its two N-
terminal zinc fingers. This small protein isoform (Bcl6S) appeared to have no 
difficulties in homo- or heterodimerisation, DNA binding, or transcriptional 
repression when compared to full length Bcl6 (Shen et al., 2008). 
1.7 Mechanism of transcriptional repression by Bcl6 
Bcl6 potentially regulates 485 target genes (Polo et al., 2007). Transcriptional 
repression is brought about by two different mechanisms, firstly Bcl6 directly 
binds to target gene promoters and secondly, Bcl6 associates with other DNA 
binding proteins. The Bcl6 zinc fingers recognise a 9 base pair (bp) consensus 
DNA sequence TTCCT(A/C)GAA that is found in the promoter region of many 
Bcl6 target genes (Chang et al., 1996, Seyfert et al., 1996). This consensus 
sequence may be located upstream or downstream of transcriptional start sites 
and transcriptional repression appears to be effective even over long distances 
(Albagli et al., 1996). Additionally, the Bcl6DNA recognition sequence is highly 
similar to that of STAT transcription factors (Seyfert et al., 1996). Consequently, 
Bcl6 is also capable of inhibiting STAT6-dependent gene transcription by 
blocking these binding sites (Chang et al., 1996, Kawamata et al., 1994b).  
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Furthermore, Bcl6 can also achieve transcriptional repression of genes that do 
not contain a Bcl6 binding site in their promoters through interaction with other 
transcription factors such as Jun proteins and Miz-1. Through interaction with 
Jun proteins (c-Jun, JunB and JunD), Bcl6 reduces their transcriptional 
activation function and represses transcription ofPRDM1 (Blimp-1) and 
CDKN1A (p21cip1/waf1) (Phan et al., 2005, Vasanwala et al., 2002). Through 
interaction with the transcriptional activator Miz-1, Bcl6 represses transcription 
of Miz-1 target genes such as CDKN1A (p21cip1/waf1) (Phan et al., 2005). 
Once bound to the regulatory areas within a target gene, Bcl6 interacts with 
class I and class II HDACs (Dent et al., 2002, Lemercier et al., 2002) through its 
various protein interaction domains (see also section 1.6 p.32). Consequently, 
the recruited co-repressors make the chromatin structure inaccessible to the 
transcriptional machinery and other activating factors. 
1.8 Bcl6 in malignant transformation 
In normal B cell development, Bcl6 transcription is active at the GC stage and 
needs to be downregulated to allow B cells to terminally differentiate (see 
sections 1.3 p.26 and section 1.5.1 p.30).Supporting evidence for the oncogenic 
potential of Bcl6 due to misregulated gene expression is provided by two 
important observations; firstly, downregulation of Bcl6 transcription in response 
to CD40 stimulation is found to be impaired in many cell lines derived from GC-
derived lymphomas (Allman et al., 1996, Gupta et al., 1999). Secondly, the 
BCL6 gene is often translocated in B cell lymphoma (see also section 1.9 
below). The BCL6 promoter and the region immediately downstream form a 
major translocation cluster (MTC) at chromosome region 3q27 (Kerckaert et al., 
1993, Otsuki et al., 1995, Ye et al., 1995). At least 20 translocation partner loci 
in which the BCL6 gene is positioned under the influence of a heterologous 
promoter have to date been reported (Albagli-Curiel, 2003). Such promoter 
substitutions render affected cells resistant to the mechanisms that 
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downregulate Bcl6 expression under physiological conditions, thereby resulting 
in persistent Bcl6 expression.  
The underlying mechanisms of the resistance of Bcl6 to transcriptional 
downregulation are the loss of the negative autoregulation of Bcl6 and to a 
lesser extend mutations in its transcribed sequence. During negative 
autoregulation, the Bcl6 protein binds to its own gene, thereby repressing its 
own transcription. A Bcl6 binding site required for negative autoregulation is 
located in non-coding exon 1 of BCL6 and can be separated from its coding 
region as a result of translocations, or can be inactivated by point mutations. 
Point mutations in the BCL6 locus are found in normal, as well as malignant GC 
B cells and seem to be resulting from aberrant targeting of the SHM machinery 
(Pasqualucci et al., 1998, Shen et al., 1998). However, because spreading of 
SHM to genes other than immunoglobulin genes is also observed in normal GC 
B cells, this process is unlikely to contribute to malignant transformation of GC 
B cells. There is, nevertheless, the interesting possibility that SHM and 
associated DNA damage within the BCL6 gene, destabilises the genomic locus 
and thereby renders it more susceptible to translocation events (Dent et al., 
2002). 
1.9 Bcl6-expressing B cell lymphomas 
Bcl6 protein is expressed in all GC-derived B cell malignancies such as 
follicular lymphoma (FL), Burkitt’s lymphoma (BL) and DLBCL (Cattoretti et al., 
1995). Follicular lymphomas almost always carry a Bcl-2 translocation 
(Tsujimoto et al., 1985). Bcl-2 inhibits apoptosis via the mitochondrial pathway, 
however, overexpression of Bcl-2 resulting from its translocation, appears to not 
be sufficient for malignant transformation as such translocations are also 
detected in normal B cells (Limpens et al., 1995). For this reason, secondary 
alterations in key cell cycle regulators such as p53, p16INK4a and c-Myc are 
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commonly observed in FL (Sanchez-Beato et al., 2003). In addition, BCL6 
translocations occur in approximately 6-14% of FLs (Bastard et al., 1994). 
By definition, Burkitt’s lymphoma is characterised by a translocation of the c-
Myc proto-oncogene (Taub et al., 1982) and BL is commonly associated with 
infection by Epstein-Barr virus (EBV). The transcription factor c-Myc regulates 
at least 10-15% of all cellular genes (Knoepfler, 2007) thereby controlling cell 
proliferation, differentiation and apoptosis (Dang et al., 2006). Overexpression 
of c-Myc alone triggers p53-mediated cell cycle arrest and apoptosis and is 
hence not sufficient for malignant transformation (Zindy et al., 1998). 
Accordingly, c-Myc translocations are almost always accompanied by additional 
defects in the p53-mediated apoptotic pathway (Eischen et al., 1999). The 
contribution of Bcl6 to malignant transformation of BL is currently poorly 
understood. Importantly, however, the target gene programs of c-Myc and Bcl6 
are highly interconnected (Figure 1.5). Interestingly, c-Myc induces genes 
involved in apoptosis, while Bcl6 can protect cells from an apoptotic response. 
The BCL6locus is found translocated in 20-40% of DLBCL(Lo Coco et al., 
1994). This mature B cell malignancy is further divided into two disease subsets 
according to their ‘cell-of-origin’ gene expression profile (Alizadeh et al., 2000). 
The GC-like subgroup has a gene expression profile that resembles that of 
normal centroblasts and expresses high levels of Bcl6, while the second 
subgroup, the activated B cell-like type, shows a post-GC gene expression 
profile and does not express Bcl6 (Alizadeh et al., 2000). Section 1.10 below 
provides further information on the role of Bcl6 in DLBCL and the associated 
potential for Bcl6 targeting therapy in this context. 
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Figure 1.5: Interconnection of Bcl6 and c-Myc target gene programs 
Bcl6 and c-Myc target genes are colour-coded in purple (Bcl6) and green (c-Myc) boxes 
respectively. Induction (+) or repression (-) of target genes is indicated in brackets. Adapted 
from (Sanchez-Beato et al., 2003). 
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1.10 Bcl6 as a therapeutic target 
Bcl6 is a novel drug target currently being validated for therapy of DLBCL. 
However, although promising inhibitors have already been developed and 
tested in vivo, many issues in drug target validation of Bcl6 have not been 
addressed to date. In this section, I am going to discuss the current views of the 
potential of Bcl6 as a drug target in DLBCL and the associated challenges. 
From a general point of view, a good drug target in a hematologic malignancy 
needs to fulfil two important requirements. Firstly, the drug target must be 
involved in a crucial biological pathway, so that therapeutic targeting can assert 
a useful effect. At the same time, however, the effects of interference with the 
candidate target must be exclusive to the malignant cell population and spare 
healthy tissue. Secondly, a good drug target needs to be ‘well validated’. For 
drug target validation, it is crucial to understand the function and interactions of 
the target protein in healthy and malignant conditions as thoroughly as possible.  
When examining the features of Bcl6 against these fundamental drug target 
requirements, there is exciting potential along with tricky challenges. Bcl6 
seems to be essential for survival of DLBCL cells and inhibition of its function 
does not harm healthy tissue (Cerchietti et al., 2010, Cerchietti et al., 2009). 
The general acceptance that GC B cells and their malignant counterparts 
depend on Bcl6 results from numerous in vitro and in vivo studies. Firstly, BCL6 
knockout mice are unable to form GCs (Dent et al., 1997), while overexpression 
of Bcl6 in mice causes increased GC formation and the development of 
lymphomas that closely resemble a human DLBCL phenotype (Cattoretti et al., 
2005). Secondly, when Shaffer and co-workers expressed a dominant-negative 
version of Bcl6 in a Burkitt’s lymphoma cell line (Raji), increased apoptosis was 
observed (Shaffer et al., 2000). Thirdly, peptides interfering with the Bcl6 
BTB/POZ domain cause growth suppression and apoptosis in DLBCL and BL 
cell lines (see section 1.9 p.38 for details on Bcl6-expressing lymphomas) and 
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human DLBCL xenografts (Cerchietti et al., 2010, Cerchietti et al., 2009, 
Chattopadhyay et al., 2006, Polo et al., 2004). 
However, although many Bcl6 target genes and co-repressors have been 
identified, the role of specific protein-protein interactions remains elusive. As a 
result, it has not been established which part of the Bcl6 molecule and which 
interaction site would be most suitable for therapeutic targeting. One reason for 
this is the lack of good model systems to study the significance of Bcl6 
interactions (see also section 1.11 below). To date, Bcl6 inhibitors have only 
targeted the POZ domain. Interference with the BTB/POZ domain appears to 
completely abolish Bcl6 function (Polo et al., 2007). Complete destruction of 
Bcl6 function, however, could be accompanied by too high toxicity in clinical 
trials. 
To date, considerations of inhibiting sites of the Bcl6 molecule other than the 
POZ domain have been extremely limited, only targeting of the Bcl6-MTA3 
interaction has been discussed in the literature. The Bcl6-MTA3 interaction is 
impaired by acetylation of Bcl6 protein by p300 and can thus be interfered with 
through inhibition of HDACs (Fujita et al., 2004). In fact, treatment of DLBCL 
with HDAC inhibitors caused the accumulation of acetylated Bcl6 that was 
unable to interact with MTA3 and enforced a differentiated phenotype 
(Bereshchenko et al., 2002). Although treatments that cause malignant cells to 
differentiate rather than kill them might appear to be too mild at first sight, such 
treatments may be of great benefit clinically because they are likely to show 
lower toxicity than approaches that trigger radical cell death. A successful 
example of this concept is the current treatment of acute promyelocytic 
leukaemia (APML). In APML, treatment with ATRA (all-trans retinoic acid) plus 
chemotherapy drives malignant cells towards differentiation into mature 
granulocytes and greatly improves patient survival (Melnick and Licht, 1999).  
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Although Bcl6 is a promising new drug target, the targeting potential of its 
multiple protein interaction sites has not been fully explored to date. Only two of 
its interaction sites have been considered for therapeutic targeting and the 
understanding of these interactions sites is nevertheless limited. In order to aid 
the development of Bcl6-targeting therapy, there is hence the need for 
developing novel model systems to study Bcl6 function and protein interactions. 
1.11 Bcl6 model systems 
As outlined in the previous section, it is essential to collect as much information 
on Bcl6 function as possible in order to optimise the development of Bcl6-
targeted therapy. The following sections provide an overview of the model 
systems currently available to study Bcl6 function and their individual strengths 
and weaknesses.  
1.11.1 Murine Bcl6 model systems 
Loss-of-function studies in mice enable investigation of gene function within the 
complexity of a whole organism. BCL6 knockout mice have been engineered by 
two independent groups and have generated valuable insight into the biological 
function of Bcl6 (Dent et al., 1997, Fukuda et al., 1997, Ye et al., 1997). BCL6 
knockout mice are born with normal lymphoid organs and no obvious defects in 
B and T cell development. Soon after birth, however, BCL6-/- mice display 
growth retardation, severe inflammatory disease and die early. When 
challenged by pathogens, defects in T cell-dependent immune responses 
become apparent. BCL6-/- B cells can differentiate into short-lived antibody 
secreting plasma cells (Tunyaplin et al., 2004, Ye et al., 1997), but not into long-
lived plasma cells (Toyama et al., 2002). Consistent with this finding, GC 
formation in BCL6-/- mice is absent, resulting in impaired affinity maturation and 
severe infections. Moreover, mice that lack Bcl6 display an inflammatory 
phenotype in many organs (Toney et al., 2000). 
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Despite the great contribution of these in vivo studies towards our 
understanding of Bcl6 function, BCL6 knockout mice are very ill, die after a few 
weeks and can hence not be studied very well. Moreover, it has to be taken into 
account that although immunological responses are well conserved between 
humans and mice, the observed phenotypes must be interpreted with caution, 
as significant differences exist between the two species. An important 
observation for example is, that the inflammatory response is regulated 
differently in mice and humans (Del Prete et al., 1993). 
1.11.2 Cell culture-based Bcl6 model systems 
Cell line work is attractive for some purposes i.e. analysis of gene regulation, 
and avoids the use of animals, which is the direction of research that scientists 
are encouraged to follow, but cannot be used to show effects on the immune 
system as a whole. A beautiful study that provided exciting insight in the target 
gene program that Bcl6 regulates was published by Shaffer and co-workers 
(Shaffer et al., 2000). The authors established cell line-based gain-of-function 
and loss-of-function models and used these to screen for possible Bcl6 target 
genes by microarray analysis. In the gain-of-function approach, the authors 
expressed Bcl6 in cell lines that usually do not express Bcl6 (K562, WI-L2, 
SUDHL5). The loss-of-function model was based on a dominant-negative 
approach in which only the zinc finger portion of Bcl6 was expressed in BL cell 
lines that express endogenous Bcl6 (Raji and BJAB). Microarray analysis of the 
effects on gene expression of these cell line-based gain-of-function and loss-of-
function models identified a large number of potential Bcl6 target genes 
involved in B cell activation, differentiation, inflammation and cell cycle 
regulation (Shaffer et al., 2000). Moreover, the authors of this study 
demonstrated that of two particular genes are direct Bcl6 target genes (cyclin 
D2 and MIP-1α), by showing that Bcl6 transcriptional repression is dependent 
on Bcl6 binding site in their promoter region (Shaffer et al., 2000).  
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Despite of the intriguing insight into the broad transcriptional regulation capacity 
of Bcl6 gained from this study, it must not be neglected that the models used to 
generate the data are far from ideal. Firstly, the gain-of-function model involved 
expression of Bcl6 in a cell line that usually does not express Bcl6 and it has 
been demonstrated in other studies that this is likely to be toxic to the cells 
(Albagli et al., 1999, Yamochi et al., 1999). Furthermore, such cell lines may not 
express the same group of Bcl6 co-repressors as GC cells. Secondly, one 
cannot be certain that the effect of expression of only the ZF domain of Bcl6 in 
the loss-of-function model is only attributed to abrogation of Bcl6 function. In 
fact, the DNA sequence recognised and bound by the ZF domain of Bcl6 
closely resembles that of STAT binding sites (Seyfert et al., 1996), hence the 
effect of abrogating Bcl6 function, might result from interfering with STAT 
transcriptional regulation. Nevertheless, this study revealed rich insights into the 
role of Bcl6 in the immune response and the development of lymphoma and 
serves as an excellent starting point for the development of more advanced 
system for studying Bcl6 function. 
1.11.3 Bcl6 knockdown model systems 
Alternatively to the dominant-negative concept chosen by Shaffer and co-
workers, cell line-based loss-of-function can be also achieved by knockout 
(gene targeting) or knockdown (small interfering RNA (siRNA)) approaches. 
Both these strategies aim to eliminate any target protein expression, either by 
disruption of the genomic locus or by degradation of mRNA transcripts. siRNA 
has been previously used to downregulate Bcl6 expression in a human BL cell 
line (BJAB), however, only a 57 % depletion of Bcl6 protein was achieved 
(Baron et al., 2007). Although others have also reduced Bcl6 protein by siRNA 
in cell lines derived from BL, chronic myeloid leukaemia (CML) and gastric 
cancer (Fernandez de Mattos et al., 2004, Hirata et al., 2009, Kinugasa et al., 
2007, Phan et al., 2005), no complete depletion was achieved and off-target 
effects of siRNAs are very common(Jackson and Linsley, 2010). 
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Alone, none of the available models for studying Bcl6 function is able to answer 
all open questions on the complex network surrounding Bcl6. I therefore 
decided to create a cell line-based model system in which complete Bcl6 
protein depletion can be achieved. To accomplish this, I used gene targeting to 
disrupt the BCL6 gene of a Bcl6-expressing, GC-derived B cell line. Due to the 
fact, however, that Bcl6 seems to be essential for the survival of GC cells, it was 
expected that a traditional knockout could be lethal. To overcome this potential 
problem, I decided to pursue a conditional knockout strategy as outlined in the 
following section.     
1.12 Experimental outline 
In order to overcome some of the limitations of the current models available for 
studying Bcl6 function, I have pursued a cell line-based conditional knockout 
strategy. My conditional BCL6 knockout model was developed using the well-
characterised BL cell line DG75. DG75 carries a c-Myc translocation and is 
deficient in p53-mediated apoptosis. Table 1 summarises some of the key 
characteristics of the parental cell line. 
The conditional BCL6 knockout approach involves gene targeting of the first 
allele of BCL6, while the product of the second BCL6 allele ensures survival 
and proliferation of the cell. Before the second allele is targeted, an inducible 
BCL6 copy is introduced, which rescues the cells when the second allele is 
targeted. Once both endogenous alleles are disrupted, the inducible copy can 
be switched off and the phenotype can be studied. Such conditional knockout 
systems have been successfully used in other cell lines, both in our lab 
(Carpenter and Porter, 2004, Itzhaki et al., 1997) and in others (Sonoda et al., 
1998, Takagaki and Manley, 1998) to study gene function. The information 
generated from this model will greatly support the development of Bcl6 
inhibitors and hopefully translate to clinical benefit for patients suffering from 
DLBCL.  
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Table 1: Summary of characteristics of the DG75 cell line 
characteristic description 
EBV status negative (Ben-Bassat et al., 1977) 
translocation t(8;14)(24;q32), MYC immunoglobulin heavy chain (IgH) (Basso et al., 1999) 
Bcl6 status 
no translocation (Yang et al., 2006) 
oneBCL6 allele carries a SNP (Zhang et al., 2005) 
no mutations in the coding region (as tested by sequencing) 
markers surface IgM kappa on its surface (Ben-Bassat et al., 1977) 
apoptosis-
resistance 
p53 mutation impairs nuclear-cytoplasmic shuttling (Crook et al., 1998) 
Bax is non-functional; frameshift mutation, premature stop codon (Brimmell et 
al., 1998) 
resistance to cisplatin (Crook et al., 1998), ionomycin and serum starvation 
(Brimmell et al., 1998) 
miscellaneous 
AID is expressed at low levels (Scheller et al., 2010) 
SHM not active (Scheller et al., 2010) 
mismatch repair deficiency (Msh2-) (Brimmell et al., 1998) 
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2.1 Bacterial culture 
Escherichia coli (E.coli) strains TOP10 (Invitrogen), NEB-10-beta (New England 
Biolabs (NEB)) or XL2-Blue (Stratagene) were used for standard cloning 
procedures. Transformation was carried out according to the manufacturer’s 
instructions. Bacterial cultures were grown in Luria Bertani (LB) medium or on 
LB agar plates (see section 2.9 p.69 for commonly used solutions) 
supplemented with 75 µg/ml ampicillin (amp) (Sigma). For zeocin (zeo) 
selection, bacteria were plated on low salt LB plates containing 25 µg/ml zeocin 
(Invivogen). For long term storage, bacterial clones were kept in 20% glycerol 
volume per volume (v/v) (Sigma) at -80 °C. 
2.2 Nucleic acid isolation 
2.2.1 Isolation of plasmid DNA 
Bacterial plasmid DNA was isolated by alkaline lysis followed by high salt 
precipitation and plasmid DNA purification using mini (Omega bio-tek) or HiLink 
Pure maxi preparation kits (Invitrogen).  
2.2.2 Isolation of mammalian RNA 
Confluent cells were washed in phosphate buffered saline (PBS) (Lonza), 107 
cells were pelleted and total RNA was extracted using the RNeasy mini kit 
(Qiagen) according to the manufacturer’s instructions. This system relies on a 
guanidine-isothiocyanate lysis followed by silica-column based purification of 
total RNA. 
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2.2.3 Isolation of mammalian genomic DNA 
Confluent DG75 cells were washed in PBS and 107 cells were pelleted. For 
cloning procedures, genomic DNA (gDNA) was extracted using the Gentra 
Puregene kit (Qiagen), for Southern blotting (see section 2.6), gDNA was 
extracted using a simplified DNA isolation procedure (Laird et al., 1991).  
2.2.4 Quantification of nucleic acids 
Nucleic acids were quantified using a BioPhotometer (Eppendorf) or a 
NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies). DNA and 
RNA concentrations were determined by measuring the optical density (OD) at 
260 nm, where 1 OD unit equals 50 µg/ml of DNA or 40 µg/ml of RNA, 
respectively.  
2.3 Mammalian cell culture 
2.3.1 Culturing 
All mammalian cells were grown in a humidified incubator (Napco 5410, 
Precision Scientific) at 37 °C with 5 % CO2. Sterile handling of cells was carried 
out in a flow hood (Faster BHG2004, Jencons-PLS).All cell lines used in this 
project (see Table 2) were cultured in RPMI 1640 medium (Lonza), 
supplemented with 10 % fetal bovine serum (FBS) (Lonza) and 1 x Penicillin-
Streptomycin-Glutamine (Invitrogen). For tetracycline (tet)-regulated transgene 
expression, 1 µg/ml tetracycline (tet) or doxycycline (dox) (both from Sigma) 
were added to the culture medium. 
All cell lines were passaged at 80 % confluency or less. For passaging, 
adherent cells were washed in PBS, trypsinised (Gibco) and diluted in fresh 
medium. Suspension cells were passaged by directly diluting the culture in 
fresh medium. For long term storage, 107mammalian cells were resuspended in 
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1ml freezing medium (see section 2.9), transferred into cryovials (CryoTube, 
Nunc), placed in a cryo-freezing container filled with isopropanol (at room 
temperature) and transferred to a -80 °C freezer. After 24 hours (hrs) at -80 °C, 
cells were transferred to liquid nitrogen. To thaw cells, cryovials were placed in 
a 37 °C water bath until the cell suspension started to thaw. Cells were 
transferred into pre-warmed medium, collected by centrifugation for 5 minutes 
(mins) at 700 x g and resuspended in complete medium, at high density, for 
recovery. 
Table 2: Mammalian cell lines used throughout this project 
2.3.2 Growth curve analysis 
For growth curve analyses, trypan blue-excluding, i.e. viable cells were counted 
and cultures were split regularly so concentrations did not exceed or fall below 
the preferred cell density of 1-9 x 105 cells/ml. The doubling time (Td) between 
time point 1 (t1) and time point 2 (t2) (in hours) was calculated by inserting cell 
concentrations at time point t1 (c1) and time point t2 (c2) into the following 
formula:  
    	
 
ln2

ln 	⁄ 

 
2.3.3 Electron microscopy 
Dr Shaun Willimott (University of Leicester, Leicester) performed cell fixation for 
electron microscopy. Briefly, cells were fixed in 2% glutaraldehyde in 0.1 M 
cell line description 
DG75 humanBL (Ben-Bassat et al., 1977) 
DG75-354 DG75-derivative that stably expresses the tetracycline transactivator 
(supplied by Dr B. Henglein, Institut Curie, Paris) 
293T human embryonic kidney cell line (Pear et al., 1993) 
K-562 human chronic myeloid leukaemia cell line (Lozzio and Lozzio, 1975) 
Jurkat human acute T cell leukaemia (Schneider et al., 1977) 
U266 human myeloma cell line (Nilsson et al., 1970) 
JJN3 human myeloma cell line (Jackson et al., 1989) 
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sodium cacodylate buffer (pH 7.4) at 4° C overnight. Dr David Dinsdale (MRC 
Toxicology Unit, Leicester) processed samples further and performed electron 
microscopy. For postfixing, cells were incubated in 1% osmium tetroxide/1% 
potassium ferrocyanide for 1 hr at room temperature. After fixation, cells were 
stained with 5% aqueous uranyl acetate overnight at room temperature, were 
dehydrated and embedded in Taab epoxy resin (Taab Laboratories Equipment 
Ltd., Aldermaston, UK). Ultrathin sections were stained with lead citrate and 
recorded using a Megaview 3 digital camera and iTEM software (Olympus Soft 
Imaging Solutions GmbH, Münster, Germany) in a Jeol 100-CXII electron 
microscope (Jeol UK Ltd., Welwyn Garden City, UK). 
2.3.4 Transient transfections 
Transient transfection of DG75 cells was carried out by nucleofection (Amaxa) 
using the V-kit in combination with nucleofection program ‘O-006’. For each 
reaction, 3 million cells were nucleofected with 3 µg plasmid DNA. Transient 
transfection of 293T cells was achieved by lipofection with lipofectamineTM2000 
(Invitrogen), according to the manufacturer’s instructions. Transgene 
expression was monitored by flow cytometry or immunoblotting.  
2.3.5 Stable transfections 
Stable transfection was achieved by electroporation as described previously 
(Feederle et al., 2004). Briefly, 3 million cells were washed in medium without 
supplements and resuspended in 250 µl of the same medium and 3 µg of 
plasmid DNA. The suspension was transferred into pre-chilled, 4 mm-gap 
electroporation cuvettes (BTX Harvard Apparatus) and placed on ice. 
Electroporation was achieved with a Gene-Pulser (BioRad) at 240 volt (V) and 
capacitance 960 µF. Cells were immediately transferred into 3 ml pre-warmed 
medium including all supplements and left to recover for 24-48 hrs. After 
recovery, cells were plated in 96-well plates (VWR) at 103cells per well, together 
with the corresponding selective antibiotic. Geneticin (G418) (Invitrogen) was 
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used at 550 µg/ml, puromycin (Sigma) at 2 µg/ml and zeo (Invivogen or 
Invitrogen) at 100 µg/ml. The medium was exchanged every 4-7 days. 
Depending on the selective agent used, clones could be expanded after 14-20 
days. 
2.3.6 Flow cytometry 
Unless otherwise indicated, 10,000 events were acquired with a FACSCalibur 
(BD). Acquisition and analysis of data were accomplished with CellQuest Pro 
software (BD) and the Flowjo software package (Treestar).  
 Cell surface staining 
Anti-IgM-fluorescein isothiocyanate (FITC), anti-CD69-FITC and isotype control 
antibodies were purchased from BD Bioscience. Approximately 5 x 105 cells 
were collected by centrifugation, washed in PBS, resuspended in 1 ml PBS with 
2 % (v/v) FBS and 3 µl of corresponding antibody and incubated on ice for 20 
mins. Prior to fluorescent activated cell sorting (FACS) analysis, cells were 
washed twice in PBS with 2 % (v/v) FBS. 
 Annexin V assay 
Apoptosis was measured using a FITC Annexin V Apoptosis Detection Kit I (BD 
Pharmingen). Briefly, 5 x 105 cells were washed in PBS, resuspended in 100 µl 
Annexin V binding buffer and incubated with 4 µl of each FITC Annexin V and 
propidium iodide (PI) staining solution for 15 minutes at room temperature in the 
dark. 400 µl Annexin V binding buffer were added to the samples prior to 
analysis by flow cytometry.  
 CFSE assay 
Proliferation analysis was carried out by intracellular staining with 
carboxyfluorescein diacetate succinimidyl ester (CFSE) as previously described 
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(Quah et al., 2007). Briefly, 7 x 106 cells were collected by centrifugation, 
resuspended in 1 ml PBS with 5% v/v FBS and transferred to a fresh 15 ml 
tube. The tube was positioned horizontally and 110 µl of PBS were added to a 
dry part at the top of the tube wall. 1.1 µl of 5 mM CFSE (Sigma) were added to 
the PBS droplet, the tube was capped, quickly inverted and vortexed, protected 
from light and incubated at room temperature for 5 minutes. Subsequently, 
10 ml of PBS with5% v/v FBS were added and cells were collected by 
centrifugation. After two more washes, stained cells were distributed between 
two 10 ml cultures (with or without doxycycline) and analysed daily by flow 
cytometry.  
 Cell cycle / DNA content analysis 
For cell cycle analysis, 106 cells were collected by centrifugation, washed in 
PBS and resuspended in 300 µl PBS. 700 µl ice-cold ethanol were added to the 
cell suspension whilst vortexing. Fixation was completed by incubation on ice 
for 1 hr or by storing samples at -20 °C over night. Fixed cells were collected by 
centrifugation, washed once in PBS and resuspended in 500 µl PBS containing 
0.2 mg/ml RNase A (Qiagen). Subsequent to digestion of RNA at 37 °C for 1 hr, 
PI (Sigma) was added to a final concentration of 40 µg/ml and cells were 
analysed by flow cytometry.  
2.4 Manipulation of nucleic acids 
2.4.1 Restriction enzyme digestion of plasmid DNA 
Restriction enzymes and protocols were from NEB. Typically, 1 µg of plasmid 
DNA was digested with 3 units of enzyme for 1 hr at the incubation temperature 
recommended. 
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2.4.2 Restriction enzyme digestion of genomic DNA 
Genomic DNA was heated up to 55 °C and gently resuspended by pipetting 
with a cut 1000 µl tip. Genomic DNA from 2x106 cells was typically digested at 
37 °C over night, in a total volume of 200 µl, supplemented with 160 units SphI 
and 5 mM spermidine (Sigma). A fraction of the gDNA digest was visualised by 
agarose gel electrophoresis (section 2.4.4) to evaluate completion of the 
reaction. Digestion of human gDNA with SphI is expected to result in an 
average fragment size of 5,000 bp (calculated from public databases by NEB). 
Occasionally, more restriction enzyme had to be added and the reaction had to 
be incubated longer, in order to achieve complete digestion. 
2.4.3 Phenol/chloroform extraction and ethanol precipitation 
Phenol/chloroform extraction and ethanol precipitation, or ethanol precipitation 
alone were performed to purify DNA. For phenol/chloroform extraction, the 
DNA-containing sample was supplemented with an equal volume of 
phenol:chloroform:iso-amyl alcohol (25:24:1) equilibrated with 10 mM Tris, pH 
8.0 (Sigma), vortexed for 1 minute and centrifuged at>10k x g for 1 min. DNA in 
the upper organic phase was subsequently purified by ethanol precipitation. 
For ethanol precipitation, the DNA-containing sample was mixed with 1/10 
volume of 3M sodium acetate and 2.5-3 volumes of ethanol (Fisher Scientific) 
were added. The sample was chilled at -20 °C up to several hrs and DNA was 
collected by centrifugation >15k x g at 4 °C for 30 mins. The DNA pellet was 
washed in 70% ethanol (v/v) in order to remove residual salt and phenol, dried 
and resuspended in tris-ethylene diamine tetraacetic acid (TE) (see section 
2.9). 
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2.4.4 Agarose gel electrophoresis 
Gels were casted with 0.5-1.5 % agarose weight per volume (w/v) (BDH or 
Bioline) in tris-acetate EDTA (TAE, see section 2.9) supplemented with Sybr 
Safe (Invitrogen). Agarose gels were run in a horizontal electrophoresis unit 
(Midi, Fisher Scientific) with TAE as running buffer at 35-125 V. DNA samples 
were mixed with DNA loading dye prior to gel electrophoresis and loaded 
alongside DNA ladders with known size standards such as 1kb ladder (NEB or 
Invitrogen), λHind marker (NEB), or 100 bp ladder (NEB). DNA was visualised 
with a blue light transilluminator (Invitrogen) and pictures were acquired with 
GrabIt software (UVP).  
2.4.5 Purification of DNA from agarose gels 
DNA-containing gel slices were excised from agarose gels using a razor blade 
and processed with the QIAquick gel extraction kit (Qiagen) as directed by the 
manufacturer. 
2.4.6 Ligation 
Ligations were carried out with T4 DNA ligase (NEB) according to the 
manufacturer’s instructions. Typically, 50 ng of digested vector were incubated 
with a 3-fold molar excess of insert, 400 units T4 ligase and 1x T4 ligase 
reaction buffer (NEB), in a total volume of 15 µl. Cohesive ends were ligated at 
16 ºC for 16 hrs, while blunt ends were ligated at room temperature for 2 hrs. 
2.4.7 End-filling 
For end-filling of 5’ overhangs, 1 µg of DNA was incubated in NEB buffer 2, 
supplemented with 33 µM each deoxyribonucleotide triphosphate (dNTP) and 1 
unit of Klenow enzyme (NEB) for 15 minutes, at room temperature, in a total 
volume of 20 µl. The reaction was terminated by addition of ethylene diamine 
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tetra-acetic acid (EDTA, section 2.9) to a final concentration of 10 mM and the 
enzyme was heat inactivated for 20 mins at 75 ºC. 
2.4.8 Radiolabelling of DNA for Southern blotting 
 Marker labelling 
Labelling of 1 µg DNA ladder (1kb, Invitrogen) was carried out in 1x restriction 
enzyme buffer 2 (NEB), supplemented with dNTPs (dATP, dTTP and dGTP 
(NEB,50 µM final concentration each), 0.5 µl of α-32P-dCTP (10 mCi/ml, Perkin 
Elmer) and 5 U of Klenow fragment (3’ to 5’ exo-) in 20 µl, for 30 minutes at 
37 ºC. 
 Probe labelling 
25 ng of DNA probe were mixed with 250 ng of random hexamers (Promega), 
boiled for 2 minutes and quickly placed on ice before the remaining components 
were added. The labelling reaction was carried out in 20 µl as for the marker, 
however, 3 µl of α-32P-dCTP were added and the reaction was incubated for 
1 hour. 
For purification if the labelling reaction, IllustraTM ProbeQuantTM G50 micro 
columns (GE Healthcare) were prespun for 1 minute at 735 x g, labelling 
reactions were made up to 100 µl with TE, applied to the column and spun for 2 
mins at 735 x g. The percentage of radioisotope incorporation into the DNA 
probe was determined by comparing Geiger counts of the labelled probe before 
and after column purification. Percentages were around 60-70 %. 
2.4.9 Phosphorylation of PCR primers 
For site-directed mutagenesis primers were phosphorylated using T4 
polynucleotide kinase (PNK). Briefly, 3 µl of primer (100 µM), 5µl ATP (10 mM, 
NEB), 5 µl of 10x T4 PNK buffer (NEB) and 1 µl T4 PNK (10U/µl) were 
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incubated in 50 µl at 37 ºC for 30 mins. PNK was then heat inactivated for 
20 mins at 65 ºC and 2.4 µl of the reaction were used per 30 µl PCR reaction. 
2.5 Cloning and PCR analysis 
2.5.1 General PCR conditions 
All polymerase chain reactions (PCR) were carried out in a Peltier Thermal 
Gradient Cycler 200 (MJ Research).  
2.5.2 Molecular cloning 
All molecular cloning was performed with PhusionTM High-Fidelity DNA 
Polymerase (Finnzymes). Each reaction consisted of PhusionTM DNA 
polymerase (0.02 U/µl), 1x High Fidelity Buffer (Finnzymes), primers (0.5 µM, 
Invitrogen), dNTPs (200 µM each, NEB), 3 % dimethyl sulfoxide (DMSO) (NEB) 
and variable amounts of template DNA, depending on the source. Typically, 
300 ng of gDNA, 10 ng of plasmid DNA or 200 ng complementary DNA (cDNA) 
were used as template. A classical PCR cycling profile for PhusionTM 
polymerase is shown below: 
 Cloning of the regions of homology for the targeting construct 
Regions of homology for the targeting construct were amplified by PCR from 
DG75 gDNA using the following primers: 
 
step temperature time 
initial denaturation 98 ºC 0:30           
denaturation 98 ºC 0:10 
25-35 cycles annealing 50-72 ºC 0:30 
extension 72 ºC 15-30 seconds (sec) / kilobase-pair (kb) 
final extension 72 ºC 10:00  
KpnI-homology-F GAT GGT ACC ATC CCA ACC GTC TCT TTC AC 
SacII-homology-R CAT CCC CGC GGC ACA CCT CTA ATA GGC TCA G 
CHAPTER 2 - Methodology 
58 
The annealing temperature of this primer set was 68 °C for 5 cycles, followed 
by 72 °C for 30 cycles. The extension time of the 10,007 bp PCR product was 6 
mins. 
 Cloning of the zeocin resistance cassette for the targeting construct 
The zeo cassette contains the zeo coding region, as well as its eukaryotic and 
prokaryotic promoter and was cloned from plasmid pCMV/Zeo (Invitrogen) 
using the following primers: 
The annealing temperature for this primer pair was 50 °C for 5 cycles, followed 
by 72 °C for 30 cycles. The extension time for the 1,161 bp product was 30 
seconds. 
 Cloning tetracycline-regulated Bcl6 
Total DG75 RNA was extracted with the RNeasy kit (Qiagen) and transcribed 
into cDNA using the Omniscript kit (Qiagen) according to the manufacturer’s 
recommendations. 2 µl of cDNA were used as template for the PCR reaction. 
Human Bcl6 was hemagglutinin (HA)-tagged at the C-terminus using the 
following primers: 
The annealing temperature of this primer pair was 72 ºC and the corresponding 
extension time for the 2,165 bp product was 1:30 mins for 30 cycles. The Bcl6 
open reading frame (ORF) was sequenced by automated fluorescent 
sequencing using ABI3730xl and ABI3130xl (Applied Biosystems) using the 
following primers: 
SbfI-LoxP-Zeo-F CAT CGA CCT GCA GGA CAT AAC TTC GTA TAG CAT ACA 
TTA TAC GAA GTT ATC GTT ACA TAA CTT ACG GTA A 
SbfI-SphI-LoxP-Zeo-R GTG CAT CCT GCA GGG CAT GCATAA CTT CGT ATA ATG TAT 
GCT ATA CGA AGT TAT GCA GTG AAA AAA ATG CTT TA 
BamHI-Bcl6-F CAG GAT CCA TGG CCT CGC CGG CTG ACA G 
HindIII-Bcl6-HA-R CAG AAG CTT TCA AGCGTAATCTGGAACATCATAAGGGTA 
GCA GGC TTT GGG 
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 Cloning of complementation constructs 
The Bcl6 ORF of all complementation constructs was sequenced using primers 
pcDNA3.1-F, pcDNA3.1-R and primers Bcl6-1R to Bcl6-4F (above). 
  
 Cloning of pcBcl6 
Full length Bcl6 was amplified from DG75 cDNA using primers Bcl6-F and Bcl6-
F (see below) (annealing temperature 72 ºC, extension time 1:30, 35 cycles). 
The 2,121 bp product was inserted into the PmeI sites of pcDNA3.1/Hygro/lacZ 
(Invitrogen) and correct orientation of the insert was verified by restriction 
enzyme digestion.  
  
 Cloning of pcBcl6-FLAG 
To generate C-terminally-FLAG-tagged Bcl6 (pcBcl6-FLAG), site-directed 
mutagenesis was performed on pcBcl6 using phosphorylated primers Bcl6-
FLAG-F and Bcl6-FLAG-R. The PCR reaction was performed using 1 ng of 
template, an annealing temperature of 72ºC, an extension time of 4 mins and 
25 cycles. Five µl of PCR product incubated with 1 µl of 10x T4 ligase buffer 
(NEB) and 1 µl of T4 ligase (20 U/µl, NEB) in a total volume of 10 µl over night 
at room temperature, prior to transformation into competent bacteria.  
pTRE-tight-1F CTC GTT TAG TGA ACC GTC AG 
pTRE-tight-4R CCT CTA CAA ATG TGG TAT GG 
Bcl6-1R CAG GTT GTT CTC CAC CAC 
Bcl6-2F GTG AGA GCA GAG CCT TTG 
Bcl6-2R CAG GCA TTC TTA CTG CTG C 
Bcl6-3F CAT CCT CCA GGC TTC TGG 
Bcl6-3R GTG TGC CTC TTG AGT GAG 
Bcl6-4F CAG ACC CAC AGT GAC AAA C 
pcDNA3.1-F CTAGAGAACCCACTGCTTAC 
pcDNA3.1-R GAGGGGCAAACAACAGAT 
Bcl6-F ATGGCCTCGCCGGCTGACAG 
Bcl6-R TCAGCAGGCTTTGGGGAGCT 
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 Cloning of pcBcl6N21K 
Site-directed mutagenesis was performed on pcBcl6 using primers N21K-F and 
N21K-R below. For the PCR reaction, an annealing temperature of 62 ºC, an 
extension time of 2:30 mins and 18 cycles were used. Following amplification, 
1 µl of DpnI (1 U/µl, NEB) was added to the reaction (total volume 50 µl) which 
was subsequently incubated for 1hr at 37ºC before DpnI was heat inactivated 
for 20 mins at 80ºC and the reaction was transformed into competent bacteria. 
  
 Cloning of pcBcl6N21K-FLAG 
pcBcl6N21K-FLAG was derived from pcBcl6N21K using the site-directed 
mutagenesis procedure described for construction of pcBcl6-FLAG above. 
 Cloning of pcBcl6∆POZ-FLAG, pcBcl6D33A-FLAG, pcBcl6R44A-FLAG, 
pcBcl6D33R/R44D-FLAG, pcBcl6QQYQ-FLAG, pcBcl6∆ETO-FLAG 
pcBcl6∆POZ-FLAG, pcBcl6D33A-FLAG, pcBcl6R44A-FLAG, pcBcl6D33R/R44D-FLAG, 
pcBcl6QQYQ-FLAG, pcBcl6∆ETO-FLAG were derived from pcBcl6-FLAG using the 
site-directed mutagenesis procedure described for construction of pcBcl6-FLAG 
above. Using the following primers: 
Bcl6-FLAG-F GGTGGAGACTACAAAGACGATGACGATAAATGAAAACCCGCTGAT
CAGCCTCGACTGTGC 
Bcl6-FLAG-R GCAGGCTTTGGGGAGCTCCGGAGG 
Bcl6-N21K-F GTTCTTCTCCAAGCTTAATCGTC 
Bcl6-N21K-R GACGATTAAGCTTGAGAAGAAC 
∆POZ-F CGGAAGTTTATTAAGGCCAGTGAAGCAGAG 
∆POZ -R CATAAACGCTAGCCAGCTTGGGTCTCCC 
D33A-F CGAGACATCTTGACTGCTGTTGTCATTGTTGTG 
D33A-R ACTCCAGAGACGATTAAGGTTGAGAAGAAC 
R44A-F ACGCGTGAGCAGTTTGCAGCCCATAAAACGGTC 
R44A-R CACAACAATGACAACATCAGTCAAGATGTC 
D33R/R44D-F AGCCGTGAGCAGTTTGATGCCCATAAAACGGTC 
D33R/R44D-R CACAACAATGACAACACGAGTCAAGATGTCTCG 
QQYQ-F CCCAAAGCCTGCAACTGGCAGCAATACCAGTTCATCGTGCTCAACAGC 
QQYQ-R GTCAGTGGGGCTCTTGGCTGGAGGGGAGCC 
∆ETO-F ACTGGTGAGAAGCCCTATCCCTGTGAAATCTG 
∆ETO-R GGGCTTCTCTCCAGAGTGAATTCGAGTGTG 
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2.5.3 PCR assays 
Analysis of genetic manipulations in DG75-354 was carried out by PCR 
analyses. PCR assays for the following modifications were developed: 
 Targeting of the BCL6 locus 
Two PCR assays were used to screen for targeted disruption of the BCL6 
locus, a ‘right homology PCR screen’ flanks the right arm of homology of pTarg-
BCL6 (see CHAPTER 3for details) and a ‘left homology PCR screen’ flanks the 
left arm of homology of pTarg-BCL6 (see CHAPTER 3 and CHAPTER 5).  
 Cre-recombination of the resistance cassette 
Two PCR assays were used to confirm excision of the zeo resistance cassette 
by Cre-mediated recombination at the first and second BCL6 allele targeted, 
respectively (see sections 3.2.6 p.85 and 5.2.3 p.109). An additional PCR assay 
was designed to detect the circular Cre-recombination product (circular pop-out 
intermediate, see sections 5.2.3 and Figure 5.6). 
Taq polymerase-based (Qiagen) assays were performed on whole cell lysates. 
Cells were collected by centrifugation and resuspended in 25 µl colony PCR 
lysis buffer supplemented with 30 µg/ml proteinase K (Qiagen). Reactions were 
incubated at 55 ºC for 1 hr. Proteinase K was then heat inactivated (15 mins at 
98ºC) and the remaining PCR components were added. The PCR components 
(25 µl) were: Taq DNA polymerase (0.1-0.2 U/µl), 1 x PCR Buffer (Qiagen), 
primers (1 µM, Invitrogen or Sigma) and dNTPs (200 µM each, NEB). Primer 
sequences and PCR conditions are listed in Table 3, a typical cycling program 
was: 
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step temperature time 
initial denaturation 94 ºC 3:00           
denaturation 94 ºC 0:10 
40-45 cycles annealing 55-63 ºC 0:30 
extension 68-72 ºC 1:00-6:00 
final extension 68-72 ºC 10:00  
 
 
Table 3: PCR assay list, primer specifications and PCR conditions 
2.5.4 Semiquantitative RT-PCR analysis 
Total RNA was extracted as described in section 2.2.2 (p.48) and reverse 
transcribed using the ProtoScript® M-MuLV first strand cDNA synthesis kit 
(NEB). Serial dilutions of 1, 1:5, 1:25, 1:125 were prepared from cDNA 
generated from 1 µg total RNA in 50 µl. One µl of each dilution was used as 
template in a 25 µl PCR reaction. PCR reactions were set up with TopTaq™ 
PCR master mix (Qiagen) and a final primer concentration of 0.2 µM. Primers 
PCR assay name primer name and sequence (5’-3’) 
(1) annealing 
(2) extension 
(3) cycle number  
(4) product size 
Gene targeting:  
Right-Homology Screen 
Right-homology-assay-F (RHAF) 
CTC GTT TAG TGA ACC GTC AG 
(1) 55 °C 
(2) 5 mins at 68 °C 
(3) 45 
(4) 5293 bp 
Right-homology-assay-R (RHAR) 
CAC ACC TCT AAT AGG CTC AG 
Gene targeting:  
Left-Homology Screen 
Left-homology-assay-F (LHAF) 
ATC CCA ACC GTC TCT TTC AC 
(1) 63 °C 
(2) 6 mins at 68 °C 
(3) 40 
(4) 5940 bp 
Left-homology-assay-R (LHAR) 
CTG ACG GTT CAC TAA ACG AG 
Cre recombination: 
1stBCL6 allele 
Cre-assay-F 
ACG GTG TCT CTC CAT TG 
(1) 55 °C  
(2) 2 mins at 72 °C 
(3) 40 
(4) 1967 bp 
Cre-assay-R 
CTA TGC CCA CAG AAC GTG 
Cre recombination: 
2ndBCL6 allele 
2nd-Cre-F 
CTC GTT TAG TGA ACC GTC AG 
(1) 55 °C  
(2) 1 min at 72 °C 
(3) 40 
(4) 925 bp 
2nd-Cre-R 
CTA TGC CCA CAG AAC GTG 
Cre recombination: 
(Detection of circular 
recombination product) 
Cre-Circular-F  
TTC GTG GCC GAG GAG CAG GA 
(1) 67.5 °C  
(2) 1 min at 72 °C 
(3) 40 
(4) 745 bp 
Cre-Circular-R  
GAG GCT GGA TCG GTC CCG GT 
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used for characterisation of BCL6-/-tetBCL6-HA cells in CHAPTER 6 (Table 4 
below) and for validation of microarray data (Table 7, p. 68) are listed. A typical 
cycling program was: 
 
 
 
 
 
 
Table 4: Sq RT-PCR primers used in CHAPTER 6 
2.6 Southern blotting 
SphI-digested gDNA (3 µg per 1 cm comb width) was separated on a 0.8 % 
agarose gel for 16 hours at 35-40 V, alongside 0.5 µl of radiolabelled marker 
mixed with 1 µg of cold marker (see also section 2.4.8 p. 56). The gel was 
subsequently rocked in denaturation solution 3 times for 15 mins, neutralised 
step temperature time 
initial denaturation 94 ºC 3:00           
denaturation 94 ºC 0:30 
30 cycles annealing 50-60 ºC 0:30 
extension 72 ºC 1:00 
final extension 72 ºC 5:00  
 
 
gene Primer sequence (5’-3’) 
(1) reference 
(2) annealing 
(3) product size 
PRDM1 (Blimp-1) TGGACATGGAGGATGCGGATATG AGGTCCTTTCCTTTGGACGGGTTG 
(1) (Teng et al., 2007) 
(2) 60 ºC 
(3) 762 bp 
PAX5 AGCGTCAGTTCCATCAACAG GCCAGCGAGGCCATGGCTGA 
(1) (Teng et al., 2007) 
(2) 60 ºC 
(3) 422 bp 
B2M AGATATGCCTGCCGTGTG AATCCAAATGCGGCATCT 
(1) (Ullmannova et al., 2003) 
(2) 55 ºC 
(3) 110 bp 
MKI67 (Ki-67) GGAGGCAATATTACATAATTTCA CAGGGTCAGAAGAGAAGCTA 
(1) (Ullmannova et al., 2003) 
(2) 60 ºC 
(3) 233 bp 
CCND3 (cyclin 
D3) 
CCAGGAAATCATGTGCAATC 
CTGGCCATGAACTACCTGGA 
(1) (Ullmannova et al., 2003) 
(2) 50 ºC 
(3) 247 bp 
CDKN1A 
(p21cip1/waf1) 
CDKN1B 
(p27kip1) 
CCTCTTCGGCCCGGTGGAC (F)  
CCGTTTTCGACCCTGAGAG (p21R) 
TCTGCTCCACAGAACCGGC (p27R) 
(1) (Ullmannova et al., 2003) 
(2) 57 ºC 
(3) 367 bp (p21),  467 bp (p27) 
MYC TACCCTCTCAACGACAGCAG  TCTTGACATTCTCCTCGGTG 
(1) (Liao et al., 2007) 
(2) 55 ºC 
(3) 478 bp 
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for the same time and rinsed in water prior to transfer (solutions are listed in 
section 2.9). The transfer stack was assembled as follows: 3mm paper 
(Whatman) was placed on a plate with two opposing 3mm paper-ends reaching 
into a reservoir filled with 10x SSC (sodium chloride sodium citrate). The gel 
was placed on top, followed by a positively charged nylon membrane 
(HybondTM-N+, Amersham), two 3mm paper sheets, a stack of paper towels (of 
approximately 20 cm in height) and a weight of 500 g. The transfer was left for 
at least 16 hrs before the membrane was washed in 2x SSC and backed for 2 
hours at 80 °C. The membrane was pre-hybridised with 15 ml Church mix at 
65 °C in a glass bottle for 2 hrs. Subsequently, the radiolabelled probe was 
denatured for 5 minutes at 100 °C and added to the membrane in Church mix. 
After, hybridisation for 16-18 hrs at 65 °C, the probe was discarded and the 
bottle was rinsed with 50 ml of 2x SSC. The membrane was washed in 2x SSC 
and in 1x SSC for 15 minutes each at 65 °C, drained, wrapped in Saran wrap 
(Dow) and exposed to Hyperfilm MP (GE Healthcare) between two intensifying 
screens, at -80 °C for 48 hours to 7 days. 
2.7 Protein analysis 
2.7.1 Sample preparation and quantification 
Cells were washed in PBS and pellets were lysed in 40-100 µl 
radioimmunoprecipitaion (RIPA) buffer with 2% (v/v) non-specific protease 
inhibitors (Sigma). The lysate was incubated on ice for 30 mins and freed of 
debris by centrifugation at 4 °C for 20 mins at 15k x g. Protein concentrations 
were then determined by bicinchoninic acid assay (Sigma), according to the 
manufacturer’s instructions. 
2.7.2 Immunoblotting 
After boiling in protein loading buffer, 20-100 µg of total protein was size 
fractionated on 7.5-15 % acrylamide gels at 100 V, using the Mini-Protean 
electrophoresis cell (BioRad). Molecular weight values were estimated using 
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prestained protein markers (Full Range Rainbow Marker (GE Healthcare) or 
ColorPlus Prestained Protein Ladder (NEB)). Transfer of proteins onto 
Immobilon-P polyvinylidene difluoride membrane (Sigma) was performed using 
a Trans-Blot SD semi-dry transfer cell (BioRad) according to the manufacturer’s 
instructions. Membranes were incubated in blocking solution (5 % w/v marvel in 
tris-buffered saline/Tween20 (TBS/T)) for 1 hr at room temperature with 
shaking, washed in TBS/T and incubated in primary antibody in blocking 
solution (5 % bovine serum albumin (BSA, Sigma) was used instead of marvel 
where indicated) for 16 hours at 4 ºC. After three washes of 10 minutes in 
TBS/T, blots were incubated with horseradish peroxidase (HRP)-coupled 
secondary antibodies with shaking, in blocking solution for 1 hr at room 
temperature. Table 5 and Table 6 list all antibodies and corresponding dilutions 
used in this project. Membranes were washed (3x 10 mins) and detected with 
ECL Blotting reagent (GE Healthcare) and X-OMAT LS-1 film (Kodak). As 
loading control, membranes were reprobed with anti-GAPDH antibody or 
stained in amido black. Briefly, membranes were incubated in amido black for 
15 mins, rinsed with water and destained in amido destain for 30 minutes. 
 
Table 5: Primary antibodies used throughout this project 
target MW (kDa) company reference 
number species dilution 
Bcl6 (aa 3-484) 87-98 Santa Cruz I2607 rabbit 1:250 
Bcl6 (C-terminus) 87-98 Cell Signaling 4242 rabbit 1:1k (5% BSA) 
Blimp-1 95-100 Cell Signaling 9115 rabbit 1:1k (5% BSA) 
Caspase-3 17/19/35 Cell Signaling 9662 rabbit 1:1k 
CDK4 30 Cell Signaling 2906 mouse 1:1k 
CDK6 36 Cell Signaling 3136 mouse 1:1k 
c-Myc 57-70 Cell Signaling 9402 rabbit 1:1k (5% BSA) 
Cyclin D3 31 Cell Signaling 2936 mouse 1:2k 
Cyclin E 42/50 Santa Cruz 247 mouse 1:200 
FLAG-tag - Cell Signaling 2368 rabbit 1:1k 
GAPDH 37 Cell Signaling 14C10 rabbit 1:5k 
HA tag - Cell Signaling 6E2 mouse 1:1k 
LC3-B 16/18 Sigma L7543 rabbit 1:1k 
p15 INK4B 15 Cell Signaling 4822 rabbit 1:1k (5% BSA) 
p21 Waf1/Cip1 21 Cell Signaling 2946 mouse 1:1k 
p27kip1 27 Cell Signaling 2552 rabbit 1:1k (5% BSA) 
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Table 6: Secondary antibodies used throughout this project 
2.8 cDNA microarray analysis 
Total RNA was extracted using RNeasy minipreps (Qiagen) (see section 2.2.2 
above) and concentration and quality were checked on the NanoDrop® ND-
1000 spectrophotometer (NanoDrop Technologies, USA) and the RNA Nano 
6000 kit (Agilent Technologies) on a 2100 Bioanalyzer (Agilent Technologies). 
One hundred ng of total RNA was processed with the GeneChip® Eukaryotic 
Whole Transcript Sense Target Labelling Assay kit (Affymetrix) according to the 
manufacturer’s details (see Figure 7.1 p.153 for a schematic representation of 
the steps involved). Hybridisation and scanning of GeneChips® was performed 
by Nathalie Lambie (CSC/IC Microarray Centre, MRC Clinical Sciences Centre 
Imperial College London). Data analysis was performed by Geraint Barton 
(Bioinformatics Support Service, Imperial College London). Briefly, pre-
processing of data was performed using GeneSpring GX 10.0.2 software 
(Agilent Technologies) which applied the ‘Exon RMA16’ algorhithm to the data 
set. Exon RMA16 performs background correction, quantile normalisation, 
median polish summarisation and variance stabilisation of 16.  
In background correction, intensity values of each individual array are corrected 
for non-specific binding by subtracting the average signal intensity of the area 
between spots from each probe set. Normalisation is required so multiple chips 
can be compared to each other. Quantile normalisation adjusts the distribution 
of probe intensity of each array analysed and so that the distribution of probe 
intensities for each array in a set of arrays is the same (Bolstad et al., 
2003).Probe summarisation refers to the conversion of probe level values (there 
target company reference number species dilution 
mouse Dako P0447 goat (HRP-coupled)  1:1k 
mouse Cell Signaling 7076 goat (HRP-coupled) 1:2k 
rabbit Cell Signaling 7075 goat (HRP-coupled) 1:2k 
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are approximately 26 probes per gene on each GeneChip®) to a single probe 
set expression value (Irizarry et al., 2003). Variance stabilisation of 16 refers to 
the addition of the value 16 to the expression values. By increasing the 
expression value, the variance of the data set is reduced and the distribution 
(defined by its mean and its variance) is stabilised (Huber et al., 2002). 
Microarray data were validated by sq RT-PCR of 23 genes, as described in 
section 2.5.4 (p.62), using the primer set listed in Table 7 below and the 
following cycling program: 
  step temperature time 
initial denaturation 94 ºC 3:00           
denaturation 94 ºC 0:30 
30 cycles annealing 60 ºC 0:30 
extension 72 ºC 1:00 
final extension 72 ºC 5:00  
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Table 7: Primers used for validation of microarray results (CHAPTER 7) 
Primer3-designed primers were located in different exons (Rozen and Skaletsky, 2000). 
gene primer sequence (5’ to 3’) product size in bp 
ARHGAP15 TGCCTGAGCCGCTCTTCCCT 
AGGCATCTGTCGCTTGAAAGGCA 
455 
BLNK ACAGCTACGAGCCGCCTCCA 
CCTCGGTGGCGTTCAGCAGG 
499 
568 
CAMK4 CCCCAGGGTACTGCGCACCT 
CCATGGCTGCTGCTGGCACT 
430 
CDC6 GGGTGAAGGCTGCGGGTTCC 
CCCTTTCCCTGGCAGGCAGC 
578 
CDKN1B TCGGACAGCCAGACGGGGTT 
CCCTGCCCTCCCTTCCCCAA 
495 
CYSLTR1 TGTGCCCTGCTCTCTCCCCT 
GGTGCTGAGGCGGCACAAGA 
658 
E2F8 GTGCGCTCAGCTGGGACCTG 
GCTGTCGGTGTCCACGGCTC 
350 
EIF2AK3 CTGCGGCCGAGGTGACTGTG 
CCACTGCGAGGTCCGACAGC 
562 
FOXP1 CGGGCGGCAGCAACCACTTA 
GGCTGCCCGGGCTGAATTGT 
577/578 
GPRIN3 GATGGGTACACCCCGGGCCT 
GGGAGGGGAGCGCAGTCAGA 
415 
IFI44 GCGGCCTGTGCAGGGATGAC 
ACAGGGTCCAGCTCCCACTCA 
424 
IFI44L TGGCCAAGCCGTAGTGGGGT 
CCCGCAGCATCTGCCTCAGTG 
605 
IKZF1 AAAGCATGGGCCTTCCGGGC 
TAGGCGCGGTGCTCCTCCTT 
622 
IRF9 AGAGATCAGCCGCCCAGCCA 
GCAACATCCATGCGGCCCCT 
390 
LYAR GGCGCTGGCTGAGAGGCAAT 
CCCCTTGCTGTTCCACGGCG 
669 
PIK3IP1 TCTGGGCTACGTGCTGGGCA 
CTCAGCCCACAGGGCCACCT 
456 
PLEK TGACCCTGCTGGGGCAGAAGA 
ACCCCTGGGCTGTTTCCCGT 
325 
RB1 CCGGAGGACCTGCCTCTCGT 
CCTCGCCTGGGTGTTCGAGG 
653 
SESN1 TGCTGCTTTGGGCCGTTTGGA 
CGCAAGGGACCAGCTGTGCT 
367 
STAT1 ACCAATGGCAGTCTGGCGGC 
GGGCACGCTCTCGCTCCTTG 
583 
STAT2 TCTGCCGGGACATTCAGCCCT 
GCGTTGCGTAGGTCCACCCC 
637 
SYK CGGCTGGAGAGCGAGGAGGA 
GGCCCAGTCTTGGGCTGCAC 
462 
TAP1 TGCTGGAAGTGCAGGTGCGG 
CGAGGGGTGCGGTCCAGGTA 
409 
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2.9 Commonly used solutions 
All chemicals were from BDH unless otherwise stated. 
 
 
 
 Standard solutions 
50 x TAE 2 M Tris, 50 mM EDTA, 57.1 % (v/v) glacial acetic acid 
DNA loading dye (10x) 0.5 % (w/v) bromophenol blue, 0.5 % (w/v) Orange G (Sigma), 60 % 
glycerol 
TE 10 mM Tris-HCl, 10 mM EDTA, pH 7-8 
 Solutions for bacteria work 
LB medium 10 % (w/v) bacto-tryptone, 5 % (w/v) bacto-yeast extract, 170 mM 
NaCl, pH 7.0 
LB agar 15 % (w/v) agarose in LB medium 
low salt LB agar 15 % (w/v) agarose in low salt LB medium 
low salt LB medium 10 % (w/v) bacto-tryptone, 5 % (w/v) bacto-yeast extract, 85 mM 
NaCl, pH 7.0 
SOC medium 20 % (w/v) bacto-tryptone, 5 % bacto-yeast extract, 9 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 20 mM glucose, pH 7.0 
  
 Solutions for cell culture 
freezing medium 10 % DMSO (v/v) in FBS 
 Solutions for Southern blotting 
Church mix 0.4 M Na2HPO4, 0.1 M NaH2PO4, 7 % (w/v) sodium dodecyl sulfate 
(SDS), 1 % (w/v) BSA 
denaturation solution 1.5 M NaCl, 0.5 M NaOH 
neutralisation solution 1 M Tris-HCl, 1.5 M NaCl, pH 7.4 
SSC (20 x) 3 M NaCl, 300 mM sodium citrate, pH 7.0 
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 Solutions for protein analysis 
20 x tris-buffered saline 
(TBS) 
400 mM Tris-HCl, 2.76 M NaCl, pH 7.4 
3 x protein loading 
buffer 
34 mM Tris-HCl pH 6.8, 5.7 % (w/v) SDS, 15 % (v/v) β-
mercaptoethanol, 28 % (v/v) glycerol, 0.06 % (w/v) bromophenol 
blue 
5 x running buffer 250 mM Tris-base, 2M glycine, 17 mM SDS 
amido destain 25 % Isopropanol, 10 % acetic acid 
amido staining 1 % amido black (Merck) in H2O 
RIPA 150 mM NaCl, 1 % NP-40, 0.5 % deoxycholic acid, 0.1 % SDS, 50 
mM Tris-HCl pH 8 
separating gel (7.5 %) 375 mM Tris-HCl pH 8.8, 7.5 % (v/v) acrylamide, 3.5 mM SDS, 0.33 
% (v/v) TEMED, 2.2 mM ammonium persulfate 
stacking gel 375 mM Tris-HCl pH6.8, 4.5 % (v/v) acrylamide, 3.5 mM SDS, 0.4 % 
(v/v) TEMED, 2.6 mM ammonium persulfate 
TBS/T 0.1 % (v/v) Tween20 in 1xTBS 
transfer buffer 200 mM glycine, 25 mM Tris, 20 % (v/v) methanol 
 Other solutions 
colony PCR lysis buffer 0.045 % NP40, 0.045 % Tween20, 320 µg/ml proteinase K (Qiagen) 
in 1x PCR buffer (Taq, Qiagen) 
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CHAPTER 3 – Targeting of the first 
BCL6 allele 
3.1 Introduction 
Homologous recombination is a naturally occurring process, which has been 
adapted by scientists to artificially modify genes in cell lines as well as whole 
organisms (Capecchi, 1989). Gene targeting by homologous recombination has 
led to ground-breaking discoveries in Biology and Medicine and a Nobel Prize 
was awarded to Mario R. Capecchi, Martin J. Evans and Oliver Smithies in 
2007 for their outstanding contributions to this field (Mak, 2007).  
The human GC B cell line DG75-354 cell line was chosen as the parental cell 
line for the conditional BCL6 knockout.DG75-354 is a DG75-derivative, which 
stably expresses the tet-transactivator and was kindly supplied by Dr B. 
Henglein (Institut Curie, Paris) (see also section 4.2.1 p.93). DG75 is a Burkitt’s 
lymphoma cell line (Ben-Bassat et al., 1977) that has previously been 
successfully used for targeted gene disruption (Feederle et al., 2004, Maier et 
al., 2005) and it was also observed in our lab that the ratio of targeted over 
random integration is remarkably high in these cells (R. Vangala and A. Porter, 
unpublished results).  
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3.2 Results 
3.2.1 Design and cloning of the BCL6 targeting construct 
The BCL6 gene has 10 exons, spread over a 26 kb genomic locus on 
chromosome 3 (band 3q27) with the start codon located in exon 3 (Kerckaert et 
al., 1993, Miki et al., 1994). The BCL6 gene encodes at least three transcripts: 
one full length transcript, one that excludes exon 1b (Kawamata et al., 1994a) 
and one that encodes a smaller Bcl6 isoform, in which the first two zinc fingers 
(exon 7) are absent (Shen et al., 2008). I planned to disrupt exon 3, which 
contains the translation start site of BCL6. Figure 3.1 shows part of the BCL6 
locus and the gene targeting strategy designed. The targeting construct 
contains a zeocin (zeo) resistance cassette that is ‘floxed’, i.e. flanked, by loxP 
(locus of crossover) sites that serve as recognition sites for Cre (causes 
recombination) recombinase. This floxed cassette is followed by a downstream 
SphI restriction site and is flanked by arms of homology that target the construct 
to the BCL6 gene, for disruption of exon 3. Furthermore, the targeting construct 
contains a single KpnI restriction site which facilitates linearisation prior to gene 
targeting. Following transformation of DG75-354 cells with the targeting 
construct and subsequent selection in zeo; targeted integration events are 
detected by PCR screening and confirmed by Southern blotting (see sections 
3.2.2, 3.2.3, 3.2.4 and 3.2.5 below). 
Gene disruption is targeted to the 11,763 bp genomic SphI fragment, which 
flanks exon 1b and finishes in exon 6 of BCL6. The large SphI fragment was 
analysed with the repeat masking program ‘Censor’ (Kohany et al., 2006) and it 
was found that ~11 % of the locus were made up of repetitive sequences (data 
not shown). Many of these repetitive elements interfered with primer design for 
amplification of the arms of homology and it was therefore decided to amplify 
and clone a larger genomic fragment, for which primer-design was easier, due 
to the absence of repetitive elements.  
 Figure 3.1: BCL6 gene targeting strategy
A) The horizontal thin line represents part of the 
sites (SphI, KpnI, Apa
targeting construct is shown above the 
cassette flanked by loxP sites (triangles) and arms of homology (thick
located downstream of the second 
targeting construct with homologous regions in the 
sites outside the region of homology that can be used as probes for Southern blotting. Both 
probes (A+B) detect an 11.9 kb 
After homologous recombination
resistance cassette has disrupted exon 3. Probe A will detect a 7.9
B a 5.1 kb SphI-fragment
and allows the targeting construct to be reused for targeting of the second 
Cre-mediated recombination
decrease from 7.9 kb to 6.7 kb
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The arms of homology for the targeting construct were subcloned as a smaller 
fragment derived from this initial big construct. The larger (~10 kb) region was 
amplified from genomic DNA (see section 2.5.2 p.57). This 9,992 bp KpnI/SacII 
fragment was ligated into pBluescript KS+ (Stratagene), resulting in vector 
p10kb-homology. The 8,918 bp ApaI/EagI fragment of p10kb-homology was 
subcloned from p10kb-homology into pBluescript KS+, generating vector 
p8.9kb-homology. For disruption of the BCL6 allele, a zeo cassette was 
inserted into the SbfI site of p8.9kb-homology (end of exon 3). This 1,245 bp 
zeo cassette (including its own promoter) was amplified from pCMV/Zeo using 
primers that added loxP sites to both ends of the zeo cassette, an SphI 
restriction site to its 3’ end and SbfI restriction sites on both ends for subcloning 
(see section 2.5.2 p.58). The SbfI-digested PCR product was cloned into the 
SbfI site of p8.9kb-homology to generate the final targeting construct pTarg-
BCL6.The orientation of the zeo cassette was verified by restriction enzyme 
digestion and the region surrounding the 5’ loxP site was sequenced. Figure 3.2 
shows the disruption of the BCL6 locus at the nucleotide level before and after 
homologous recombination of the BCL6 locus with pTarg-BCL6. After targeting 
of the first BCL6 allele, cells can be transiently transfected with Cre-
recombinase (pMC-Cre kindly supplied by H. Gu, University of Köln), which will 
excise the region between the loxP sites. The premature stop codon generated 
by targeted BCL6 gene disruption is likely to result in the mRNA being 
degraded by nonsense-mediated decay (NMD) (Byers, 2002). The potential 
translation of the message would result in a 55 aa truncated protein which is 
expected to be non-functional and quickly degraded. Once zeo resistance is 
lost, the same targeting construct will be used to knockout the second BCL6 
allele. 
  
  
Figure 3.2: Disruption of
A) Exon 3 of wildtype 
restriction site used for insertion of the resistance cassette. Exons are shown in upper case, 
intronic sequences in lower case. Splice donor (gt) and splice acceptor sites (ag) are depicted 
in bold letters. B) Succ
genomic SbfI site. The disruption cassette 
a ‘floxed’ (grey triangle) 
the cassette into the locus destroys the splice donor signal (gt, bold)
nucleotides (AC) disrupt the 
(*TAA) encoded by the 
cassette by Cre-mediated recombination, the splice signal is still disrupted and the premature 
stop codon still present.
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3.2.2 Design of PCR assay ‘Right-Homology’ to screen for 
successful targeting of the BCL6 locus 
When the targeting construct pTarg-BCL6 integrates into the genome of DG75 
it can either do so by homologous recombination, leading to knockout of BCL6, 
or by random integration. In both situations, the resulting clones are resistant to 
zeo because the zeo cassette contains its own promoter. Hence, a PCR assay 
was established to discriminate targeted, from random integrations (see section 
2.5.3 p.61). The first PCR primer, Right-Homology-Assay-F (RHAF), anneals to 
the zeo cassette and the second primer Right-Homology-Assay-R (RHAR) 
anneals in the BCL6 locus, outside the region of homology of pTarg-BCL6 
(Figure 3.3A). In the event of targeted integration a 5.3 kb PCR product can be 
amplified. If the targeting construct integrates into the genome randomly, no 
PCR product can be synthesised because one primer site (RHAF) is located at 
the site of random integration of the targeting construct (in the zeo cassette), 
not within reach of the second primer annealing site (RHAR, anneals in BCL6 
locus) which was lost in the subcloning step, from p10kb-homology to 
p8.9kb-homology (Figure 3.3B).  
A positive control was designed to optimise PCR assay conditions and to 
ensure that a rare targeted event will not be missed due to insufficient 
sensitivity. The positive control construct mimicking successful targeting of 
BCL6 was derived from p10kb-homology (parental vector of p8.9kb-homology). 
A unique EcoRI restriction site in vector p10kb-homology (3’ of the genomic 
SbfI site, therefore located in the right arm of homology after insertion of the zeo 
cassette) was deleted by digestion with EcoRI, end-filling and re-ligation. The 
resulting construct (p10kb-homology-EcoRI) was modified by insertion of the zeo 
cassette into its SbfI site, as for pTarg-BCL6, resulting in p10kb-homology-
EcoRI/Zeo. This construct mimics targeted gene disruption and serves as a 
positive control in the PCR assay because it contains both primer annealing 
sites. Both, constructp10kb-homology-EcoRI/Zeo and a BCL6 allele disrupted by 
pTarg-BCL6, can give rise to a 5.3 kb PCR product amplified by primer set 
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RHAF and RHAR, but only the PCR product of the latter can be cut by EcoRI 
(Figure 3.3A+C). This is important because p10kb-homology-EcoRI/Zeo can 
potentially contaminate other samples during PCR screening and give rise to 
false positive PCR signals. 
  
  
Figure 3.3: PCR Assay ‘Right Homology’
A) Targeting of the BCL6
‘Right-Homology-Assay’ (RHAF and RHAR) 
amplified. The resulting PCR product is cleavable by 
synthesised if the targeting construct (pTarg
(black double line). pTarg
(RHAR). C) Vector p10kb
(RHAF+RHAR) and can give rise to a 5.3
resistant to cleavage by 
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3.2.3 Optimisation of PCR assay ‘Right-Homology’ and screening 
for successful targeting of the BCL6 locus 
The sensitivity of PCR assay ‘Right-Homology’ was determined in order to 
screen a large number of clones for targeted disruption of BCL6. For this 
purpose DG75-354 cells were stably transfected with p10kb-homology-EcoRI/Zeo 
and a single clone was isolated by plating transfected cells at limiting dilution. It 
was found that a robust PCR signal could be detected when 104 cells were 
used as a template (data not shown) and this number was subsequently used 
to screen pTarg-BCL6-transfected,zeo resistant colonies (see also section 2.5.3 
p.61). 
Five zeo resistant clones isolated after transfection of DG75-354 with KpnI-
linearised pTarg-BCL6 were screened with the RHA, alongside positive (DG75-
354 cells stably transfected with p10kb-homology-EcoRI/Zeo) and negative 
(DG75-354 cells) controls. One clone was found to be positive and showed the 
expected 5.3 kb PCR product (Figure 3.4A). PCR products of the positive 
control and clone BA11 were gel extracted and digested with EcoRI and the 
digested products were visualised alongside the PCR products (Figure 3.4B). 
Only the PCR product derived from clone BA11 could be digested into the 
expected 3.6 kb and 1.7 kb fragments (see section 3.2.2 p.76 and Figure 3.4B). 
This confirmed successful disruption of the first BCL6 allele in clone BA11 and 
ruled out contamination with the positive control. It was planned to test more 
clones in order to estimate the relative gene targeting frequency for the BCL6 
locus in DG75; however, the PCR assay suddenly stopped working and could 
not be optimised (see discussion in section 3.3.1 below). A new PCR assay 
was therefore designed to screen more clones (see section 3.2.4). 
  
  
 
Figure 3.4: Screening 
assay 
A) Five pTarg-BCL6-transfected and 
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transfected DG75-354 cells served as negative control. B) PCR products from A were gel 
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3.2.4 Optimisation of PCR assay ‘Left-Homology’ and screening for 
successful targeting of the BCL6 locus 
A new PCR assay was designed to screen more clones for successful targeting 
of the BCL6 gene and to determine the targeting frequency that can be 
detected at this locus. The design of the new Left-Homology-Assay (LHA) is 
similar to the initial assay (RHA). The first primer, Left-Homology-Assay-R 
(LHAR) anneals to the zeo cassette and the second primer, Left-Homology-
Assay-F (LHAF), anneals outside the region of homology of pTarg-BCL6 but 
within the left arm of homology of constructs derived from p10kb-homology 
(Figure 3.5). Consequently, vector p10kb-homology-EcoRI/Zeo could again be 
used as positive control. I decided, however, not to use this construct as 
positive control because there was no way to differentiate between PCR 
products derived from p10kb-homology-EcoRI/Zeo and a successfully targeted 
clone (high risk of false positive PCR signals due to cross contamination). 
Instead, I chose to use successfully targeted clone BA11 (BCL6+/-(zeo)) 
(Figure 3.4) as positive control. 
The sensitivity of the LHA was determined with decreasing concentrations of 
BA11 cells and it was found that 104 cells generated a robust signal (data not 
shown). Thirteen pTarg-BCL6-transfected and zeo resistant clones were 
screened alongside positive and negative controls and five showed the 
expected 5.9 kb PCR product indicative for successfully targeting of the BCL6 
locus (Figure 3.5C). Another 26 clones were screened with this assay out of 
which 7 were found to be positive (data not shown).In summary, out of 44 zeo-
resistant clones screened by PCR assays (sections 3.2.3 and 3.2.4), 13 had 
knocked out one of their BCL6 alleles. This translated to a relative gene 
targeting frequency of 30 % (percentage of targeted over random integration). 
 
 Figure 3.5: PCR Assay ‘Left Homology’ 
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3.2.5 Screening for targeting of the BCL6 locus by Southern blotting 
After targeting of the first BCL6 allele was confirmed for 13 out of 44 pTarg-
BCL6-transfected and zeo resistant clones by PCR assays, 7 out of these 13 
clones were expanded and tested for disruption of theBCL6locus by Southern 
blotting (see Figure A p.208 for an overview of all important clones generated in 
this project). Six out of 7 clones analysed by Southern blotting had successfully 
disrupted one of their BCL6 alleles. Figure 3.6 shows the Southern blotting 
results for the targeted clone BA11 (BCL6+/-(zeo)). 
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Figure 3.6: Analysis of the BCL6 locus structure after gene targeting 
SphI-digested genomic DNA of DG75-354 (BCL6+/+) and BA11 (BCL6+/-(zeo)) was probed 
with 2 probes. Both probes were excised from vector p10kb-homology (see section 3.2.1); 
probe A is a 345 bp KpnI/ApaI-fragment and probe B a 730 bp EagI/SacII-fragment. The BCL6 
wildtype allele yields an 11.8 kb SphI fragment when detected with either probe A or B. DG75-
354 has two wildtype BCL6 alleles (BCL6+/+). A targeted allele is detected as a 7.9 kb band 
when detected with probe A and a 5.1 kb band when detected with probe B. Clone BA11 carries 
a wildtype BCL6 allele detected as an 11.8 kb fragment by probes A and B, as well as a 
targeted BCL6 allele detected as a 7.9 kb band with probe A and a 5.1 kb band with probe B 
(BCL6+/-(zeo)). See Figure 3.1 (p.73) for a graphic representation of this assay design and 
section 2.6 (p.63) for methodology. 
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3.2.6 Cre-mediated deletion of the zeocin resistance cassette 
Cre-recombination after targeting of the first BCL6 allele leaves the first BCL6 
allele disrupted and allows the targeting vector pTarg-BCL6 to be reused for 
targeting of the second BCL6 allele. Cre recombination will be detectable by 
Southern blotting and clones will have lost their zeo-resistance. In addition, a 
quick PCR assay was designed to screen for this event (Figure 3.7). In this 
PCR assay, primers flanking the zeo cassette can amplify three differently-sized 
PCR products. The wildtype BCL6 allele gives rise to a 722 bp product that is 
resistant to cleavage by SphI (Figure 3.7A), while a targeted BCL6 allele (that 
contains the zeo cassette) will result in a 1967 bp product (Figure 3.7B). A 
BCL6 allele that was targeted by homologous recombination and modified by 
Cre-recombinase will produce a773 bp PCR product that can be cleaved into 
two fragments of 543 and 230 bp by SphI (Figure 3.7C). After transient 
transfection of clone BA11 (BCL6+/-(zeo)) with pMC-Cre (Gu et al., 1993) (see 
section 2.3.4 p.51), cells were plated at limiting dilution and 53 clones were 
tested for deletion of the zeo resistance cassette by PCR assay (Figure 3.7A-
D). Two out of these 53 clones were found to have deleted the zeo cassette 
and died in zeocin (clones 4G12 and 7D4, BCL6+/-, see also Figure A p.208). 
Figure 3.7D shows the PCR assay screen of clone 4G12. 
  
Figure 3.7: PCR assay ‘Cre
A) Cre-assay primers (see section 
product from a wildtype allele
C) A 773 bp PCR product is amplified from a 
mediated recombination
bp). D) BA11 cells (BCL6+/
isolated by plating at limiting dilution
BCL6 wildtype allele gives rise to a 722 bp PCR product, resistant to 
gel extraction (DG75-
recombination yields a 773 bp PCR product cleavable into 543 and 230 bp by 
BCL6+/-).  
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3.3 Discussion 
3.3.1 Disruption of the first BCL6 allele 
Gene targeting frequencies by homologous recombination are generally 
extremely low in mammalian cells, therefore, PCR-based methods are often 
used to screen for this event. For such a PCR assay, one primer is chosen that 
anneals to a region unique to the targeting vector and a second primer that 
anneals to the genomic DNA sequence of the target locus (Kim and Smithies, 
1988). In theory, this primer pair will only generate a PCR product, if the 
targeting vector has integrated in the desires genomic region. In the event of 
random integration of the targeting construct, no PCR product should be 
amplified. In practice, however, PCRs are very susceptible to contamination 
(especially when positive controls are used) and false positives can also arise 
due to non-specific primer annealing or artefacts (Frohman and Martin, 1990). 
For these reasons, gene targeting of clones identified by PCR screens should 
be confirmed by Southern blotting.  
PCR assay RHA (Figure 3.3) detected one targeted clone in 5 (Figure 3.4A) 
and it was confirmed by restriction enzyme digestion that the generated PCR 
product did not arise from the positive control vector used (Figure 3.4B). After 
the initial PCR screen, the assay stopped working and several attempts to 
reproduce the results, failed. PCR reactions produced smeary products 
between 5 kb and 500 bp (data not shown). All reagents were exchanged and 
the procedure was closely monitored for variations in sample processing. It was 
found that the smeary background appeared at high cycle numbers (>30) but 
the cycle number could not be reduced because the signal could not be 
detected at lower cycle numbers. The problem also occurred without any 
template, pointing towards a primer problem. I aimed to design new primers, 
however, this proved difficult as the locus contains many repetitive sequences 
(see also section 3.2.1). In order to design alternative primers I would have had 
to amplify a much larger PCR product (greater than 7 kb) which I did not 
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consider sensible. The RHA PCR assay required 40 PCR cycles at an 
extension time of 6 minutes greatly challenging Taq DNA polymerase; therefore 
adapting the extension time to an even larger PCR product was no favourable 
option. I tried to add fresh PCR reagents after 25 cycles but this too did not 
work. However, a new PCR assay designed (LHA) did not show any 
complications at high cycle numbers and was subsequently used to screen a 
larger number of clones. Overall, 44 clones were screened for integration of 
pTarg-BCL6 into the BCL6 locus by PCR assays out of which 13 were found 
positive (see also Figure A p.208). 
Seven clones found positive for gene targeting by PCR assays were further 
analysed by Southern blotting and six were found to contain the expected 
genomic modifications in the BCL6 locus (data only shown for clone BA11 in 
Figure 3.6). This points towards an unusually high gene targeting frequency in 
DG75 which is in accordance with the literature, with frequencies up to 69% 
being reported (Feederle et al., 2004). Gene targeting frequencies are, 
nevertheless, strongly locus-dependent, as frequencies as low as 5% were 
observed for a different locus in DG75 (Maier et al., 2005). Overall, however, 
frequencies reported for DG75 are extraordinarily high as frequencies in other B 
cell lines only reach 1-2% (Faili et al., 2002, Grawunder et al., 1998) or 11 % in 
the special case of Nalm-6 (Adachi et al., 2006).  
As already mentioned by others (Feederle et al., 2004), DG75 is in many ways 
comparable to the chicken B cell line DT40, which been used extensively for 
knockout studies of both lineage-specific and non-lineage specific genes 
(Buerstedde and Takeda, 1991). DG75 and DT40 cell lines are similar because 
they both are of B cell lineage, support efficient homologous recombination and 
have a c-Myc translocation(Chang and Delany, 2004). DG75, however, has 
many advantages over DT40 regarding the functional analysis of human genes. 
Firstly, DT40 is an avian cell line and chickens have a different immune system 
to that of human. Chickens do not diversify their antibody repertoire by SHM but 
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gene conversion (Reynaud et al., 1994). Moreover, while human antibody 
maturation takes place in GCs, in chickens, antibody maturation takes place in 
the Bursa of Fabricius, a specialised organ located on the dorsal wall of the 
cloaca. Secondly, DG75 is karyotypically very stable, while DT40 has many 
cytogenetic abnormalities. The karyotypes of DT40 cell lines from different labs 
often vary due to its genetic instability. In addition to its c-Myc translocation 
t(8;14), a trisomy of chromosome 2, monosomy of chromosome 4 and a variant 
4p have been reported for DT40 (Riley and Gordon, 1992). Although DG75 has 
a mismatch repair deficiency (Msh2-) (Brimmell et al., 1998), its karyotype is 
very stable, even after long periods in culture. The DG75 derivative DG75-354 
used in this project has an additional t(1;3)(p35?;q21) translocation (as tested 
by Valeria AS De Melo and Dr Alistair G Reid, Cytogenetics Laboratory, 
Hammersmith Hospital, London).  
3.3.2 Cre-mediated deletion of the zeocin resistance cassette 
The Cre/Lox recombination system is a very powerful tool in genetic 
modifications in vitro and in vivo. Cre recombinase interacts with specific loxP 
binding sites and deletes the sequence between them (Sternberg and Hamilton, 
1981). LoxP sites consist of 13 bp inverted repeat sequences and an 8 bp 
asymmetric core which ensures directionality of recombination (Hoess and 
Abremski, 1985). By flanking a selectable marker of a targeting construct with 
loxP sites, the marker can be ‘recycled’ and the targeting construct can be 
reused for the knockout of the second allele. The concept of marker recycling 
has been proposed previously (Abuin and Bradley, 1996) and is an elegant way 
that simplifies gene targeting designs. After targeting of the first BCL6 allele 
(see CHAPTER 3), clone BA11 (BCL6+/-(zeo)) was transiently transfected with 
pMC-Cre (Gu et al., 1993) and clones were isolated by plating at limiting 
dilution. Out of 53 clones tested, only 2 were found to have lost their zeo 
resistance and it was confirmed by PCR assay that Cre-recombination at the 
targeted BCL6 locus had taken place (resulting in BCL6+/-) (Figure 3.7D) (see 
also Figure A p.208). The Cre-recombination efficiency observed in this project 
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seems rather low, as the efficiency of Cre-recombination between two loxP 
sites reaches almost 100% in vivo (Hennet et al., 1995, Kuhn et al., 1995), 
therefore efficiencies in cell culture systems should depend mostly on 
transfection efficiency. In DG75-354, typically 60-80 % of the transfected and 
viable population express the transgene (Figure 4.2C); therefore the low Cre 
recombination efficiency observed after nucleofection with pMC-Cre is likely to 
be caused by other reasons. This finding will be discussed in more detail in 
section 5.3.3 below. 
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CHAPTER 4 - Conditional Bcl6 
expression in DG75-354 
4.1 Introduction 
Before the second endogenous BCL6 allele could be disrupted, a tetracycline 
(tet)-regulatable Bcl6 expression had to be introduced into BCL6+/- cells. This 
conditional Bcl6 expression was established with the Tet-Off system (Gossen 
and Bujard, 2002) which has been previously used in our laboratory (Carpenter 
and Porter, 2004, Sullivan et al., 2001). The Tet-Off system employs the 
tetracycline transactivator (tTA), which, in the absence of tetracycline, binds to a 
tet-response element (TRE) in the promoter region of the gene of interest and 
thereby promotes transcription by RNA polymerase II. In the presence of 
tetracycline (or doxycycline (dox)), the tTA is released from the promoter region 
and transcription ceases (Figure 4.1). 
  
  
Figure 4.1: The Tet-Off system
The tetracycline transactivator (tTA) is expressed from a constitutive promoter and induces 
transcription of the gene of interest (GOI) by 
(TRP). Binding of tetracycline (tet)
dissociation from the TRP and transcription ceases.
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4.2 Results 
4.2.1 Validation of DG75-354 as a suitable system for conditional 
gene regulation 
The Tet-Off system relies on a tTA, which in the absence of tetracycline (or 
doxycycline), binds to the tetracycline responsive promoter of the gene of 
interest and activates its transcription. DG75-354 is a DG75-derivative, which 
stably expresses the tet- transactivator and was kindly supplied by Dr B. 
Henglein (Institut Curie, Paris). To generate DG75-354, DG75 was stably 
transfected with a derivative of pUHD15-1 (Gossen and Bujard, 1992), which 
expresses the tTA, as well as a puromycin resistance gene. In order to test the 
potency of tet-regulation in this cell line, DG75-354 was nucleofected with a tet-
regulated green fluorescent protein (GFP) construct, pTARG4 (Brough et al., 
2007) and subsequently cultured with or without tetracycline. Figure 4.2 shows 
that good tet-regulation can be achieved in this cell line. In the absence of 
tetracycline, over 70 % of pTARG4-transfected DG75-354 cells express GFP 
(Figure 4.2C). However, 18-48 hours after transfection with pTARG4 and 
addition of tetracycline, GFP expression is remarkably reduced to less than 3 % 
(Figure 4.2B). 
 
Figure 4.2: Transient tet
DG75-354 cells were grown up for transfection in the absence of tetracycline
flow cytometry 18 and 48 hrs
channel and percentages represent gated populations
details on flow cytometry. 
nucleofected with tet-regulated
medium supplemented with 
GFP (pTARG4 (Brough et al., 2007)
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A) Negative control cells were nucleofected without DNA. B) Cells were 
 GFP (pTARG4 (Brough et al., 2007)) 
tetracycline (1 µg/ml). C) Cells were nucleofected with tet
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4.2.2 Establishing stable tet-regulated Bcl6 expression in BCL6+/- 
cells 
Tetracycline-regulated Bcl6 was amplified and cloned from DG75 cDNA and 
tagged with the hemagglutinin (HA) peptide sequence YPYDVPDYA (see 
section 2.5.2 p.57). The 2,154 bp Bcl6-HA insert was introduced into the BamHI 
and HindIII sites of pTRE-tight (Clontech) and the resulting construct pTRE-
Bcl6-HA was sequenced with 4 sets of primers covering both DNA strands in 
order to validate that no mutations are present. 
A heterozygous BCL6 knockout BCL6+/-clone (7D4) was co-electroporated with 
pTRE-Bcl6-HA and pSV2-neo (Southern and Berg, 1982) (molar ration 10:1). 
The resulting G418-resistant clones were isolated by plating at limiting dilution 
and tested for tet-regulatable Bcl6-HA expression by Western blotting. Figure 
4.3 shows three clones that stably expressed Bcl6-HA from the pTRE-Bcl6-HA 
construct and this expression was stringently regulatable by tetracycline. No 
more protein was detected 24 hrs after the addition of tetracycline. Having 
established conditional Bcl6 expression in the heterozygous knockout clone 
(BCL6+/-;tetBCL6-HA), I moved on to target the second BCL6 allele.  
  
  
 
 
 
Figure 4.3: Stable and t
A) A number of clones were screened for tet
pattern of three typical clones in the absence and presence (72h) is shown. B
(BCL6+/-;tetBCL6-HA) 
anti-hemagglutinin antibody was used for detection
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4.3 Discussion 
4.3.1 Validation of DG75-354 as a suitable system for conditional 
gene regulation 
Conditional gene expression is popular in molecular biology and many systems 
are now available to achieve robust regulation and tet-dependent gene 
regulation is a widely used system (Gossen and Bujard, 2002). For the 
conditional BCL6 knockout project, it is important that gene regulation is tightly 
controlled and that complete depletion of Bcl6 protein is achieved. Figure 4.2 
shows that stringent transgene regulation is feasible in DG75-354 with less than 
1% of cells expressing GFP protein 48 hrs after transfection and addition of tet. 
It is likely that even tighter regulation can be achieved, when a clonal population 
is monitored for transgene regulation as it has been reported that tetracycline 
regulation occurs homogeneously on the single cell level of a clonal population 
(Fukagawa et al., 1999).  
4.3.2 Establishing stable tet-regulated Bcl6 expression in BCL6+/- 
cells 
A hemagglutinin (HA) tag was attached to the Bcl6 protein in order to be able to 
differentiate it from endogenous Bcl6 protein (Ledoux et al., 1996). Epitope tags 
are widely used in molecular biology studies because high affinity antibodies 
are available for their detection (Jarvik and Telmer, 1998). However, one has to 
take into account that the addition of such a tag may abolish or interfere with 
the function of the protein of interest. For this project, the influenza-
hemagglutinin peptide has been chosen because it has been extensively used 
in recombinant expression systems (Field et al., 1988). It is hoped that it does 
not interfere with Bcl6 function due to its small size.  
The characteristics of expression achieved in BCL6+/-;tetBCL6-HA clones are 
in accordance to expectations. The stringency of tet-regulation is known to be 
very tight for the system used and has already been confirmed in DG75-354 by 
CHAPTER 4 - Conditional Bcl6 expression in DG75-354 
98 
flow cytometry (Figure 4.2). The time it takes for all tet-regulated protein to 
disappear strongly depends on the specific half-life of the protein of interest 
which has been reported to be around 4-6 hrs in the case of Bcl6 (Niu et al., 
1998). It is therefore not surprising that complete Bcl6 protein depletion is 
observed 24 hrs after addition of tet.   
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CHAPTER 5 – Targeting of the 
second BCL6 allele 
5.1 Introduction 
I was hopeful that successful targeting of the second BCL6 allele could be 
achieved because it is generally believed that gene targeting efficiency is 
dependent on the genomic locus targeted and the quality of the targeting 
construct used. As the same genomic locus had been successfully targeted 
before and the same targeting construct was to be used (see CHAPTER 3 
above), similar gene targeting frequencies were expected. 
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5.2 Results 
5.2.1 Targeting of the second BCL6 allele 
For targeting of the second BCL6 allele, BCL6-/+;tetBCL6-HA cells (clone ∆H3) 
were cultured without tetracycline and transfected by electroporation with KpnI-
linearised pTarg-BCL6. Seventeen zeocin-resistant clones were isolated and 
screened by PCR assay LHA (see Figure 3.5 p.82), in which one primer is 
located in the resistance cassette of pTarg-BCL6 and the second in the BCL6 
locus. The 5.9 kb PCR product can hence only be amplified if the targeting 
construct has integrated into the BCL6 locus. A typical result of such a screen is 
shown in Figure 5.1A. Out of 17 clones screened, 4 were found to have 
integrated the targeting vector into the BCL6 locus (approximately 24%) (see 
also Figure A p.208). Due to the fact that I used a marker recycling gene 
targeting approach, such clones could have either re-targeted the already 
targeted BCL6 allele, or have disrupted the second allele. I therefore performed 
an additional PCR assay to distinguish between these two events (Figure 5.1B) 
and a typical result of the screen is shown in Figure 5.1B. It was found that 
three out of four clones tested had targeted the second BCL6 allele (clones 
2D7, 5D7, 6D1), and only one (clone 5D6) had retargeted the first allele. 
Following this initial PCR screen, the results obtained were confirmed by 
Southern blotting. 
 
Figure 5.1: PCR screens 
A) In PCR assay ‘Left Homology’ 
targeting construct and one primer is located in the 
targeted disruption of the 
were transfected with pTarg
PCR screen is shown, clones
disrupted a BCL6 allele.
targeting of the first BCL6
primers used for this screen
product for a targeted 
(543 + 230 bp) by Sph
existence of the 543 bp band after cleavage of the PCR product with 
BCL6 allele was not retargeted. 
in A). Clones 2D7, 5D7 and 6D1
the PCR product with 
5D6 re-targeted the first 
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detect targeting of the second BCL6 allele
one primer anneals within the zeocin disruption cassette of the 
BCL6 locus - a 5.9 kb PCR product 
BCL6 allele (Figure 3.5 p.82). BCL6+/-;tetBCL6
-BCL6 and screened by LHA PCR assay. 
 2D7, 5D6, 5D7 and 6D1 (very weak signal)
 B) The ‘Cre-recombination’ PCR assay can differentiate between re
 allele and gene targeting of the second allele
 amplify a 722 bp product for a wildtype BCL6
BCL6 allele and a 773 bp product that is cleavable into two fragments 
I for a targeted BCL6 allele that has undergone Cre recombination. The 
Sph
‘Cre recombination’ PCR assay results for clones found positi
 (very weak) show the desired 543 bp band after digestion of 
SphI. Hence three clones targeted the second 
BCL6 allele.  
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Southern blotting was performed to confirm that only a single integration of the 
targeting vector had occurred, and that this integration had occurred at the 
BCL6 locus. In order to demonstrate that only one integration of the construct 
had occurred, I chose a hybridisation probe specific for the targeting vector. The 
1218 bp probe used for this purpose is the zeocin resistance gene, which was 
excised from vector pCMV/Zeo using restriction enzymes XhoI and EcoRI. 
Figure 5.2A shows the resulting Southern blot. As expected; only the clones 
that contain the zeocin disruption cassette in one of their BCL6 alleles show the 
predicted 7.9 kb SphI fragment recognised by the zeocin probe (Figure 3.1 
p.73).The hybridisation site of the zeocin probe is located on a 6.3 kb SphI-KpnI 
fragment; KpnI was used for linearisation of the targeting vector and SphI was 
used for digestion of genomic DNA prior to Southern blotting. Therefore any 
additional integration of the targeting construct elsewhere in the genome would 
be detected as an additional band recognised by the zeocin probe that is equal 
to or greater than 6.3 kb. 
In addition to confirming that only one integration of the cassette had occurred 
in each targeted clone, I also intended to demonstrate that the targeting 
construct had disrupted the correct i.e. the BCL6 locus. In order to show this, I 
re-probed the same blot (Figure 5.2A) with a probe that hybridises to the BCL6 
locus but is not part of the targeting vector (probe B see also Figure 3.1 p.73). 
Figure 5.2B shows the resulting Southern blot confirming that all three clones 
tested (2D7, 5D7 and 6D1) successfully disrupted both endogenous BCL6 
alleles and also that only a single copy of the tet-regulated Bcl6-expression had 
integrated into their genome. 
 
 Figure 5.2: Southern b
transfectedcells and targeting of the second 
A) SphI-digested genomic DNA of control and knockout clones was probed with a 
probe. Targeting of a BCL6
see Figure 3.1 p.73). A second random integration of the targeting vector would result in an 
additional band detected that is 
in A) was re-probed with probe B which detects an 11.8 kb 
and a 5.1 kb fragment for a targeted 
the zeocin probe (as in A).
coding region of Bcl6 and thus part of the vector pTRE
heterozygous knockout clone
detected in clones 2D7, 5D7 and 6D1. 
hybridise to the tet-regulatable Bcl6 construct. The
slightly weaker than th
11.8 kb). All three clones
(Figure 4.3, clone ∆H3), which explains why the band is the same in all clones in
found. Moreover, this finding confirms that only one copy of the tet
has integrated. 
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5.2.2 Detection of an aberrant Bcl6 protein variant in BCL6+/-(zeo) 
and BCL6-/-(zeo);tetBCL6-HA cells 
In addition to confirming the disruption of both BCL6 alleles by Southern 
blotting, Western blot analysis was performed to verify that complete Bcl6 
protein depletion has been achieved in BCL6-/-(zeo);tetBCL6-HA clones. 
Unexpectedly, an antibody raised against the N-terminal two thirds of Bcl6 
(Santa Cruz, see Table 5 p.65) detects an additional protein of approximately 
80-85 kDa in BCL6-/-(zeo);tetBCL6-HA clones which is absent in parental cells 
(DG75-354; BCL6+/+) (Figure 5.3A). It is likely that the protein originated from 
the endogenous BCL6 allele rather than the exogenous Bcl6 expression, as it is 
neither tet-regulatable (Figure 5.3A) nor detected with an antibody recognising 
the HA tag (Figure 4.3 p.96). In order to determine the origin of the additional 
Bcl6 protein variant, all clones generated during the construction of the 
conditional knockout clone were probed with a Bcl6 antibody raised against a 
peptide located at the carboxy terminus of Bcl6 (Cell Signalling, see Table 5 
p.65). This antibody also detects a Bcl6 variant protein of approximately 80-
85 kDa in all clones carrying a zeocin cassette in their BCL6 locus (Figure 
5.3B). 
  
  
Figure 5.3: Bcl6 protein expression of targeted clones
A) Bcl6 protein (MW 92
conditional knockout cells (
tetracycline. Bcl6 is switched off after culturing conditional
µg/ml) for 24 hours. A 
an additional protein of approximately 80
Signaling anti-Bcl6 antibody 
of 80-85 kDa for the heterozygous 
(zeo); clone BA11) and homozygous 
2D7 (#1) and 5D7 (#2)
BCL6+/+) or heterozygous knockout clones in which the 
(BCL6+/-;tetBCL6-HA, clones 
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There is the possibility that the cytomegalovirus (CMV) promoter or an 
enhancer element in the zeocin cassette activates transcription of the BCL6 
locus, downstream of the site disrupted by gene targeting. As the BCL6 allele 
was disrupted at the end of exon 3 (see Figure 3.1 p.73), such an aberrant 
transcript would lack the first coding exon of Bcl6 (exon 3) but translation could 
potentially be initiated from an alternative downstream start codon within a 
subsequent exon, thus generating an N-terminally truncated Bcl6 variant 
protein. 
With the aim of exploring the possibility that an N-terminally truncated Bcl6 
version is generated, the Bcl6 protein coding nucleotide sequence was 
screened for alternative start codons. It transpired that the Bcl6 coding 
sequence contains 38 ATG codons including 18 alternative in-frame start 
codons which could potentially generate N-terminally truncated Bcl6 proteins. 
Figure 5.4A shows the Bcl6 amino acid sequence with all in-frame start codons 
highlighted, the potential truncated Bcl6 proteins and their predicted molecular 
weights are listed in Figure 5.4B.  
In order to speculate which of these in-frame start codons is likely being used 
by cells that carry the zeocin cassette in one of their BCL6 alleles, it has to be 
taken into account that the Bcl6 wildtype protein does not run at its predicted 
molecular weight when analysed on Tris-Glycine acrylamide gels (Onizuka et 
al., 1995). The predicted molecular weight of Bcl6 is 79 kDa but its apparent 
molecular weight is 92-98 kDa. This difference is attributed to its high degree of 
phosphorylation and its amino acid composition. When dephosphorylated, Bcl6 
protein runs as a single band of 87 kDa, suggesting that differential 
phosphorylation accounts for a difference of 5-11 kDa (Onizuka et al., 1995). 
The remaining difference of 8 kDa (87 kDa dephosphorylated Bcl6 versus 79 
kDa predicted MW), is attributed to the high proline content of Bcl6, affecting its 
electrophoretic mobility (Onizuka et al., 1995). Taking this into account, an N-
terminally truncated version of Bcl6 with an apparent molecular weight of 80-85 
CHAPTER 5 – Targeting of the second BCL6 allele 
107 
kDa would correspond to a predicted molecular weight of around 66/67 kDa. 
The first alternative start codon is located in exon 3 (codon position 51, Figure 
5.4), however, translation from this site would terminate after only 5 amino acids 
due to a premature stop codon generated by the targeted disruption of the 
BCL6 gene (see Figure 3.2 p.75). Therefore an alternative start codon 
downstream of exon 3 would have to be used. The first alternative start codon 
in exon 4 lacks the first 89 amino acids of Bcl6 and thus lacks a major part of 
the Bcl6 POZ domain (aa 1-121) and an important charged pocket which is 
viewed as being essential for co-repressor interaction (Melnick et al., 2002). 
Moreover, a mutagenesis study revealed that the deletion of part of the POZ 
domain of PLZF (corresponding to Bcl6 residues 1-54) disabled PLZF 
dimerisation and the protein almost completely lost its ability to repress 
transcription (Melnick et al., 2000). Because the POZ domains of PLZF and 
Bcl6 are highly similar, a Bcl6 protein that lacked the first 89 amino acids would 
most likely be non-functional. However, in order to rule out that any residual 
function of the truncated Bcl6 variant interfered with the conditional knockout 
phenotype, I aimed to delete the zeocin cassette from the second targeted 
BCL6 allele by Cre recombination. 
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Figure 5.4: Alternative start codons in the Bcl6 coding sequence and potential Bcl6 
truncations 
A) The open reading frame of Bcl6 codes 706 amino acids. Alternative in-frame translation start 
sites (methionine (M)) are highlighted in yellow. B) List of potential N-terminally truncated Bcl6 
variants translated from alternative in-frame start codons highlighted in A) and predicted 
molecular weights. 
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5.2.3 Cre-mediated deletion of the zeocin cassette in BCL6-/-
(zeo);tetBCL6-HA cells 
Given that the truncated Bcl6 protein appears to be expressed only when the 
zeocin cassette is present in exon 3 of BCL6 (Figure 5.3B), it was attempted to 
remove the cassette by Cre recombination in BCL6-/-(zeo);tetBCL6-HA cells. 
The efficiency of Cre recombination was expected to be low (see section 3.3.2 
p.89), as only 2 out of 53 clones were found to have removed the cassette 
when it was attempted to excise it from the first BCL6 allele targeted. The PCR 
screen that tests for Cre recombination at the second BCL6 allele used a 
forward primer specific for the zeo cassette and a reverse primer that anneals in 
the BCL6 locus further downstream. These primers amplify a 925 bp region of a 
BCL6 allele that has been disrupted by the zeo resistance cassette (Figure 
5.5A) but cannot generate a product once successful Cre recombination has 
taken place (Figure 5.5B). 
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Figure 5.5: PCR assay screen to identify Cre recombination of the second BCL6 allele 
A) A BCL6 allele that is disrupted by the zeo resistance cassette in exon 3 gives rise to 
amplification of a 925 bp PCR product. The forward primer (Right-Homology-F see sections 
3.2.2 and 3.2.3) anneals to the zeo cassette and the reverse primer (Cre-R section 3.2.6) 
anneals to the intronic region downstream of exon 3 of BCL6. B) PCR primers cannot amplify a 
PCR product from a targeted BCL6 allele that has been subjected to Cre recombination.  
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Using this PCR assay (Figure 5.5), I screened 410 clones isolated after 
nucleofection of BCL6-/-(zeo);tetBCL6-HA cells with pMC-Cre in the absence of 
tetracycline. These 410 clones were derived from 3 independent nucleofections 
of clones 2D7 and 5D7 and I could not detect a single clone that had 
successfully deleted the zeo resistance cassette. In order to account for the 
possibility that deletion of the zeo cassette, and associated loss of the Bcl6 
variant protein, conferred a disadvantage to cell proliferation, I paid special 
attention to clones that took longer than average to grow up. Because PCR 
screening for loss of a PCR signal is particularly susceptible to cross 
contamination, I also tested clones for their ability to survive in zeocin following 
screening by PCR, however, without success. This led to the idea that the 
desired clones may not be viable because they depend on the truncated protein 
for survival and that its loss may not be adequately compensated for by the tet-
regulated Bcl6 copy introduced earlier (see section 4.2.2 p.95). In order to test 
this idea and rule out any technical problem associated with Cre recombination, 
I aimed to demonstrate that Cre recombination does take place at the BCL6 
locus shortly after nucleofection with the Cre-expression construct (pMC-Cre). 
In order to demonstrate that Cre recombination does occur at the BCL6 locus, I 
developed a PCR assay that can detect the Cre-recombination product shortly 
after nucleofection with Cre recombinase. In this assay, two primers anneal to 
the zeo cassette but face away from each other and can therefore only amplify 
a product after circularisation of the zeo cassette by Cre-recombination (Figure 
5.6). Using this assay, successful Cre recombination of the BCL6 allele can be 
detected shortly after transfection, even though the clones may not be viable 
enough to proliferate and grow up after the genetic manipulation. The circular 
zeo cassette (pop-out intermediate)could be detected when whole cell lysates 
of clones containing the floxed zeo resistance cassette were incubated with Cre 
recombinase in vitro, proving that the locus is capable of undergoing efficient 
Cre recombination. However, no PCR signal could be detected after transient 
nucleofection of BCL6-/-(zeo);tetBCL6-HA cells with pMC-Cre (data not shown). 
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I concluded that the event either did not occur at all, or that it occurred at a too 
low frequency to be detected by the PCR assay. As other lab members had 
successfully used the same pMC-Cre construct and plasmid preparation for Cre 
recombination in different cell lines, a defect in the plasmid itself was 
considered unlikely. This left the possibility that transient expression of Cre-
recombinase from this vector was too inefficient in my cell line. Dr Timothy Ley 
and his colleagues (Washington University, St Louis, USA) made the 
observation that Cre recombination after transient transfection of embryonic 
stem cells with pMC-Cre is very inefficient (1-2%). Consequently, the group 
cloned a Cre-expression vector, which was capable of increasing the efficiency 
of Cre recombination to 50 % in mouse embryonic stem cells. The improved 
vector is derived from pCAGGS (Niwa et al., 1991) in which the gene of interest 
is expressed from a chicken β-actin promoter supported by an upstream CMV 
enhancer. The group inserted a Cre recombinase modified with an N-terminal 
NLS into pCAGGS, resulting in vector pTurbo-Cre (Westervelt et al., 2003). 
When nucleofection of the BCL6-/-(zeo);tetBCL6-HA clone was repeated with 
this improved Cre expression vector, the circular pop-out intermediate could be 
detected 18 hrs after transfection (Figure 5.6B).  
 
 
Figure 5.6: PCR assay for monitoring Cre recombination
BCL6 locus 
A) During Cre recombinati
single loxP site in the recombined locus and a 
Primers cannot amplify a PCR product from the un
pointing in opposite directions. The
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Having established that deletion of the zeo cassette from exon 3 of the BCL6 
locus is possible when the improved Cre-expression construct pTurbo-Cre is 
used (Figure 5.6B), I next isolated clones from BCL6-/-(zeo);tetBCL6-HA cells 
(clone 5D7) nucleofected with pTurbo-Cre in the absence of tetracycline. Out of 
84 clones screened, 3 were found to have successfully deleted the zeo 
cassette. Figure 5.7A shows an example PCR screen of nine clones, amongst 
them are the 3 clones that have deleted the resistance cassette: AB7, CD9 and 
FA8 (see also Figure A p.208). Moreover, all 3 clones died when cultured in the 
presence of zeocin.  
Following deletion of the zeo cassette, it remained to be shown that the 
truncated Bcl6 protein was no longer expressed in the BCL6-/-;tetBCL6-HA 
clones. Western blotting confirms that all 3 isolated clones completely switch off 
Bcl6 protein expression when cultured in doxycycline and that the truncated 
Bcl6 protein is almost completely absent (Figure 5.7B). Furthermore, Bcl6 
expression is still inducible in BCL6-/-;tetBcl6-HA cells (Figure 5.7C). The faint 
residual expression of the variant Bcl6 protein will be discussed further in 
section 5.3.3 below.  
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Figure 5.7: PCR screening forBCL6-/-;tetBCL6-HA clones and validation of loss of Bcl6 
protein by Western blotting 
A) BCL6-/-(zeo);tetBCL6-HAcells (clone 5D7) were transfected with pTurbo-Cre, single clones 
were isolated by plating at limiting dilution and screened for loss of the zeo cassette in the 
second BCL6 allele by PCR assay (Figure 5.5 p.110). Negative controls: lane 1 (no DNA) and 
3 (DG75-354, BCL6+/+); positive control: lane 2 (BCL6-/-(zeo);tetBCL6-HA, clone 5D7), clones 
screened: lanes 9 to 12. B) Detection of Bcl6 protein in BCL6 knockout clones. BCL6-/-
(zeo);tetBCL6-HA cells (clone 2D7 (#1) and clone 5D7 (#2)) were cultured in the absence of 
doxycycline (express Bcl6-HA). BCL6-/-;tetBCL6-HA clones (clones AB7 (#1), CD9 (#2), and 
FA8 (#3)) were cultured in doxycycline (1 µg/ml) for 3 days (no Bcl6-HA expression). The 
truncated Bcl6 protein detected in BCL6+/-(zeo)(clone BA11) and BCL6-/-(zeo);tetBCL6-HA 
clones (Figure 5.3) is almost completely absent in BCL6-/-;tetBCL6-HA cells. C) Bcl6 protein is 
still inducible in conditional BCL6 knockout cells. BCL6-/-;tetBcl6-HA cells (clone AB7) were 
cultured without doxycycline (-dox) or with doxycycline for 16, 48, or 96 hrs. Jurkat cells serve 
as a negative control for Bcl6 expression, DG75-354 cells (BCL6+/+) allow for comparison of 
Bcl6 protein expression between parental and conditional BCL6-/- cells. 
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5.3 Discussion 
5.3.1 Targeting of the second BCL6 allele 
Following successful targeting of the first BCL6 allele in CHAPTER 3, knockout 
of the second BCL6 allele was expected to be equally efficient. In fact, 4 out of 
17 zeo-resistant clones isolated were found to have undergone gene targeting 
integration after transfection with the BCL6-targeting construct. This relative 
gene targeting frequency of ~24% is similar to that observed for targeting of the 
first BCL6 allele (see section 3.3.1). However, an additional screen to determine 
which allele has been disrupted by the targeting vector was necessary because 
the same construct was used for targeting of the first and second BCL6 allele, 
and hence no selection against re-targeting of the first BCL6 allele exists. In 
theory, chances of retargeting of the first BCL6 allele and targeting of the 
second BCL6 allele are expected to be equal. In fact, out of four clones tested, 
three had successfully targeted the second BCL6 allele as confirmed by PCR 
screening and Southern blotting (Figure 5.1 and Figure 5.2) (see also Figure A 
p.208).  
5.3.2 Detection of an aberrant Bcl6 variant in BCL6+/-(zeo) and 
BCL6-/-(zeo);tetBCL6-HA cells 
An aberrant Bcl6 protein variant was detected in BCL6+/-(zeo) and BCL6-/-
(zeo);tetBCL6-HA cells by Western blotting (Figure 5.3) which coincided with 
the integration of the zeo resistance cassette into either of the two BCL6 alleles 
targeted. The occurrence of this aberrant protein was unexpected, as I 
predicted that any mRNA transcripts generated from a targeted BCL6 allele 
would be degraded by nonsense-mediated decay (NMD). NMD is a cellular 
control mechanism that prevents the expression of truncated or erroneous 
proteins through detection of premature termination codons (PTCs) in mRNAs. 
During mRNA splicing in the nucleus, a protein complex is deposited 20-24 
nucleotides upstream of exon-exon junctions (Le Hir et al., 2001). These exon 
junction complexes (EJCs) are displaced by the ribosome during translation 
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until a stop codon is reached. In aberrant transcripts, however, the ribosome 
reaches a PTC before all downstream EJC have been displaced and this will 
trigger NMD i.e. degradation of the non-functional mRNA (Chang et al., 2007). 
As the BCL6 gene was disrupted at the third out of ten exons, the PTC at the 
end of exon 3 (see Figure 3.2 p.75) should activate the NMD machinery and 
degradation of the non-functional BCL6 mRNA transcript. There is, however, 
the possibility that exon 3 is spliced out of the transcript or that a transcript 
starts downstream of exon 3, thereby bypassing recognition by the NMD 
pathway. In fact, the occurrence of the aberrant protein coincided with the 
presence of the zeo cassette in one of the BCL6 alleles (Figure 5.3B). It is 
therefore highly likely that the enhancer element of the zeo cassette activates a 
cryptic promoter downstream of exon 3 of BCL6. Such a cryptic promoter might 
express a Bcl6 transcript that starts downstream of the PTC engineered to 
disrupt the reading frame at the end of exon 3 and an alternative start codon in 
the Bcl6 ORF could be used to start translation (Figure 5.4). To identify such a 
transcript, 5’ RACE (rapid amplification of cDNA ends) could be performed. In 5’ 
RACE analysis, the 5’-untranslated region of a messenger RNA is amplified by 
PCR and subsequently sequenced (Scotto-Lavino et al., 2006). Once the 
5’UTR of such a message is known, this may help to predict the translational 
start site used to generate the truncated Bcl6 protein expressed. Although such 
analysis would be interesting, I decided to focus on the deletion of the zeocin 
from the BCL6 locus in order to eliminate the aberrant protein.  
5.3.3 Cre-mediated deletion of the zeocin cassette in BCL6-/-
(zeo);tetBCL6-HA cells 
Cre-mediated deletion of the zeo cassette in BCL6-/-(zeo);tetBCL6-HA cells 
was expected to be difficult because only 2 out of 53 clones could be isolated 
when the same genetic modification was performed on the first BCL6 allele 
targeted (see sections 3.2.6 and 3.3.2). When Cre-recombination was 
attempted on the second BCL6 allele targeted, 410 clones derived from 3 
independent transfections with pMC-Cre were screened for Cre recombination 
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and not one clone could be identified to have deleted the resistance cassette. 
Although other lab members had successfully used the same Cre-expression 
construct and plasmid preparation, there is the possibility that Cre-expression 
from pMC-Cre is less efficient in DG75. When reviewing the literature, I found 
an alternative Cre expression construct pTurbo-Cre (Westervelt et al., 2003). In 
this construct, Cre-recombinase is equipped with a nuclear localisation signal 
(NLS) and a CAG promoter drives its expression. In fact, an older study (Araki 
et al., 1997) compared Cre-recombination efficiency in mouse embryonic 
fibroblast cells using 4 different promoters. Amongst those promoters tested 
were the polyoma enhancer/herpes simplex virus thymidine kinase promoter 
(MC promoter; as in pMC-Cre) and the CAG promoter (as in pTurbo-Cre). The 
study reported a Cre-recombination frequency less than 0.3 % for the MC 
promoter and a frequency of up to 25 % for the CAG promoter (Araki et al., 
1997). When I used the CAG-driven Cre-expression construct I managed to 
isolate 3 out of 84 clones (Figure 5.7A) and although this frequency of ~4 % is 
far lower than what has been reported in the literature, it is sufficient when 
working with an immortalised cell line and potent screening assays are 
available. 
The deletion of the zeo resistance cassette generated a conditional BCL6 cell 
line (Figure 5.7C). Levels of Bcl6 protein expressed in parental cells are higher 
than in BCL6-/-;tetBcl6-HA cells cultured without doxycycline. Options to more 
closely match conditional Bcl6 protein levels to that of parental cells are 
discussed in section 6.3.3 below. Deletion of the zeo resistance cassette in this 
cell line almost completely eliminated the truncated Bcl6 protein variant (Figure 
5.7B) and any potential residual function of it that could interfere with the 
conditional BCL6 knockout phenotype. It is not entirely clear why a weak band 
is still detected. The only difference between a wildtype and the knockout BCL6 
allele is the presence of a loxP site at the end of exon 3. The possibility remains 
that the loxP site interferes with mRNA splicing thereby expressing a low 
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amount of the Bcl6 variant. However, as discussed in sections 5.2.2 and 5.3.2, 
such a protein is likely to be non-functional. 
Characterisation of the resulting conditional BCL6 knockout cell line (BCL6-/-
;tetBcl6-HA) was subsequently performed and the results are presented in the 
following chapters. 
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CHAPTER 6 - Characterisation of 
BCL6-/-;tetBCL6-HA cells 
6.1 Introduction 
On the grounds of the general acceptance that Bcl6 target genes are especially 
involved in cell cycle regulation and B cell differentiation (Shaffer et al., 2000),I 
focused particularly on these processes in the course of the characterisation of 
the BCL6-/-;tetBCL6-HA cell line. Nonetheless, for the reason that the 
conditional knockout cell line was derived from a cancer cell line, one has to 
bear in mind and carefully account for known pre-existing genetic abnormalities 
when interpreting the phenotype.  
Like many cancer cell lines, DG75 has accumulated genetic alterations in the 
cell cycle machinery, an overview of which is illustrated in Figure 6.1. Three 
aberrations of cell cycle regulators have to date been reported in DG75. Firstly, 
p53 is inactivated due to a mutation causing its exclusion from the nucleus and 
preventing induction of p53-dependent apoptosis (Brimmell et al., 1998, Crook 
et al., 1998). Secondly, DG75 has inactivated the cyclin-dependent kinase 
(CDK) inhibitor p16ink4a. p16ink4a inhibits the kinase activity of cyclin D-
CDK4/6 and can thereby induce cell cycle arrest in G1 (Serrano et al., 1993). 
p16ink4a is found to be inactivated by point mutations in the protein coding 
region, or by hypermethylation of its promoter in most BLs (Klangby et al., 
1998, Lindstrom and Wiman, 2002). In fact, treatment of DG75 with a 
demethylating agent revealed that the locus encoding p16ink4a is 
hypermethylated in DG75 (Poirier et al., 2001). Thirdly, DG75 cells have an 
altered cyclin D3 / p27kip1 expression pattern. Cyclin D1 and D2 are not 
expressed in GC B cells and cyclin D3 is essential for GC formation (Peled et 
al., 2010). Normal GC-B cells do not express any detectable p27kip1 protein, 
consistent with their high proliferative index. However, like many aggressive B 
cell lymphomas, DG75 expresses an unusually high amount of cyclin D3 along 
CHAPTER 6 – Characterisation of BCL6-/-;tetBCL6-HA cells 
121 
with detectable p27kip protein (Barnouin et al., 1999). p27kip1 in these cells, 
however, does not seem to restrict cell cycle progression, as p27kip1 is found 
to be almost exclusively bound and sequestered by overexpressed cyclin D3 
(Sanchez-Beato et al., 1999). 
One of the key characteristics of GC B cells is their extremely short doubling 
time in conjunction with the absence of detectable CDK inhibitor p27kip1 
protein (Quintanilla-Martinez et al., 1998, Sanchez-Beato et al., 1999). In fact, 
Bcl6 contributes to this phenotype by promoting proliferation of GC-B cells 
through suppression of transcription of the CDKN1B gene (encoding p27kip1 
protein). At the G1 to S phase transition, p27kip1 is a potent inhibitor of CDK2 
which, when in complex with cyclin E, promotes entry into S phase. p27kip1 
mRNA is downregulated in response to Bcl6 expression in cells without 
endogenous Bcl6, however, a direct regulation could not be demonstrated 
(Shaffer et al., 2000). A further cell cycle inhibitor gene known to be repressed 
by Bcl6 is CDKN1A (encoding p21cip1/waf1 protein). p21cip1/waf1 inhibits 
CDK4-cyclin D activity at the G1 to S phase transition and its transcription is 
induced upon p53 activation (Sherr and Roberts, 1999). Bcl6 represses 
transcription of CDKN1A through interaction with Miz-1 and this enables GC 
cells to sustain the elevated degree of DNA damage resulting from SHM and 
CSR (Phan et al., 2005). 
Besides inhibition of the negative cell cycle regulators p27kip1 and 
p21cip1/waf1, Bcl6 also appears to repress transcription of the positive cell 
cycle regulator cyclin D2. A Bcl6 binding site was identified in the CCND2 
promoter (encoding cyclin D2) and the functional interaction was confirmed by 
electrophoretic mobility shift assays as well as reporter gene assays (Shaffer et 
al., 2000). It is not clear why Bcl6 represses a gene that promotes cell cycle 
progression but an interesting suggestion is, that another D-type cyclin may be 
better suited for the rapid cell cycle progression of germinal centre cells (Dent 
et al., 2002).  
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Figure 6.1: Alterations the G1/S transition in DG75 
Mitogenic signalling increases expression of cyclin D, which complexes with CDK4 and CDK6. 
Cyclin D-CDK4/6 is bound by cip/kip inhibitors (p27kip, p21cip1/waf1, p57kip2) but it seems 
that this does not impair its kinase activity. Cyclin D alone can bind and thereby sequester 
p27kip1. Cyclin D-CDK4/6 complexes phosphorylate the retinoblastoma (Rb) protein, thereby 
leading to degradation of Rb and activation of transcription of E2F target genes. Amongst the 
E2F target genes are regulators of S phase progression and CCNE (encoding cyclin E protein). 
Cyclin E complexes with CDK2, the kinase activity of which is greatly inhibited by p27kip1. Only 
once cyclin D and D-CDK4/6 complexes have sequestered enough p27kip1 away from E-
CDK2, can E-CDK2 phosphorylate remaining Rb and mediate entry into S phase of the cell 
cycle. Three aberrations of the cell cycle machinery in DG75 have been documented in the 
literature and are marked in the above scheme by yellow bolts. 
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As outlined above, an activated B cell that enters into the GC reaction must 
apply important changes to its cell cycle regulation to adapt the GC B cell 
phenotype and also repress lineage inappropriate genes, i.e. B cell activation 
genes. Bcl6 contributes to this development through repression of the B cell 
activation genesCD69 and CD44 (Shaffer et al., 2000). CD69 and CD44 are 
early activation markers involved in migration of both B and T lymphocytes 
(Aruffo et al., 1990, Sanchez-Mateos et al., 1989). A Bcl6-binding site was 
identified in the promoter region of CD69 (Shaffer et al., 2000), its functional 
significance, however, has yet to be demonstrated. With regard to stabilisation 
of the GC-B cell phenotype, Bcl6 also prevents terminal plasma cell 
differentiation through suppression of PRDM1 gene that encodes Blimp-1, the 
master transcription factor regulating plasma cell differentiation (see section 1.3 
p.26) (Shaffer et al., 2002, Shaffer et al., 2000). The PRDM1 gene contains two 
Bcl6-binding sites, the functional importance of which has been demonstrated 
by chromatin immunoprecipitation (Parekh et al., 2007, Tunyaplin et al., 2004). 
When Bcl6 is downregulated towards the end of the GC reaction, suppression 
of PRDM1 released, so that Blimp-1 subsequently prompts plasma cell 
development.  
With Bcl6’s impact on cell cycle progression and differentiation in mind, I next 
asked how my BCL6-/-;tetBCL6-HA cells reacted, when depleted of Bcl6 
protein. 
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6.2 Results 
6.2.1 Bcl6-depletion causes morphological changes and reduced 
growth properties 
The response of BCL6-/-(zeo);tetBCL6-HA cells to Bcl6-depletion caused by 
the addition of doxycycline was followed for several days. Distinct 
morphological changes manifested approximately 3 days after switching off 
wildtype Bcl6 expression. Cells appeared slightly smaller, more granular and 
displayed irregular shapes and blebs (Figure 6.2). 
In addition to the morphological changes observed, BCL6-/-;tetBCL6-HA cells 
required much less frequent splitting when cultured in doxycycline. Growth 
curve analysis revealed that, while the addition of doxycycline to the culture 
medium had almost no effect on cell growth of parental cells (BCL6+/+, DG75-
354), all three conditional BCL6 knockout clones (BCL6-/-(zeo);tetBCL6-HA; 
AB7, CD9 and FA8) showed dramatically reduced growth in response to Bcl6-
depletion (Figure 6.3). Some evidence suggested that growth rates of Bcl6-
depleted cells increased slightly following an initial crisis within the first week 
after addition of doxycycline. Although this effect was difficult to confirm and 
quantify, it could potentially result from the accumulation of mutations in 
response to high selective pressure and will be discussed further in section 6.3 
below. I next tested whether the perceived overall reduction of cellular growth 
was caused by cell death (see section 6.2.2 below). 
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Figure 6.3: Growth characteristics of 
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6.2.2 Bcl6-depletion does not cause cell death 
The reduced cell size, membrane irregularities, enhanced granularity observed 
by phase contrast microscopy (Figure 6.2) and the dramatically reduced growth 
properties (Figure 6.3) suggested, that cells were dying when depleted of Bcl6 
protein. Annexin V / PI staining was performed in order to test for cell death; 
however, no increase in apoptotic or dead cells was detected (Figure 6.4). 
Moreover, no caspase 3 activation was detected by Western blotting in 
response to Bcl6 depletion (Figure 6.5). This is not entirely surprising as DG75 
cells have a defect in the p53-mediated apoptotic response (see sections 1.12 
p.46 and 6.1 above). 
In addition to apoptosis and necrosis, cells can utilise a third mode of cell death 
i.e. autophagy (Hotchkiss et al., 2009). Similarly to apoptosis, the induction of 
autophagy is also mediated by p53 (Levine and Abrams, 2008), however, the 
autophagic response has been reported to be mediated by cytoplasmic p53 
(Tasdemir et al., 2008) and should accordingly be functional in DG75. In order 
to investigate whether Bcl6-depletion activates autophagy in the conditional 
BCL6 knockout cell line, we performed electron microscopic analysis of the cell 
line, however, no phagophores (cytosolic smooth, ribosome-free double 
membrane cisternae) or autophagosomes (single membrane enclosing 
cytoplasmic structures) indicative of autophagy (Klionsky et al., 2008, Larsen 
and Sulzer, 2002) could be detected (Figure 6.6). To confirm these results, I 
also tested BCL6-/-;tetBCL6-HA cells for post-translational modification of the 
autophagy marker light chain 3B (LC3B) (Wu et al., 2006). During autophagy 
the 18 kDa LC3B-I isoform becomes lipidated and converted into the 16 kDa 
LC3B-II isoform (Kabeya et al., 2004). Figure 6.5 shows a low level of lipidated 
LC3B-II isoform in Bcl6-expressing BCL6-/-;tetBcl6-HA cell which appears to be 
induced when doxycycline is added and Bcl6 protein is downregulated. 
Although this upregulation of lipidated LC3B-II isoform in response to Bcl6-
depletion is not as strong as observed for the positive control (K562 cells), this 
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effect could potentially be studied further. After ruling out that the reduced 
growth rates observed (Figure 6.3) were caused by cell death, I concluded that 
Bcl6-depletion reduces the proliferative capacity and I performed DNA content 
analysis to monitor alterations in cell cycle progression. 
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Figure 6.4: BCL6-/-;tetBCL6
Annexin V / PI staining was performed on 
and on BCL6-/-;tetBCL6
doxycycline (1 µg/ml) over a time course of 5 days.
V and necrotic and dead cells stain positive for both Annexin V and PI.
for technical details. 
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Figure 6.5: No apoptosis or autophagy is observed in Bcl6
cells 
Detection of caspase 3 cleavage a
;tetBCL6-HA cells (clone CD9). Jurkat cells were treated with 10 µM etoposide (Sigma) for 
24 hrs were used as a positive control for caspase 3 activation. The antibody used detects full
length caspase-3 (35k Da) and the large fragment (17/19 kDa) generated after act
cleavage of caspase 3. K562 cells were treated with 25 µM chloroquine (CQ) (Sigma) and 0.25 
µM imatinib (IM) for 48 hrs as a positive control for LC3B activation 
354 cells (BCL6+/+) served as negative control. 
without (0) or with 1 µg/ml doxycycline for 1, 2, 3 and 5 days.
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Figure 6.6: Electron microscopic analysis of 
BCL6-/-;tetBCL6-HA cells (clone AB7) were cultured without (top) or with 1 
(bottom) for 5 days prior to electron microscopic analysis by Dr Shaun Willimott and Dr
Dinsdale (see section 2.3.3
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6.2.3 Bcl6-depletion causes accumulation of cells in G0/G1-phase of 
the cell cycle 
Aiming to elucidate the reason for reduced growth properties of Bcl6-depleted 
BCL6-/-;tetBCL6-HA cells (see section 6.2.1 above), I conducted cell cycle 
analysis by flow cytometry. DNA content analysis revealed, that Bcl6-depletion 
increases the percentage of cells in the G0/G1-phase of the cell cycle (see 
Figure 6.7). This could either be due to some of the cells exiting the cell cycle 
while others continued to proliferate or due to homogeneous prolongation of 
G0/G1-phase of all cells in the population. In order to investigate which of the 
two possibilities was causing the apparent growth retardation, I labelled cells 
with CFSE prior to Bcl6-depletion and followed their divisions by flow cytometry. 
Figure 6.8 shows that all CFSE-labelled populations proliferate homogeneously 
and that no non-dividing cell population is left behind. Having established that a 
key phenotype of the BCL6-/-;tetBCL6-HA cell line lies in their reduced 
proliferative capacity, I next set out to examine changes in expression of key 
regulators of cell cycle progression and differentiation (see section 6.2.4 
below). 
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Figure 6.8: Cell proliferation assay of Bcl6-depleted BCL6-/-;tetBCL6-HA cells 
BCL6+/+ (parental cells, DG75-354) or BCL6-/-;tetBCL6-HA(clone FA8) were labelled with 
CFSE and subsequently incubated without doxycycline or with 1 µg/ml doxycycline for 7 days. 
Cells were analysed by flow cytometry daily and overlay histograms of cells grown without 
(black) or with doxycycline (red) were produced. Numbers in histograms show corresponding 
mean fluorescence intensities (see section 2.3.6 p.52 for further details). 
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6.2.4 Influence of Bcl6-depletion on Bcl6-target genes and 
regulators of proliferation and differentiation 
Flow cytometry (Figure 6.9 and Figure 6.10), Western blotting (Figure 6.11 and 
Figure 6.12) and semiquantitative (sq) RT-PCR analysis (Figure 6.13) were 
applied to test for changes in expression of known Bcl6 target genes and key 
regulators of differentiation and cell cycle progression.  
Bcl6 represses genes involved in B cell activation and a Bcl6 binding site has 
been detected in the promoter region of the CD69 gene (Shaffer et al., 2000). 
CD69 is a cell surface marker and a change in expression can therefore be 
monitored by flow cytometry. Figure 6.9 shows that little if any CD69 expression 
is induced upon depletion of Bcl6 in response to addition of doxycycline. 
Further to inhibiting genes involved in earlier B cell development, Bcl6 also 
suppresses terminal B cell differentiation through inhibition of thePRDM1 gene 
encoding Blimp-1 (Shaffer et al., 2000). However, neither induction of Blimp-1 
mRNA nor protein could be detected in response to Bcl6-depletion (Figure 6.11 
and Figure 6.13). I moreover observed an increase in Pax5 mRNA expression, 
the expression of which is expected to be downregulated once Blimp-1 
expression is induced (Figure 6.13).  
CSR of BCL6-/-;tetBCL6-HA cells would be detected as complete loss of IgM-
expression of some or all cells of the population. However, this effect was not 
observed in response to Bcl6-depletion, indicating that no progression towards 
terminal B cell differentiation is taking place (Figure 6.10). There is some 
evidence, however, that IgM-expression is slightly decreased in response to 
Bcl6-depletion in BCL6-/-;tetBCL6-HA cells and this could potentially be studied 
further (Figure 6.10).  
When I focused on gene expression changes of key regulators of cell cycle 
regulation in response to Bcl6-depletion, I found no changes in expression of c-
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Myc (Western blotting and sq RT-PCR), p15ink4B (Western blotting), CDK4/6 
(Western blotting), cyclin E (Western blotting) and cyclin D3 (Western blotting 
and sq RT-PCR) between conditional BCL6-/- cells cultured in the absence or 
presence of doxycycline (Figure 6.11-Figure 6.13).  
Although no changes in p21cip1/waf1 mRNA expression were detected 
between conditional BCL6-/- cells cultured in the absence or presence of 
doxycycline (Figure 6.13), p21cip1/waf1 protein levels changed with BCL6 
status and Bcl6 protein expression (Figure 6.12). Somewhat surprisingly, 
p21cip1/waf1 protein was barely detectable in parental DG75-354 cells 
(BCL6+/+), however, much more strongly expressed in Bcl6-expressing BCL6-
/-;tetBcl6-HA cells. Furthermore, the significant level of p21cip1/waf1 protein 
expressed in BCL6-/-;tetBcl6-HA cells is downregulated upon Bcl6 protein 
depletion to a level still exceeding that of parental DG75-354 (BCL6+/+) cells 
(Figure 6.12). This finding will be further discussed in section 6.3 below. 
Encouragingly, I detected an upregulation of p27kip1 both by Western blotting 
and sq RT-PCR (Figure 6.12 and Figure 6.13).  
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Figure 6.9: No CD69 expression is induced in Bcl6-depleted BCL6-/-;tetBCL6-HA cells 
Jurkat cells were stimulated with 0.1 % (v/v) phytohemagglutinin (PHA; M form, Invitrogen) for 
24 hrs. BCL6-/-;tetBCL6-HA cells (clone FA8) were cultured without or with 1 µg/ml doxycycline 
and analysed daily. All graphs are overlays of α-CD69-FITC (clone FN50) (red line) and the 
mouse IgG1κ isotype control (clone MOPC-21)stained cells (BD Biosciences) (black line). Values 
in graphs denote mean fluorescence intensities of isotype controls (black) and α-CD69 (red) (see 
section 2.3.6 p.52 for further details). 
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Figure 6.10: No class switch recombination is induced in Bcl6-depleted BCL6-/-
;tetBCL6-HA cells 
IgM-expressing BCL6-/-;tetBCL6-HA cells (clone FA8) were cultured without or with 1 µg/ml 
doxycycline for 15 days and analysed after 3, 9 and 15 days. IgE-expressing U266 cells served 
as negative control. All graphs are histogram overlays of α-IgM-FITC (clone G20-127) (red line) 
and mouse IgG1κ isotype control (clone MOPC-21)stained cells (black line) (BD Biosciences). 
Values in graphs represent mean fluorescence intensities (see section 2.3.6 p.52 for further 
details). 
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Figure 6.11: No changes in Blimp
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Figure 6.12: Effect of Bcl6
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Figure 6.13: Sq RT-PCR analysis of selected 
regulation and differentiation in Bcl6
Total RNA from JJN3 cells and 
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6.3 Discussion 
6.3.1 Bcl6-depletion does not induce cell death in BCL6-/-;tetBCL6-
HA cells 
Analysis of the BCL6-/-;tetBCL6-HA phenotype by microscopy, flow cytometry, 
sq-RT-PCR and Western blotting revealed that Bcl6-depletion reduces the 
proliferative capacity of the cell line. Contrary to our expectations, Bcl6-
depletion did not cause cell death as no apoptosis, necrosis or autophagy was 
detected by flow cytometry, electron microscopy and Western blotting (Figure 
6.4, Figure 6.6 and Figure 6.5). As already reviewed in section 1.10 (p.41), it is 
believed that GC B cells and their malignant counterparts depend on Bcl6 
expression for survival. This view was based on BCL6 knockout mice studies 
(Dent et al., 1997), microarray analysis of a BL cell line (Raji) (Shaffer et al., 
2000) and several studies in which the Bcl6 POZ domain was inhibited 
(Cerchietti et al., 2010, Cerchietti et al., 2009, Chattopadhyay et al., 2006, Polo 
et al., 2004). It is not entirely clear why Bcl6-depletion in our system does not 
confirm the absolute requirement of Bcl6 for survival but it should be 
considered that the DG75 cell line is severely compromised in its apoptotic 
pathway (see section 1.12) and that some of the models that had been used to 
establish that Bcl6-depletion in GC-cells is lethal, may not be optimal to draw 
such a conclusion. 
Like all Burkitt lymphomas, DG75 carries the t(8;14) translocation, which places 
the c-Myc gene under the control of the immunoglobulin heavy chain promoter, 
resulting in overexpression of c-Myc. Typically, c-Myc induces p19ARF, in turn 
sequestering Mdm2, resulting in p53 activation and cell cycle arrest or 
apoptosis (Zindy et al., 1998). In order to overcome this tumour suppressor 
mechanism, most Burkitt lymphomas accummulate mutations in the p53-
pathway. In fact, DG75 carries a heterozygous p53 mutation, which impairs p53 
shuttling into the nucleus. The respective mutant p53 protein acts in a 
dominant-negative way, by homodimerising with and thereby sequestering 
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wildtype p53 in the cytoplasm (Crook et al., 1998). Moreover, DG75 cells lack 
expression of one of the pro-apoptotic Bcl2-family members. A frameshift 
mutation in the Bax coding region further desensitises DG75 cells to p53-
dependent cell death (Brimmell et al., 1998). Taken together, these aberrations 
could possibly contribute to the absence of increased apoptosis observed in the 
BCL6-/-;tetBCL6-HA model system.  
The apoptotic defect in DG75 cells is one explanation for the unexpected 
absence of cell death in response to Bcl6-depletion in my system; however, it 
must also be considered that the models that were used to demonstrate the 
apparent strong correlation between Bcl6-depletion and the apoptotic response 
may not be suitable to draw such a conclusion. While studies in BCL6 knockout 
mice only demonstrated that Bcl6 is required for GC formation i.e. proliferation 
of GC B cells (Dent et al., 1997), cell death was only demonstrated when a 
dominant-negative Bcl6 variant was transiently expressed in the BL cell line 
Raji (Shaffer et al., 2000) and when Bcl6-expressing cells were treated with 
Bcl6 POZ domain inhibitors (Cerchietti et al., 2010, Cerchietti et al., 2009, 
Chattopadhyay et al., 2006, Polo et al., 2004). The dominant-negative 
approach involved transient overexpression of only the zinc finger domain of 
Bcl6 in a cell line and it cannot be ruled out that this artificial protein interferes 
with cellular functions unrelated to Bcl6. It is possible that conformational 
changes resulting from the deletion of the larger part of the Bcl6 protein alter 
the DNA binding affinity of the zinc finger domain. The Bcl6 zinc fingers have 
been shown to not only operate in DNA binding but also interact with other 
proteins such as ETO (Chevallier et al., 2004). Therefore, the interaction of the 
Bcl6 ZF portion with other proteins might be altered and overexpression of such 
a mutant protein could potentially sequester an unpredictable range of other 
cellular proteins, thereby triggering an apoptotic response unrelated to specific 
Bcl6-depletion.  
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Off-target side effects have to be considered for expression of the dominant-
negative Bcl6 truncation and also for the utilisation of Bcl6 inhibitors. Although 
the authors of the corresponding studies have demonstrated that such 
inhibitors only cause apoptosis in cell lines expressing Bcl6 (Cerchietti et al., 
2010, Cerchietti et al., 2009, Chattopadhyay et al., 2006, Polo et al., 2004),this 
does not prove that the apoptotic response is solely attributable to Bcl6 
inhibition.  
It could well be that off-target side effects of Bcl6 inhibitors differ between Bcl6-
expressing and not Bcl6-expressing cell lines. Furthermore, it is possible that a 
combination of off-target side effects and Bcl6-depletion is required to cause 
cell death, and that either alone is insufficient. It would therefore be incredibly 
interesting to test whether the phenotype I observed for Bcl6-depleted BCL6-/-
;tetBCL6-HA cells can be reproduced when Bcl6 inhibitors are added to DG75 
cells or BCL6-/-;tetBCL6-HA cells cultured without tet or dox (Bcl6-expression is 
on). If such an experiment reproduced the BCL6-/- knockout phenotype I 
observed in this project, this would provide solid support for the specificity of 
Bcl6 inhibitors. However, should Bcl6 inhibitors produce a more severe 
phenotype or even cell death in DG75 cells or Bcl6-expressing BCL6-/-
;tetBCL6-HA cells, this would argue strongly for a combinatorial effect of Bcl6 
inhibition and off-target side effects and thereby challenge the current belief 
that Bcl6 is essential not only for proliferation but also survival of GC B cells. 
6.3.2 Bcl6-depletion does not affect differentiation of BCL6-/-
;tetBCL6-HA cells 
Besides the unexpected absence of cell death in Bcl6-depleted BCL6-/-
;tetBCL6-HA cells, my model system also did not confirm the absolute 
requirement of Bcl6 for maintaining the GC-B cell stage of B cell development.  
I detected no upregulation of genes involved in earlier or later stages of B cell 
differentiation in response to Bcl6-depletion. CD69 is one of the earliest 
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expression markers of lymphocyte activation and is involved in migration and 
cytokine secretion and is regulated by Bcl6, probably to manifest the GC 
phenotype (Shaffer et al., 2000). CD69 gene expression seems to be regulated 
differently in B and T cells and is only poorly understood to date (Vazquez et 
al., 2009). The biological significance of the Bcl6-binding site of the CD69 
promoter could not be demonstrated to date (Shaffer et al., 2000) but there is a 
potential alternative way, how Bcl6 could suppress CD69 transcription. As 
mentioned in section 1.7 (p.36), Bcl6 interacts with Jun proteins that are 
components of the activator protein 1 (AP-1) complex and can thereby repress 
transcription of PRDM1 (Blimp-1) (Vasanwala et al., 2002). Interestingly AP-1 is 
one of the activating transcription factors that regulate CD69 expression 
(Castellanos et al., 1997). However, whether Bcl6 regulates CD69 expression 
directly through binding to its binding site in the CD69 promoter or indirectly via 
interaction with Jun proteins of the AP-1 complex, remains to be explored 
experimentally. I failed to detect any marked surface CD69 expression in 
response to Bcl6-depletion in my conditional Bcl6 expression model. This is not 
entirely surprising as activation of CD69 transcription appears to be activated 
by interplay of not only the AP-1 but also EGR and ATF/CREB families 
(Castellanos Mdel et al., 2002), which are likely being repressed by Bcl6-
independent mechanisms in GC B cells. 
Besides the lack of evidence for differentiation back to developmental stages 
earlier than the GC-stage of Bcl6-depleted BCL6-/-;tetBCL6-HA cells, I have 
collected no unequivocal data suggesting a progression of cells towards 
terminal plasma cell differentiation. As overexpression of Blimp-1 in mature B 
cells causes plasma cell differentiation, Blimp-1 appears to be both necessary 
and sufficient for plasma cell differentiation (Shapiro-Shelef and Calame, 2005). 
PRDM1 can be considered the best characterised Bcl6-target gene, somewhat 
surprisingly, however, no Blimp-1 upregulation was observed in response to 
Bcl6 depletion in my system - no Blimp-1 protein and more importantly no 
Blimp-1 mRNA could be detected. Although the PRDM1 locus can be altered in 
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DLBCL cells (Pasqualucci et al., 2006) and I have not formally confirmed the 
integrity of the PRDM1 locus in DG75, I provisionally concluded, that Bcl6 
downregulation is required but not sufficient for Blimp-1 expression. Blimp-1 
expression is assumed to be mainly regulated on the transcriptional level, as no 
experimental evidence has been reported to date that indicates 
posttranslational modifications. Moreover, Blimp-1 mRNA expression appears 
to correlate well with protein expression. Bcl6 is a well-established, but not the 
only repressor of PRDM1 transcription. Apart from Bcl6, two additional 
transcriptional repressors of PRDM1 are likely being expressed in DG75, i.e. 
Pax5 and Bach2 (Calame, 2008) (see Figure 6.14). 
Pax5 is expressed from the pro-B cell stage throughout development until it is 
downregulated upon plasmacytic differentiation and functions in suppressing 
lineage-inappropriate genes. Pax5 represses PRDM1 transcription through 
binding to its exon 1 (Mora-Lopez et al., 2007) and this repressive effect is 
likely to be active in BCL6-/-;tetBCL6-HA cells as parental DG75 cells express 
Pax5 protein (Renne et al., 2006) and an increase in mRNA abundance in 
response to Bcl6-depletion was detected by sq RT-PCR in my model system 
(Figure 6.13). Bach2, a further repressor of the PRDM1 gene, is expressed 
from the pro-B cell stage, only silenced upon plasmacytic differentiation and 
therefore very likely to be expressed in DG75. BACH2 knockout mice show a 
defect in GC formation and have elevated Blimp-1 mRNA levels without any 
alteration in Bcl6 expression (Muto et al., 2004). On a molecular basis, Bach2 
alone can repress PRDM1 expression in reporter gene assays, while Bcl6 had 
no effect in the system. However, maximal repression of Blimp-1 expression 
was only achieved when Bach2 an Bcl6 were co-expressed (Ochiai et al., 
2008). 
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Figure 6.14: Transition of transcription factor network from GC B to plasma cells 
(Igarashi et al., 2007) 
“In B cells, Bach2, Bcl6, MITF and Pax5 repress the plasmacytic transcription factors (left). 
Blimp-1, IRF-4 and Xbp-1 promote plasma cell differentiation (right). Red boxes indicate genes 
that are expressed. Gray boxes indicate genes that are not expressed. Bold lines and arrows 
indicate effective repression and effective activation, respectively. Dashed arrows represent 
biological outputs.” (Igarashi et al., 2007) 
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In addition to its regulation by transcriptional repressors, PRDM1 expression is 
also controlled by the transcriptional activators IRF4, STAT3, STAT5, AP-1 and 
NF-κB (Calame, 2008). IRF4 is expressed in immature B cells in the bone 
marrow, absent in centroblasts and re-expressed in some centrocytes and 
plasma cells (Pernis, 2002). Accordingly, the Blimp-1 activator IRF4 is not 
normally expressed in DG75 (Xu et al., 2008). Moreover, PRDM1 expression is 
activated by STAT3 and STAT5 in response to cytokine stimulation. STAT3 is 
often found constitutively activated in EBV positive BLs, however, this is not 
true for DG75 (Kube et al., 2001, Weber-Nordt et al., 1996). It would certainly 
be interesting to test whether induced STAT3 activation in Bcl6-depleted BCL6-
/-;tetBCL6-HA cells provides the necessary signal for PRDM1 induction. 
Binding of the transcriptional activator AP-1 to the PRDM1 promoter has also 
been reported, however, it seems that it is not essential for PRDM1 expression 
(Ohkubo et al., 2005). 
An upregulation of PRDM1 expression was detected when the zinc finger 
domain of Bcl6 was transiently expressed in Raji (BL) cells (Shaffer et al., 
2000) and Bcl6 was shown to bind to the PRDM1 promoter in chromatin 
immunoprecipitation analysis of Ramos cells (BL) and WIL2 cells 
(lymphoblastoid B cell lymphoma) (Parekh et al., 2007, Tunyaplin et al., 2004), 
however, Blimp-1 was not induced in response to Bcl6-depletion in my system 
(Figure 6.11 and Figure 6.13). In order to discuss this finding, one has to take 
into account that the above mentioned study was based on a different cell line. 
Even though Raji and DG75 cell lines both share a BL phenotype, the 
accompanying genetic lesions in both cell lines are diverse. DG75 is EBV 
negative and cytogenetically very stable, while Raji is EBV positive and 
displays several cytogenetic abnormalities the functional consequences of 
which have not been studied (Karpova et al., 2005). In summary, various 
transcriptional repressors and activators regulate expression of PRDM1 but it 
remains to be investigated which transcription factors impose the strongest 
impact on PRDM1 transcription and how the removal of individual repressors 
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and induction of individual activators collaborate to induce PRDM1 expression 
and plasma cell differentiation. The results obtained in my BCL6-/-;tetBCL6-HA 
model strongly suggest that although necessary, the selective removal of only 
Bcl6 from the centroblast gene expression program is not sufficient to induce 
PRDM1 and terminal plasma cell differentiation. 
6.3.3 Bcl6-depletion reduces proliferation of BCL6-/-;tetBCL6-HA 
cells 
The influence of Bcl6 on repression of negative cell cycle regulators such as  
p27kip1 is well established (Shaffer et al., 2000) and it is hence perhaps not 
surprising to observe reduced growth rates and cell cycle progression in 
response to Bcl6 depletion in my BCL6-/-;tetBCL6-HA system (Figure 6.3 and 
Figure 6.7). Growth curve analysis revealed a severely reduced proliferation 
following Bcl6-depletion (Figure 6.3). Although not quantified, proliferation rates 
slightly increased again after an initial crisis that lasted approximately 7 days. 
This is likely due to the powerful selective pressure imposed on these cells 
upon withdrawal of Bcl6. One way cells could overcome this unfavourable 
condition, would be to accumulate mutations in the tetracycline transactivator. 
The tTA is required for Bcl6-HA expression in BCL6-/-;tetBCL6-HA cells and 
inactivated when bound to tetracycline or doxycycline. Mutations that impair 
binding of the transactivator to tet/dox could thereby reactivate Bcl6-HA 
expression, causing a weakening of the phenotype and a growth advantage. 
This could be tested by re-analysing Bcl6 protein depletion in BCL6-/-;tetBCL6-
HA cells after long-term culture in doxycycline. For characterisation of the 
BCL6-/-;tetBCL6-HA cell line, it is therefore essential to focus on early rather 
than late phenotypic changes as there is a chance that late changes are being 
caused by directed evolution rather than Bcl6-depletion. 
It is not clear why, in contrast to parental DG75-354 cells, BCL6-/-;tetBCL6-HA 
cells express p21cip1/waf1 protein (Figure 6.12). It has been previously shown 
by Northern blotting that p21cip1/waf1 mRNA abundance is very low in DG75 
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and that it cannot be induced by cisplatin treatment due to the inability of 
mutant p53 to translocate into the nucleus (Crook et al., 1998). This suggests 
that p21cip1/waf1 expression has been activated during the process of 
constructing the conditional BCL6-/- cell line. It remains to be tested whether 
the remaining two BCL6-/-;tetBCL6-HA clones (AB7 and FA8) also express 
p21cip1/waf1. If this is the case, it needs to be investigated at which stage 
during the construction of the BCL6-/-;tetBCL6-HA cell line p21cip1/waf1 
expression started. Once it is known at what point p21cip1/waf1 expression 
started, it could be considered to repeat some of the genetic modifications with 
an alternative clone or to investigate the mechanism by which p21cip1/waf1 
expression has been activated. Although I have not formally analysed it, a 
possible explanation for this finding is that p21cip1/waf1 expression is caused 
by the reduced Bcl6-protein expression in BCL6-/-;tetBCL6-HA cells over 
parental cells (Figure 5.3B p.105 and Figure 5.7B p.115). p21cip1/waf1 
transcription is not only activated by p53 in response to DNA damage, but also 
repressed by Bcl6 during the GC reaction via interaction with Miz-1 (Phan et 
al., 2005). It may well be that the reduced amounts of Bcl6 protein expressed in 
BCL6-/-;tetBCL6-HA cells activate p21cip1/waf1 transcription without the need 
for nuclear p53. To adjust the exogenous (tet-regulatable) Bcl6 expression in 
BCL6-/-;tetBCL6-HA cells to a level that closer resembles that of parental 
DG75-354 cells, it could be tried to target the second BCL6 allele of a clone 
that expresses higher tet-regulatable Bcl6 protein levels (such as ∆B12 
(BCL6+/-;tetBCL6-HA) in Figure 4.3 p.96), or one could alternatively introduce 
an additional tet-regulatable Bcl6 copy into BCL6-/-;tetBCL6-HA cells (clone 
AB7, CD9 or FA8). 
However, the above mentioned possibility that lower than physiological Bcl6 
protein levels in BCL6-/-;tetBCL6-HA cells could account for reactivation of 
p21cip1/waf1 expression, does not explain why p21cip1/waf1 protein 
expression is downregulated in Bcl6-depleted BCL6-/-;tetBCL6-HA cells (Figure 
6.12). I am not sure why this is the case, but as the experiment was only 
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performed once it should best be repeated on different clones in order to 
confirm the finding.  
The results obtained from growth curve analysis, proliferation assay, Western 
blotting and sq RT-PCR are consistently reflecting a reduced proliferative 
capacity of BCL6-/-;tetBCL6-HA cells in response to Bcl6-depletion (Figure 6.3, 
Figure 6.7, Figure 6.8, Figure 6.12 and Figure 6.13). In summary, however, the 
phenotypic changes observed for Bcl6-depleted BCL6-/-;tet-BCL6-HA cells, 
such as the altered morphology (Figure 6.2), cannot not be solely attributed to 
increased p27kip1 expression. In order to gain a wider view on molecular 
pathways likely altered in my conditional knockout cells and to identify future 
perspectives in the field of studying Bcl6 function, I decided to monitor the 
entire transcriptome of BCL6-/-;tet-BCL6-HA by cDNA microarray analysis (see 
CHAPTER 7 below).  
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CHAPTER 7 - Gene expression 
profiling of BCL6-/-;tetBCL6-HA cells 
7.1 Introduction 
Following the examination of growth behaviour and gene/protein expression 
changes of a limited number of genes in Bcl6-depleted BCL6-/-;tetBCL6-HA 
cells (CHAPTER 6), I decided to perform microarray analysis. DNA microarray 
analysis can simultaneously measure gene expression of the entire cellular 
transcriptome and also provides hints towards cellular pathways altered under 
certain conditions. Microarray technology is therefore a powerful tool for the 
characterisation of a specific phenotype and has previously been used to 
identify putative Bcl6 target genes (Shaffer et al., 2000). 
One important consideration in the design of a microarray experiment is 
whether two-colour or single-colour arrays are used. In two-colour analysis, two 
samples are labelled with different fluorophores and are hybridised to the same 
array, while in single-colour arrays each sample is labelled with the same 
fluorophore and hybridised to a separate array. While it appears more 
economical to only use one array for two samples, it has been shown that the 
labelling efficiency of different fluorophores varies and that such experiments 
require additional controls in which the dyes on the samples are swapped and 
hybridised to a second array (Dombkowski et al., 2004). Therefore, I used 
GeneChip® technology (Affymetrix) which relies on single channel detection 
(Figure 7.1). GeneChip® technology (Human GeneChip 1.0 ST Array, 
Affymetrix) allows for the detection of 28,869 well-annotated mRNA transcripts, 
each of which is represented by approximately 26 probes on the array. Figure 
7.1 shows a schematic representation of the procedure.  
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7.2 Results 
I had two choices in the design of the microarray experiment. (1) Analysing six 
arrays including three biological replicates of a control sample (-doxycycline) 
and three biological replicates from one time point after Bcl6-depletion or (2) 
analysing four arrays including the control sample and three different time 
points after Bcl6-depletion (excluding biological replicates). Ideally, I would 
have used three biological replicates of multiple time points. Because of 
economical reasons and the wish to follow gene expression changes over a 
couple of days, I decided to pursue the latter option. Bcl6-/-;tetBCL6-HA cells 
(clone AB7) were either grown without doxycycline (control) or with 1 µg/ml 
doxycycline for 16, 48 or 96 hours. Further information on methodology 
involved can be found in section 2.8, p.66. The quality of microarray data was 
subjectively evaluated by scatter plot analysis (Figure 7.2). Ideally, data should 
be distributed along a straight line, based on the assumption that expression of 
most genes does not change during the experiment. If microarray data 
presents itself ‘banana-shaped’ or ‘boomerang-shaped’ then the variation 
between the arrays more likely reflects obscuring variation (resulting from 
technical variation) rather than interesting variation (resulting from biological 
variation) (Bolstad et al., 2003). 
Two hundred and five genes with a ≥2-fold up-or downregulation in any sample 
cultured in doxycycline (16 hours, 48 hours or 96 hours) compared to the 
control (-doxycycline) were identified. Thirteen out of these 205 transcripts were 
excluded from further analysis because no complete coding sequence is known 
for them or their existence is only supported by expressed sequence tags or 
computational prediction. The remaining 192 genes corresponded to well-
curated transcripts and these were selected for further analysis. Interestingly, 
out of these 192 genes, 163 genes (85 %) were upregulated in response to 
Bcl6-depletion, nicely correlating with the fact that Bcl6 is a transcriptional 
repressor. Table 8 lists these 192 genes in alphabetical order. For validation of 
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microarray data, 23 genes were selected from Table 8 and expression changes 
were confirmed by sq RT-PCR analysis (Figure 7.3). In the selection process of 
genes to be validated, genes with no alternative transcripts (ease of primer 
design) and those with bigger expression changes were favoured. Validation of 
these genes was not performed on the same clone on which microarray 
analysis was performed (clone AB7) but on mRNA isolated from a different 
clone (clone FA8). Furthermore, validation by sq RT-PCR was only performed 
once, the results of which are shown in Figure 7.3. 
In sq RT-PCR, 14 out of 23 genes (61 %) fully supported the microarray data. 
These were IFI44L, CYSLTR1, IFI44, SESN1, IKZF1, STAT1, SYK, PIK3IP1, 
FOXP1, IRF9, STAT2, E2F8, CDC6 and LYAR. Eight out of 23 genes (35 %) 
failed to support the changes detected by microarray analysis. These were 
PLEK, CAMK4, ARHGAP15, RB1, BLNK, CDKN1B, EIF2AK3 andGPRIN3. The 
result for the TAP1 gene showed a clear difference to the microarray data 
(Figure 7.3). However, taking the limits of sq RT-PCR analysis into account and 
bearing in mind that the experiment was only performed once on a clone 
different to the one that the microarray data was generated from, these results, 
together with quality control data (Figure 7.2) were of sufficient quality to 
perform pathway analysis.  
In order to identify biological pathways altered in response to Bcl6-depletion, I 
submitted the genes listed in Table 8 to the publicly available ‘DAVID 
bioinformatics database’ (Dennis et al., 2003, Huang da et al., 2009) and 
performed pathway mapping. The integrated pathway mapping tool of DAVID, 
compares a submitted gene list to biological pathways in the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000) and 
thereby identifies pathways that are altered under the experimental condition 
studied. Using this integrated pathway-mapping tool, I identified three cellular 
pathways affected by Bcl6. These are (1) cell cycle regulation, (2) BCR 
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signalling and (3) calcium signalling (Figure 7.4 - Figure 7.7). The influence of 
Bcl6 on these pathways will be discussed in section 7.3 below. 
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Figure 7.2: Quality control of microarray data by scatter plot analysis 
Scatter plots compare normalised intensity values (base-2 logarithm) of gene expression 
between two arrays and thereby visualise data distribution. Data were generated from clone 
AB7 (BCL6-/-;tetBCL6-HA) cultured without doxycycline (x-axis) or with doxycycline (y-axis) for 
16 hrs (A), 48 hrs (B) or 96 hrs (C). Genes represented by data points outside the region 
between the three diagonal lines have a greater than 2-fold change in expression between the 
2 arrays compared. Colours encode signal intensities of the control sample (- doxycycline, x-
axis), i.e. blue reflects low, yellow/orange reflect medium and red reflects high transcript 
expression. 
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Table 8: Genes displaying largest fold mRNA expression changes in response to Bcl6-
depletion in BCL6-/-;tetBCL6-HA cells 
Listing of gene expression changes in response to Bcl6-depletion as detected by microarray 
analysis. Genes listed were selected on the basis that at least one of the samples incubated in 
doxycycline (for 16, 48 or 96 hours) displayed an at least 2-fold change compared to the control 
to which no doxycycline was added. Genes are listed in alphabetical order. Last three columns 
list fold-changes, most of which are upregulated. Downregulations are highlighted in grey. 
gene symbol gene description 16 48 96 
7A5 putative binding protein 7a5 2.28 2.32 2.42 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 1.79 1.97 2.04 
ACSM3 acyl-CoA synthetase medium-chain family member 3 1.19 2.06 2.11 
AIM1 absent in melanoma 1 2.06 1.86 2.16 
ALDOC aldolase C, fructose-bisphosphate 2.52 1.16 1.06 
ANKRD44 ankyrin repeat domain 44 2.26 2.12 2.34 
ARHGAP15 Rho GTPase activating protein 15 2.52 2.35 2.39 
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 1.79 2.50 3.04 
ATM|NPAT 
ataxia telangiectasia mutated | nuclear protein, ataxia-
telangiectasia locus 1.75 1.83 2.26 
ATP2A2 
ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 1.33 1.57 2.02 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 2.06 2.12 2.34 
BCL2A1 BCL2-related protein A1 2.42 2.68 3.22 
BLNK B-cell linker 1.57 1.92 2.36 
BMI1 BMI1 polycomp ring finger oncogene  1.69 1.71 2.06 
BST2 bone marrow stromal cell antigen 2 1.25 1.52 2.12 
BTN3A1 butyrophilin, subfamily 3, member A1 1.84 1.95 2.03 
BTN3A2 butyrophilin, subfamily 3, member A2 1.81 2.03 2.32 
BTN3A3 butyrophilin, subfamily 3, member A3 1.63 1.77 2.31 
C10orf64|WD
FY4 
chromosome 10 open reading frame 64 | WDFY family 
member 4 1.37 2.18 2.42 
C11orf53 chromosome 11 open reading frame 53 1.25 1.72 2.30 
C13orf18|LO
C728970 
chromosome 13 open reading frame 18 | hypothetical 
LOC728970 3.13 3.65 3.55 
C18orf17 chromosome 18 open reading frame 17 1.95 1.93 3.25 
C5orf13 chromosome 5 open reading frame 13 1.89 1.58 2.05 
CAMK4 calcium/calmodulin-dependent protein kinase IV 2.30 2.37 2.48 
CASP1 
caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 1.59 1.78 2.28 
CCL3 chemokine (C-C motif) ligand 3 1.65 2.09 2.74 
CCL3L1 chemokine (C-C motif) ligand 3-like 1 1.76 2.63 3.51 
CCPG1 cell cycle progression 1 1.02 1.49 2.31 
CCR7 chemokine (C-C motif) receptor 7 1.02 1.71 2.77 
CD180 CD180 antigen 1.96 1.73 2.31 
CD48 CD48 antigen 1.39 1.79 2.25 
CD72 CD72 receptor  1.16 1.49 2.25 
CDC25A cell division cycle 25 homolog A (S. pombe) 1.33 1.92 2.07 
CDC2L6 cell division cycle 2-like 6 (CDK8-like) 2.05 1.82 1.87 
CDC6 cell division cycle 6 homolog (S. cerevisiae) 1.43 1.99 2.03 
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CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) 2.19 1.74 2.08 
CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 1.08 1.52 2.60 
CHML choroideremia-like (Rab escort protein 2) 2.15 2.31 2.20 
CNR2 cannabinoid receptor 2 (macrophage) 1.37 1.63 2.15 
CTDSP2 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase 2 1.96 1.76 2.10 
CTH cystathionase (cystathionine gamma-lyase) 1.05 1.79 2.68 
CXorf21 chromosome X open reading frame 21 3.16 2.66 3.60 
CYSLTR1 cysteinyl leukotriene receptor 1 5.51 5.60 10.2 
DDIT4 DNA-damage-inducible transcript 4 2.30 2.05 3.40 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 1.50 1.66 2.04 
DGKD diacylglycerol kinase, delta 130kDa 1.50 1.73 2.11 
DNMBP dynamin binding protein 1.87 2.47 2.87 
DTX3L deltex 3-like (Drosophila) 1.90 2.10 2.96 
DZIP3 DAZ interacting protein 3, zinc finger 1.87 1.85 2.14 
E2F8 E2F transcription factor 8 1.38 1.81 2.03 
EBI2 
Epstein-Barr virus induced gene 2 (lymphocyte-specific 
G protein-coupled receptor) 1.41 1.76 3.33 
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 1.56 1.50 2.08 
EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3 2.10 2.00 2.03 
ENPP3 ectonucleotide pyrophosphatase/phosphodiesterase 3 1.32 1.51 2.29 
ERAP2 endoplasmic reticulum aminopeptidase 2 1.62 1.87 2.06 
EVI2A|EVI2B 
ecotropic viral integration site 2A | ecotropic viral 
integration site 2B 3.03 3.02 4.08 
FAIM3 Fas apoptotic inhibitory molecule 3 1.29 1.58 3.52 
FLI1|EWSR1 
Friend leukemia virus integration 1 | Ewing sarcoma 
breakpoint region 1 2.84 2.45 3.34 
FLJ31958 Hypothetical protein FLJ31958  1.23 2.02 1.93 
FNBP1 formin binding protein 1 1.55 1.58 2.08 
FOXP1 forkhead box P1 1.66 1.69 2.14 
FRYL FRY-like 2.01 1.62 1.77 
FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 2.24 2.16 2.70 
GAB1 GRB2-associated binding protein 1 2.37 2.25 3.08 
GCET2 germinal center expressed transcript 2 2.00 2.01 2.95 
GPR174 G protein-coupled receptor 174 2.75 2.60 2.70 
GPRIN3 GPRIN family member 3 2.75 1.67 1.58 
HEG1 HEG homolog 1 (zebrafish) 1.83 1.65 2.02 
HERC2P2|L
OC283755|L
OC440248|H
ERC2P3 
hect domain and RLD 2 pseudogene 2 | hypothetical 
protein LOC283755 | hect domain and RLD 2 
pseudogene 3 1.62 1.70 2.02 
HERC2P4 hect domain and RLD 2 pseudogene 4 1.61 1.85 2.07 
HIST1H2BK histone cluster 1, H2bk 1.45 2.29 3.11 
HIVEP2 
human immunodeficiency virus type I enhancer binding 
protein 2 2.57 2.11 2.65 
HMGCS1 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
(soluble) 2.48 1.92 1.99 
HSPA5 
heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa) 1.91 1.85 2.47 
ID3 
inhibitor of DNA binding 3, dominant negative helix-
loop-helix protein 3.13 1.98 2.42 
IFI16 interferon, gamma-inducible protein 16 1.83 1.81 2.08 
IFI27 interferon, alpha-inducible protein 27 1.18 1.66 11.4 
IFI35 interferon-induced protein 35 1.45 1.87 2.16 
IFI44 interferon-induced protein 44 2.06 2.96 5.05 
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IFI44L interferon-induced protein 44-like 2.54 4.58 31.8 
IFI6 interferon, alpha-inducible protein 6 1.32 1.37 2.45 
IFIH1 interferon induced with helicase C domain 1 1.67 1.64 2.28 
IFIT1 
interferon-induced protein with tetratricopeptide 
repeats 1 1.54 2.04 2.56 
IFIT2 
interferon-induced protein with tetratricopeptide 
repeats 2 1.25 1.93 2.58 
IFIT3 
interferon-induced protein with tetratricopeptide 
repeats 3 1.23 1.67 2.85 
IFITM1 interferon induced transmembrane protein 1 (9-27) 1.30 1.52 3.59 
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 1.76 1.85 2.19 
IGF2R insulin-like growth factor 2 receptor 1.63 1.89 2.27 
IGJ 
immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides 1.76 1.88 2.16 
IKZF1 IKAROS family zinc finger 1 (Ikaros) 2.39 2.47 2.96 
IKZF2 IKAROS family zinc finger 2 (Helios) 2.45 1.74 2.49 
IL10RA interleukin 10 receptor, alpha 1.73 2.09 2.03 
IRF9 interferon regulatory factor 9 1.31 1.57 2.07 
ITPR1 inositol 1,4,5-triphosphate receptor, type 1 2.02 1.92 2.06 
ITPR2 inositol 1,4,5-triphosphate receptor, type 2 1.61 1.90 2.37 
KBTBD8 kelch repeat and BTB (POZ) domain containing 8 1.59 2.07 1.85 
KIAA1618 Ring finger protein 213  2.00 2.33 2.91 
KLRC4|KLRK
1 
killer cell lectin-like receptor subfamily C, member 4 | 
killer cell lectin-like receptor subfamily K, member 1 2.13 2.26 2.36 
KLRK1|KLRC
4 
killer cell lectin-like receptor subfamily K, member 1 | 
killer cell lectin-like receptor subfamily C, member 4 1.66 1.89 2.58 
LAPTM5 
lysosomal associated multispanning membrane protein 
5 2.33 5.76 8.59 
LGALS9|LOC
284194|LOC
654346 
lectin, galactoside-binding, soluble, 9 (galectin 9) | 
galectin-9 like | similar to galectin 9 short isoform 1.20 1.67 2.64 
LGALS9|LOC
654346|LOC
284194 
lectin, galactoside-binding, soluble, 9 (galectin 9) | 
similar to galectin 9 short isoform | galectin-9 like 1.30 1.73 2.67 
LGMN legumain 1.96 1.82 2.13 
LMO4 LIM domain only 4 1.82 1.98 2.40 
LOC389765 similar to KIF27C 2.29 2.16 1.68 
LOC85389 RNA, small nucleolar 1.28 1.26 2.02 
LOC85391 RNA, small nucleolar 1.29 1.08 2.61 
LRRC33 leucine rich repeat containing 33 1.26 1.59 2.17 
LRRN3 leucine rich repeat neuronal 3 2.68 2.24 2.34 
LYAR Ly1 antibody reactive homolog (mouse) 1.42 1.59 2.01 
MAML3 mastermind-like 3 (Drosophila) 2.30 2.35 2.59 
MAP1A microtubule-associated protein 1A 1.17 1.31 2.08 
MAPK10 mitogen-activated protein kinase 10 1.80 1.36 2.00 
MCTP2 multiple C2 domains, transmembrane 2 1.78 1.82 2.06 
MEF2C myocyte enhancer factor 2C 2.41 2.12 2.23 
MEIS2 Meis homeobox 2 2.04 2.11 2.48 
MGAT5 
mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase 1.76 1.86 2.17 
MGC16169 TBC1 domain containing kinase  2.08 1.21 1.91 
MLKL mixed lineage kinase domain-like 1.59 2.09 2.53 
MLLT3 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 3 2.21 2.34 2.26 
MRTO4 mRNA turnover 4 homolog (S. cerevisiae) 1.56 1.60 2.12 
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NEK7 NIMA (never in mitosis gene a)-related kinase 7 2.18 1.64 1.50 
OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa 1.60 1.86 3.40 
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 1.87 2.10 5.41 
OXR1 oxidation resistance 1 1.49 1.74 2.10 
PARP9 poly (ADP-ribose) polymerase family, member 9 2.31 2.41 3.67 
PCMTD1 
protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 1 1.79 1.65 2.10 
PDCD4 
programmed cell death 4 (neoplastic transformation 
inhibitor) 2.58 2.91 3.62 
PIK3IP1 phosphoinositide-3-kinase interacting protein 1 1.29 1.75 2.43 
PLEK pleckstrin 1.60 1.90 2.63 
PLSCR1 phospholipid scramblase 1 1.88 1.55 2.01 
PLXNC1 plexin C1 1.79 1.95 2.04 
PMEPA1 prostate transmembrane protein, androgen induced 1 1.83 1.84 2.01 
PML promyelocytic leukemia 1.43 1.64 2.37 
PNRC1 proline-rich nuclear receptor coactivator 1 1.38 1.70 2.29 
PRDM15 PR domain containing 15 1.88 1.98 2.12 
PSAT1 phosphoserine aminotransferase 1 1.08 1.40 2.28 
PSCD1 
pleckstrin homology, Sec7 and coiled-coil domains 
1(cytohesin 1) 1.49 1.97 2.20 
PSCDBP 
pleckstrin homology, Sec7 and coiled-coil domains, 
binding protein 2.26 1.70 2.09 
PTK2B Pyk2  1.61 1.64 2.14 
PTPN6 protein tyrosine phosphatase, non-receptor type 6 1.74 1.78 2.23 
PTPRC protein tyrosine phosphatase, receptor type, C 2.10 1.44 1.62 
RAPGEF1 Rap guanine nucleotide exchange factor (GEF) 1 1.63 2.23 2.37 
RASSF6 
Ras association (RalGDS/AF-6) domain family 
member 6 2.64 2.42 1.96 
RB1 retinoblastoma 1 (including osteosarcoma) 2.27 1.82 2.37 
RCN2 reticulocalbin 2, EF-hand calcium binding domain 2.07 1.59 1.58 
RCSD1 RCSD domain containing 1 2.05 1.69 2.09 
REPIN1 replication initiator 1 2.12 2.31 2.73 
RNF213 ring finger protein 213 1.98 2.52 3.03 
RP5-
1022P6.2 hypothetical protein KIAA1434 1.48 2.02 1.95 
RPL27A ribosomal protein L27a 1.83 1.51 2.11 
RPS29 ribosomal protein S29 1.22 1.53 2.10 
S100A10 S100 calcium binding protein A10 1.06 1.83 2.78 
SAMD9 sterile alpha motif domain containing 9 1.82 1.68 2.22 
SAMD9L sterile alpha motif domain containing 9-like 2.10 2.71 3.60 
SCN3A sodium channel, voltage-gated, type III, alpha subunit 2.24 2.07 2.08 
SERPINA9 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 9 1.85 1.43 2.04 
SESN1 sestrin 1 2.66 2.72 3.56 
SESN3 sestrin 3 2.38 2.05 2.33 
SFRS6 splicing factor, arginine/serine-rich 6 1.76 1.82 2.17 
SLC1A4 
solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 1.01 1.81 2.12 
SLC30A4 solute carrier family 30 (zinc transporter), member 4 2.27 1.88 1.62 
SLC44A5 solute carrier family 44, member 5 1.75 1.74 2.11 
SLC7A11 
solute carrier family 7, (cationic amino acid transporter, 
y+ system) member 11 1.16 1.83 3.26 
SMAP2 
stromal membrane-associated GTPase-activating 
protein 2 1.74 2.00 2.55 
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SNORD50B small nucleolar RNA, C/D box 50B 1.29 1.35 2.35 
SNORD75 small nucleolar RNA, C/D box 75 1.71 1.51 2.07 
SNTB1 
syntrophin, beta 1 (dystrophin-associated protein A1, 
59kDa, basic component 1) 1.98 2.09 2.06 
SP110 SP110 nuclear body protein  2.14 2.42 3.64 
SP140 SP140 nuclear body protein  1.55 2.47 4.67 
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 1.49 1.83 2.26 
STAMBPL1 STAM binding protein-like 1 2.03 1.58 1.31 
STAT1 
signal transducer and activator of transcription 1, 
91kDa 1.46 1.95 2.96 
STAT2 
signal transducer and activator of transcription 2, 
113kDa 1.61 1.57 2.05 
SYK spleen tyrosine kinase 2.18 2.54 2.71 
TAGAP T-cell activation RhoGTPase activating protein 1.34 1.43 2.11 
TAP1 
transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 1.62 1.70 2.01 
TBCEL tubulin folding cofactor E-like 2.02 1.87 2.31 
TFRC transferrin receptor (p90, CD71) 1.56 1.74 2.31 
TIPIN TIMELESS interacting protein 1.43 1.73 2.04 
TMEM154 transmembrane protein 154 2.06 2.17 2.07 
TNFSF8 tumor necrosis factor (ligand) superfamily, member 8 1.30 1.41 2.64 
TP53INP1 tumor protein p53 inducible nuclear protein 1 2.10 2.39 2.79 
TP63 tumor protein p63 2.23 3.16 3.35 
TRIM22 tripartite motif-containing 22 1.37 1.76 2.05 
TUBB2C tubulin, beta 2C 1.34 1.80 2.08 
UGCG UDP-glucose ceramide glucosyltransferase 1.87 1.73 2.45 
UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7 1.01 1.42 3.45 
UTRN utrophin 1.86 2.04 2.54 
VSTM3 V-set and transmembrane domain containing 3 1.24 1.72 2.10 
WDFY4|C10
orf64 
WDFY family member 4 | chromosome 10 open 
reading frame 64 1.36 1.98 2.37 
XAF1 XIAP associated factor 1 1.90 2.39 4.74 
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Figure 7.3: Validation of microarray data by sq RT
Microarray analysis was performed on 
results by sq RT-PCR was performed on 
1:5, 1:25 and 1:125 (left to right) were prepared and used as template for the PCR reaction. 
See section 2.5.4 and Table 
represents the control (cells cultured without doxycycline) while the lower panel corresponds to
PCR reactions based on cDNA generated from cells cultured in presence of doxycycline 
(1 µg/ml) for 96 hours. Below each gene symbol is the fold up (+) or do
expression expected based on microarray results obtained for 
(Table 8). B2M (β-2 microglobulin) served as control.
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Figure 7.4: Bcl6 affects transcription of cell cycle regulators 
Genes listed in Table 8 (192 genes) were submitted to the pathway mapping tool of the ‘DAVID functional annotation program’ (Dennis et al., 2003, Huang da 
et al., 2009) and four of these genes (CDC6, CDC25A, CDKN1B and RB1) were mapped to the cell signalling KEGG pathway (indicated by red stars, 
diagram was generated by pathway mapping tool) (Kanehisa and Goto, 2000). 
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Figure 7.5: Bcl6 affects transcription of BCR signalling components 
Genes listed in Table 8 (192 genes) were submitted to the pathway mapping tool of the ‘DAVID functional annotation program’ (Dennis et al., 2003, Huang da 
et al., 2009) and fife of these genes (BLNK, CD72, IFITM1/LEU13, PTPN6/SHP-1 and SYK) were mapped to the BCR signalling KEGG pathway (indicated by 
red stars, diagram was generated by pathway mapping tool) (Kanehisa and Goto, 2000). 
  
166
 
Figure 7.6: Bcl6 affects transcription of calcium signalling components 
Genes listed in Table 8 (192 genes) were submitted to the pathway mapping tool of the ‘DAVID functional annotation program’ (Dennis et al., 2003, Huang da 
et al., 2009) and six of these genes (ATP2A/SERCA, CAMK4, CYCLTR1/GPCR, ITPR1/2/IP3Rand PTK2B/FAK2) were mapped to the BCR signalling KEGG 
pathway (indicated by red stars, diagram was generated by pathway mapping tool) (Kanehisa and Goto, 2000). 
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Figure 7.7: Graphic representation of fold gene expression changes of selected genes
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7.3 Discussion 
7.3.1 Quality control of microarray data 
Quality control of microarray data was performed by subjective inspection of 
scatter plots (Figure 7.2). However, statistical analysis of data was not 
performed, as no biological replicates were included in the analysis for 
economical reasons. In order to reduce the signal to noise ratio, it is generally 
advised to use three replicates for each sample and even more when working 
with very heterogeneous cell populations (such as tissue) or when only very 
few starting material is available for a sample. As the cell line BCL6-/-;tetBCL6-
HA is a very homogeneous cell population that is derived from a single cell 
clone and availability of large cell numbers is no point of concern, the signal to 
noise ratio of samples was found to be very low. This was judged by the fact 
that expression of most genes analysed did not change when each of the data 
sets derived from Bcl6-depleted samples was compared to the control (-
doxycycline) (Figure 7.2). Nevertheless, the experimental design could be 
improved by including biological replicates and hence the data generated must 
be carefully validated and can only serve as a guide as to which biological 
pathways are influenced by Bcl6 and warrant further study.  
Microarray data are often validated by sq RT-PCR analysis (Chuaqui et al., 
2002) and typically less than 10 genes are selected for validation (Al Moustafa 
et al., 2002, Porkka et al., 2002). I validated 23 genes by sq RT-PCR (Figure 
7.3). For validation by sq RT-PCR, I chose a clone different to the one I 
performed microarray analysis on, in order to demonstrate a degree of 
universality of the microarray results (microarray analysis clone AB7, sq RT-
PCR clone FA8) (Chuaqui et al., 2002). Supportive results were obtained for 14 
out of 23 genes analysed, no supporting effect was observed for 8 out of 23 
genes and 1 out of 23 (TAP1) showed a clear discrepancy to the microarray 
data (Figure 7.3). It is not clear why a discrepancy was detected for TAP1. In 
order to maximise accuracy of the sq RT-PCR experiment, all 96 PCR 
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reactions were performed on the same day. There is the possibility the clone 
chosen for validation (FA8) may behave slightly different to that used in the 
microarray experiment (AB7). In order to determine the exact cause of this 
discrepancy, validation for the TAP1 gene would have to be repeated, ideally 
on both clones. Overall, however, quality control results (Figure 7.2 and Figure 
7.3) are satisfactory and sufficient to obtain an overview of the biological 
pathways involved in the BCL6 knockout phenotype of BCL6-/-;tetBCL6-HA 
cells. 
7.3.2 Bcl6 and cell cycle regulation 
Pathway mapping with the ‘DAVID functional annotation program’ of microarray 
data provided an interesting insight into the gene expression changes 
correlating with the reduced proliferative capacity of Bcl6-depleted BCL6-/-
tetBCL6-HA cells (Figure 7.4). I detected an upregulation of the demonstrated 
Bcl6 target gene CDKN1B (p27kip2) (Shaffer et al., 2000), which is in 
accordance with the upregulation of p27kip2 mRNA and protein demonstrated 
in CHAPTER 6 (Figure 6.12 p.140 and Figure 6.13 p.141). No change in 
transcript expression was observed for p21cip1/waf1 in microarray analysis 
although a decrease in protein abundance was observed in section 6.2.4 
(Figure 6.12 p.140), while no difference was detected in sq RT-PCR analysis 
(Figure 6.13 p.141). Although p21cip1/waf1 protein analysis needs to be 
repeated in BCL6-/-;tetBCL6-HA cells (see discussion section 6.3 p.149), 
posttranscriptional regulation of p21cip1/waf1 is possible.   
In addition to changes in CDKN1B (p27kip2), microarray analysis identified 
gene expression changes of further regulators of cell cycle progression namely 
CDC25A, CDC6, E2F8 and RB1. Transcription of CDC25A, CDC6, and E2F8 
was downregulated in response to Bcl6-depletion; hence they cannot be direct 
Bcl6 target genes, RB1 transcription was upregulated (Table 8). Cdc25A is a 
phosphatase that can remove inhibitory phosphorylations from CDKs involved 
in G1/S as well as G2/M phase transition (Aressy and Ducommun, 2008). 
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Following DNA damage, Cdc25A is rapidly degraded leading to cell cycle arrest 
(Zhao et al., 2002). Cdc6 is a component of the pre-replication complex and 
contributes to regulation of DNA replication in S phase (Yan et al., 1998). E2F8 
is an E2F-like cell cycle regulator that inhibits transcription of E2F target genes 
by blocking their binding sites in target gene promoter regions (Christensen et 
al., 2005). Interestingly, CDC25A, CDC6 and E2F8 are all E2F target genes 
(Christensen et al., 2005, Vigo et al., 1999, Yan et al., 1998) and were 
downregulated in response to Bcl6-depletion. Because the E2F transcriptional 
activators are inactive when bound to retinoblastoma (Rb), upregulation of RB1 
in response to Bcl6-depletion (Table 8) provides a possible explanation for the 
downregulation of E2F target genes. Not much is known about how RB1 gene 
expression is regulated. The RB1 promoter closely resembles that of typical 
housekeeping genes, which is in agreement with its ubiquitous expression 
(Goodrich, 2003) and its regulation by posttranslational mechanisms. 
Phosphorylation of Rb by CDKs in G1/S phase causes its degradation and 
activates transcription of E2F-dependent gene program (Giacinti and Giordano, 
2006). According to my microarray data, RB1 expression is upregulated in 
response to Bcl6-depletion, however, a link between Bcl6 and RB1 has not 
been demonstrated to date. It would be interesting to perform reporter gene 
assays to elucidate whether RB1 is a direct Bcl6 target gene or whether its 
gene expression is upregulated as a secondary event. 
7.3.3 Bcl6 and B cell receptor signalling 
Expression of six genes with key functions in B cell receptor signalling was 
upregulated in response to Bcl6-depletion; these genes were SYK, BLNK, 
PTPRC (CD45), IFITM1 (LEU13), CD72 and PTPN6 (SHP-1).SYK, BLNK, 
CD45 and LEU13 are activators of BCR signalling, while CD72 and SHP-1 
negatively modulate the BCR signal. A simplified overview of BCR signalling is 
shown in Figure 7.8.  
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Figure 7.8: BCR and calcium signalling adapted from (Nitschke and Tsubata, 2004) 
Upon ligation of the BCR (IgM), tyrosines (Y) of the intracellular BCR-associated Igα-Igβ 
heterodimer are phosphorylated by Lyn. This phosphorylation facilitates association and 
activation of SYK (spleen tyrosine kinase), which in turn phosphorylates and activates the B 
cell linker (BLNK). BLNK activation recruits and activates phospholipase C (PLC) which 
hydrolyses phosphatidyl 4,5-bisphosphate (PIP2) and thereby produces the second 
messenger inositol 1,4,5-triphosphate (IP3). IP3 in turn activates the IP3 receptor (IP3R) in the 
endoplasmatic reticulum (ER), which in response releases calcium (Ca2+) into the cytoplasm. 
Rise of intracellular Ca2+ levels induces various cellular responses.  
The inhibitory BCR co-receptor CD72 binds and activates SHP-1, which dephosphorylates 
and thereby inactivates intracellular signalling molecules that induce the BCR signal. The 
phosphatase CD45 is a positive co-regulator of BCR signalling that can remove inhibitory 
phosphorylations from LYN (Hermiston et al., 2003). Another BCR-activating effect is provided 
by the CD19/CD21 complex that consists of CD19, CD21, CD81 and Leu13 (Fearon and 
Carroll, 2000). The CD19/CD21 complex has been shown to prolong the signal generated 
from the BCR, possibly through direct interaction with the BCR (Cherukuri et al., 2001). CD72 
is a negative regulator of BCR signalling (Li et al., 2006). In response to BCR engagement, 
LYN not only phosphorylates the BCR-associated Igα-Igβ heterodimer but also the 
intracellular portion of the inhibitory BCR co-receptor CD72 (Adachi et al., 1998). 
Phosphorylation of CD72 recruits and activates the phosphatase SHP-1, which moves on to 
inactivate intracellular signalling molecules functioning in BCR activation (Nitschke and 
Tsubata, 2004). 
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Bcl6-depletion upregulates mRNA transcripts of at least four activators of BCR 
signalling (SYK, BLNK, CD45 and LEU13).It cannot be evaluated whether 
these changes are a direct effect of Bcl6-depletion (i.e. that the upregulated 
genes are direct Bcl6 target genes) or whether they are secondary results of 
Bcl6-induced changes but this could be tested by reporter gene assays. 
Nothing is known about the transcriptional regulation of PTPRC (CD45) and 
SYK; however, some information is available for the remaining three 
candidates. BLNK transcription is activated by Pax5 (Schebesta et al., 2002b) 
and repressed by NF-κB (Gupta et al., 2008). IFITM1 (LEU13) has been 
suggested to be Bcl6 target gene. Gain-of function (overexpression of Bcl6 in 
cell lines that do not normally express Bcl6) and loss of function (expression of 
dominant-negative Bcl6 in BL cell line) models studied by Shaffer and co-
workers provided evidence for transcriptional regulation of IFITM1 by Bcl6 (see 
also section 1.11.2 p.44), although no information on putative Bcl6 binding sites 
in the IFITM1 is available to date (Shaffer et al., 2000). 
CD72 and SHP-1 function in negative regulation of BCR signalling and their 
expression was upregulated in response to Bcl6-depletion. It has been shown 
that Bcl6 can bind the CD72 promoter through interaction with PU.1 in Ramos 
and BJAB cells, as demonstrated by chromatin immunoprecipitation (Wei et al., 
2009). Although not demonstrated for CD72, downregulation of Bcl6 in BJAB 
cells by siRNA upregulated expression of genes that Bcl6 can interact with 
through PU.1 (Wei et al., 2009). Together with the results obtained from my 
BCL6-/-;tetBCL6-HA model system, it appears highly likely that CD72 is a direct 
Bcl6 target gene in GC B cells. Less evidence, however, is available for PTPN6 
(encoding SHP-1). The PTPN6 promoter contains a STAT1 binding site, the 
deletion of which was shown to reduce transcription in reporter gene assays 
performed in mouse embryonic fibroblasts (An et al., 2008). Interestingly, 
STAT1 itself was also found to be upregulated in response to Bcl6-depletion 
(Table 8), which could potentially account for the upregulation of PTPN6 
expression. Interestingly, EBV-negative BL cell lines and primary centroblasts 
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have been previously shown to express reduced SHP-1 protein levels 
(Delibrias et al., 1997). This observation was proposed to account for a lower 
threshold of cytokine and BCR signalling at this particular stage of B cell 
development (Delibrias et al., 1997). 
Overall, Bcl6 appears to regulate components involved in positive and negative 
regulation of BCR signalling in BCL6-/-;tetBCL6-HA cells. The influence of Bcl6 
on BCR signalling has been previously reported. In DLBCL, Bcl6 is found to 
repress transcription of the SYK phosphatase PTPROt (Juszczynski et al., 
2009). Reporter gene assays in HEK293T cells and modulation of Bcl6 
expression in naive B cells and centroblasts validated the direct influence of 
Bcl6 on PRPROt gene expression (Juszczynski et al., 2009). By repressing the 
SYK inhibitor PTPROt, Bcl6 contributes to activation of BCR signalling, Bcl6-
depletion would lead to reduced BCR signalling. 
Although this project was carried out in a BL cell line, the findings generated 
from the BCL6-/-;tetBCL6-HA model may also have implications for the 
understanding of Bcl6 function in DLBCL. DLBCLs are classified by their gene 
expression profile. When Monti and co-workers performed microarray analysis 
on nodal biopsies obtained from 176 newly diagnosed DLBCL patients, they 
identified three DLBCL subsets based on the enrichment of gene expression of 
functional gene expression clusters (Monti et al., 2005). The ‘Ox/Phos’ subset 
expressed genes involved in oxidative phosphorylation, mitochondrial function 
and the electron transport chain. The second subgroup, termed ‘host 
response’, expressed markers of the T cell-mediated immune response, the 
classical complement pathway as well as inflammatory mediated and 
connective tissue components. The third DLBCL subset termed 
‘BCR/proliferation’ expressed genes enriched in cell cycle regulation, DNA 
repair, BCR signalling as well as B cell-specific transcription factors (Monti et 
al., 2005). Interestingly, Bcl6 overexpression and translocations were 
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significantly associated with the BCR/proliferation subgroup of DLBCL (Monti et 
al., 2005), underscoring the importance of Bcl6 in this molecular pathway. 
It is not entirely clear why Bcl6 represses genes involved in positive as well as 
negative regulation of BCR signalling. GC B cells are under great selective 
pressure to improve BCR binding for its antigen because they depend on BCR 
signals for survival (see sections 1.2.2 and 1.2.3). It is possible that both 
mechanisms exist in vivo to fine-tune BCR signalling at the GC stage of B cell 
development. 
7.3.4 Bcl6 and calcium signalling 
The concentration of intracellular calcium is an important regulator of cellular 
function and gene transcription. Intracellular calcium concentration is increased 
either by release of calcium from cellular stores such as the endoplasmatic 
reticulum (ER) or it can enter the cytosol from the extracellular space via 
specialised ion channels and pumps (Cahalan et al., 2001). BCR signalling 
leads to phosphorylation and activation of the B cell linker (BLNK) which in turn 
recruits BTK and phospholipase C (PLC) (Scharenberg et al., 2007). When 
BTK and PLC are brought together by BLNK, BTK phosphorylates and thereby 
activates PLC (Kurosaki and Tsukada, 2000). Activated PLC hydrolyses the 
membrane phospholipid phosphatidyl 4,5-bisphosphate (PIP2), thereby forming 
the second messenger molecule inositol 1,4,5-trisphosphate (IP3) (Rhee, 
2001). IP3 then diffuses to the ER where it activates IP3-dependent ion 
channels to release calcium from the ER into the cytosol (Patterson et al., 
2004) (see also Figure 7.8). Elevated cytosolic calcium binds and activates 
calmodulin which in turn activates calmodulin/calcium-dependent kinases 
(CAMK). Once these effector kinases such as CAMK4 are activated, they 
phosphorylate and thereby activate downstream effectors, such as transcription 
factors or components involved in the remodelling of the cytoskeleton (Berridge 
et al., 2003). 
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Genes involved in the calcium signalling pathway that were altered in response 
to Bcl6-depletion are CYSLTR1 (GPCR), ATP2A (SERCA1), ITPR1/ITPR2 
(IP3R), CAMK4 and PTK2B (FAK2, Pyk2) (Table 8). The CYSLTR1 gene 
encodes a G-protein-coupled receptor (GPCR) located in the plasma 
membrane (Lynch et al., 1999) and its expression was upregulated in Bcl6-
depleted BCL6-/-;tetBCL6-HA cells. Upon binding of its ligand leukotriene 
LTD4, CYSLTR1 undergoes a conformational change and activates 
downstream signalling molecules such as PLCβ, thereby inducing calcium 
signalling independently of the BCR (Capra et al., 2004). Most research on 
CYSLTR1is centered on its role in chronic inflammation in human asthma, 
where it is thought to play a role in chemotaxis of eosinophils (Mita et al., 
2001), however, there are yet no data on its function or transcriptional 
regulationin B cells. 
The calcium ATPase SERCA1 (encoded by ATP2A) was downregulated in 
Bcl6-depleted BCL6-/-;tetBCL6-HA cells, hence it is no direct transcriptional 
target of Bcl6 but is more likely downregulated by an unknown mechanism as a 
secondary effect resulting from Bcl6-depletion. SERCA1 resides in the ER 
membrane where it pumps cytosolic Ca2+ back into the lumen (MacLennan et 
al., 1997).  
The ITPR1 and ITPR2 genes encode members of the IP3R family that reside in 
the ER membrane, where they release calcium into the cytosol upon activation 
by the second messenger IP3 (Coquil et al., 1999). Both ITPR1 and ITPR2 were 
upregulated in response to Bcl6-depletion, hence they could potentially be 
direct Bcl6 target genes, however, no data exist about their transcriptional 
regulation in cells of the immune system. While the transcription factors AP-1, 
AP-2, NF-κB were suggested to bind to the ITPR1 promoter (Kirkwood et al., 
1997), the promoter of murine ITPR2 is suggested to behave like that of a 
housekeeping gene, in accordance with its ubiquitous expression pattern 
(Tamura et al., 2001). 
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Bcl6-depletion also upregulated transcription of CAMK4.Intracellular calcium 
complexes with calmodulin and binds to CAMK4, thereby activating it 
(Anderson and Kane, 1998). Activated CAMK4 then activates calcium-
responsive transcription factors (Healy et al., 1997). No data on CAMK4 
transcriptional regulation in immunologic cells or connection to Bcl6 have been 
described to date.  
Another gene involved in calcium signalling and upregulated in response to 
Bcl6-depletion is PTK2B. PTK2B encodes the protein tyrosine kinase Pyk2 
which becomes phosphorylated and activated as a result of BCR signalling and 
plays a role in regulating B cell morphology (Tse et al., 2009). In monocytes, 
PTK2B is regulated by the MEK/ERK pathway through C/EBP (Park et al., 
2008), however, no information is available for transcriptional regulation of 
PTK2B in the B cell lineage. Nevertheless, the upregulation of PTK2B mRNA in 
Bcl6-depleted BCL6-/-;tetBCL6-HA cells presents a possibly intriguing 
explanation for the morphological changes observed for Bcl6-depleted BCL6-/-
;tetBCL6-HA cells in CHAPTER 6 (Figure 6.2 p.125). Pyk2 is a known regulator 
of macrophage motility (Okigaki et al., 2003) and Bcl6 is also expressed in 
macrophages (Yamochi et al., 1997). Macrophages from BCL6-/- mice have an 
altered morphology; they display large numbers of small apical membrane 
protrusions, increased pseudopodia formation and migrate more slowly, 
probably due to loss of cell polarisation caused by increased RhoA activation 
(Pixley et al., 2005). Moreover, Pyk2 appears to be required for marginal zone 
B cells (Guinamard et al., 2000). PTK2B-/- mice cannot produce marginal zone 
B cells, most likely due to defects in cell motility and responsiveness to 
chemokines resulting in a failure of B cells to localise to corresponding niche 
(Guinamard et al., 2000). 
In summary, microarray analysis provided an exciting insight into the 
transcriptional changes resulting from Bcl6 protein depletion and the data 
generated supply much inspiration for future directions of study. The list of 163 
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genes upregulated in response to Bcl6-depletion likely contains many novel 
Bcl6 target genes that await validation. Implications of these results for future 
work and Bcl6-expressing lymphomas will be further discussed in CHAPTER 8. 
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CHAPTER 8 - Final discussion and 
future work 
8.1 Rationale for developing the BCL6-/-;tetBCL6-HA cell line 
Bcl6 has proven to be a promising drug target in DLBCL first in vitro and then in 
in vivo experiments in mice and it is tempting to hope that Bcl6-targeting 
therapy could follow on to a success story similar to that of Bcr-Abl-targeting 
therapy for treatment of chronic myeloid leukaemia (Goldman and Melo, 2008). 
This may just be possible because Bcl6, like Bcr-Abl, has been shown to be 
sufficient for development of malignant disease in mouse models (Cattoretti et 
al., 2005, Van Etten, 2001), and Bcl6 appears to be required for survival of 
primary DLBCL and DLBCL cell lines (Cerchietti et al., 2009). However, unlike 
Bcr-Abl, which is uniquely expressed in leukaemic cells, Bcl6 is widely 
expressed. 
In order to create the best possible potential for this to happen, it is essential to 
collect as much information as possible on Bcl6 function within its wide 
interaction network in B cells. The two most powerful systems for studying Bcl6 
function to date are the knockout-mouse model and cell line-based gene 
expression analysis using gain-of-function and loss of function systems (Dent et 
al., 1997, Fukuda et al., 1997, Shaffer et al., 2000, Ye et al., 1997). Both 
models, however, have major limitations. The fact that BCL6 knockout mice 
suffer from severe inflammatory disease and die early, underscores the 
importance of Bcl6 in the lymphoid lineage and also other tissues. At the same 
time, however, working with mice suffering from such a severe phenotype 
makes studying Bcl6 function difficult in this model.  
The second source of information that has been very valuable to our 
understanding of the impact of Bcl6 on a wide range of regulatory networks was 
CHAPTER 8 - Final discussion and future work 
179 
based on microarray gene expression analysis (Shaffer et al., 2000). The two 
systems examined in this study were the gain-of function (i.e. Bcl6 
overexpression in cells that do not express Bcl6) and a loss of function system 
(i.e. expression of dominant-negative Bcl6 in Bcl6-expressing BL cell lines) (see 
section 1.11.2 p.44). Both these systems, however, were based on transient 
transfections of cell lines. In such transfections expression of the construct of 
interest is temporary and uncontrolled and this makes results difficult to 
reproduce. I have therefore generated a novel model system that allows for 
precise Bcl6-protein depletion, by gene targeting of the BCL6 locus.  
8.2 Generation of the BCL6-/-;tetBCL6-HA cell line 
The genetically tractable human B cell line BCL6-/-;tetBCL6-HA was derived 
from the cell line DG75. This Burkitt lymphoma cell line expresses high levels of 
Bcl6 protein and has been previously shown to support efficient somatic gene 
manipulation (Feederle et al., 2004, Maier et al., 2005). In the initial step 
towards generating my model system, I have disrupted the first BCL6 allele by 
gene targeting (CHAPTER 3). The targeting vector I designed contains a 
‘floxed’ zeocin resistance cassette, which allowed me to excise the selectable 
marker after successful targeting of the first BCL6 allele so that I could reuse 
the same targeting construct to disrupt the second allele (CHAPTER 5). Before 
the second BCL6 allele was targeted, I stably introduced a tetracycline-
regulated BCL6 gene into the cell line, which compensated for loss of 
endogenous Bcl6 expression when the second BCL6 allele was targeted 
(CHAPTER 4). Unexpectedly, the presence of the zeo cassette and its strong 
CMV promoter in the BCL6 locus generated a truncated Bcl6 protein variant. 
Despite technical difficulties, the zeo cassette was deleted from the second 
BCL6 allele. After deletion of the zeo cassette from the second BCL6 allele, 
expression of the truncated Bcl6 variant protein stopped, ruling out any 
falsification of the phenotype observed in BCL6-/-;tetBCL6-HA cells (CHAPTER 
5).  
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8.3 Characterisation of the BCL6-/-;tetBCL6-HA cell line 
I have carried out detailed analysis of the BCL6-/-;tetBCL6-HA cell line and 
have demonstrated the contribution of Bcl6 to cell cycle regulation in this 
modelsystem (CHAPTER 6). Somewhat surprisingly, I detected no changes in 
gene expression of Bcl6 target genes involved in B cell activation and terminal 
plasma cell differentiation that were identified in previous studies (Schebesta et 
al., 2002a, Shaffer et al., 2000). Possible explanations for this are provided in 
the discussion of CHAPTER 6 (section 6.3). In the particular case of Blimp-1 
(PRDM1), I concluded that the expression of other transcriptional repressors in 
addition to Bcl6 are responsible for the fact that no Blimp-1 expression can be 
induced in the DG75-based BCL6-/-;tetBCL6-HA system. An interesting 
experiment would therefore be to downregulate the additional transcriptional 
repressors of PRDM1, i.e. Pax5 and Bach2 and to induce expression of the 
PRDM1 transcriptional activator IRF4. In this context, the BCL6-/-;tetBCL6-HA 
system would serve as a powerful model to test the precise requirements 
necessary for induction of PRDM1 expression and thereby greatly contribute to 
our understanding of terminal B cell differentiation. 
Microarray analysis revealed that Bcl6 protein-depletion in BCL6-/-;tetBCL6-HA 
cells affects not only genes involved in cell cycle regulation but also BCR and 
calcium signalling (CHAPTER 7). These data, together with a long list of 
putative Bcl6 target genes awaiting validation, provide exciting direction for 
future experiments. 
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8.4 Complementation analysis 
Another exciting potential of theBCL6-/-;tetBCL6-HA cell line will be its use in 
complementation analyses. The cell line canbe used as a platform to precisely 
dissect the interactions between Bcl6 and its various co-repressors. I have 
already designed, cloned and performed preliminary tests on eight Bcl6 
complementation constructs that can be introduced into BCL6-/-;tetBCL6-HA 
cells (Figure 8.1). These complementation constructs express C-terminally 
FLAG-tagged (and mutated) Bcl6 from vector pcDNA3.1/Hygro/lacZ (Invitrogen) 
(see section 2.5.2 p.57). 
(1) pcBcl6-FLAG encodes FLAG-tagged Bcl6 which is expected to be fully 
functional as it produces a similar band pattern to that of wildtype Bcl6 when 
transiently expressed in 293T cells (compare Figure 8.1 to Figure 5.7 p.115). 
When introduced into BCL6-/-;tetBCL6-HA cells, pcBcl6-FLAG is expected to 
completely rescue the phenotype observed when tet-regulated Bcl6 is switched 
off in BCL6-/-;tetBCL6-HA cells.  
(2) pcBcl6∆POZ-FLAG lacks the entire Bcl6 BTB/POZ domain (aa 1-121) of 
Bcl6. Most of the interactions between Bcl6 and its co-repressors are mediated 
through its POZ domain (see section 1.6 p.32), which is also the domain 
targeted by all Bcl6 inhibitors published to date because is thought to be the 
most important site for Bcl6 function (Chattopadhyay et al., 2006, Polo et al., 
2004, Cerchietti et al., 2008). It is not entirely clear whether the POZ domain 
truncated Bcl6 variant is properly folded, as expression was found to be low in 
293T cells and the band pattern is not as diffuse as observed for full length Bcl6 
(Figure 8.1). The diffuse banding pattern for Bcl6 is attributed to heavy 
phosphorylation of its PEST domains in the central portion of the protein 
(Onizuka et al., 1995), which is still present in the truncation. Nevertheless, this 
construct could become a valuable control for complementation studies that will 
be unable to, or only rescue very little of the BCL6 knockout phenotype.  
 Figure 8.1: Testing Bcl6 complementation constructs in 2
Cell lysates of 293T alone (293T) or 293T cells lipofected with pcBcl6
FLAG (D33A), pcBcl6
FLAG (∆POZ), pcBcl6
(∆ETO) were analysed by Western blotting 
Signaling) 24 hours after transfection.
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(3) The Bcl6 variant expressed from pcBcl6N21K-FLAG seems to be functionally 
folded, as its expression pattern in 293T cells closely resembles that of wildtype 
Bcl6 (Figure 8.1). The N21K mutation disables the interaction between Bcl6 and 
SMRT and NCoR (Ahmad et al., 2003). When Bcl6-expressing DLBCL cell lines 
were treated with a peptide targeting the SMRT binding site of Bcl6, this led to 
growth suppression and apoptosis (Polo et al., 2004). A new study from the 
same group reports a peptomimetic inhibitor of Bcl6 targeting the SMRT 
interaction site which suppressed the growth of human DLBCL xenografts in 
mice and killed primary human DLBCL cells, but had no effect on normal 
lymphoid tissue or other tumors (Cerchietti et al., 2010, Cerchietti et al., 2009). 
Therefore, the disruption of this major co-repressor interaction is expected to 
rescue, very little, if any of the phenotype of Bcl6-depleted BCL6-/-;tetBCL6-HA 
cells. 
(4)-(6) Constructs pcBcl6D33A-FLAG, pcBcl6R44A-FLAG and pcBcl6D33R/R44D-
FLAG were created to express Bcl6 variants resistant to inhibition by the 
peptide aptamer (Apt48), which was previously reported to encourage terminal 
differentiation of Bcl6-expressing Burkitt cell lines (Chattopadhyay et al., 2006). 
This resistance to inhibition by Apt48 is accomplished by charge switching at 
the interphase of the Apt48 – Bcl6 interaction through point mutations such as 
D33A, R44A and D33R/R44D (Ko Ferrigno, personal communication). These 
constructs could potentially be used to mimic therapeutic targeting of Bcl6 by 
Apt48 and would therefore be of great use in translational research. However, 
when tested in 293T cells it was found that all three mutated Bcl6 variants 
appeared very unstable (Figure 8.1). This finding is in agreement with an in-
depth mutagenesis study of the POZ domain, in which it was found that 
alterations at this site of the Bcl6 molecule lead to severe protein folding defects 
that rendered Bcl6 non-functional (Melnick et al., 2000). These three mutant 
Bcl6 versions will therefore not be used for future complementation studies. 
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(7) pcBcl6QQYQ-FLAG encodes a Bcl6 variant with an alteration in its central 
domain that is thought to regulate the interaction MTA3 complex (Fujita et al., 
2004). Interaction of Bcl6 with MTA3 can be abolished by mutating the central 
acetlyation motif KKYK to a motif mimicking constitutive acetylation (QQYQ) 
(Mendez et al., 2008).Robust amounts of Bcl6QQYQ-FLAG can be expressed in 
293T cells and hence this variant is believed to retain the remaining functions of 
the Bcl6 protein (Figure 8.1). The difference in banding pattern observed for 
Bcl6QQYQ-FLAG (less diffuse) when compared to Bcl6-FLAG can be explained 
by the interference of the QQYQ mutation with the phosphorylation sites of Bcl6 
(Figure 8.1). In plasma cell lines, overexpression of Bcl6 and MTA3, but not 
Bcl6 alone, downregulated Bcl6 target genes involved in plasma cell 
differentiation (such as Blimp-1) while B cell markers were upregulated (Fujita et 
al., 2004). Furthermore, it has been observed that depletion of MTA3 from 
lymphoma cells induces plasma cell differentiation in DLBCL cells (Parekh et 
al., 2007). It would be interesting to see to what extend complementation with 
this construct rescues the BCL6-/- phenotype, as Blimp-1 induction was not 
observed in the BCL6-/-;tetBCL6-HA system. Should a residual phenotype 
remain, then this would argue strongly for a function of Bcl6 acetylation that 
extends transcriptional repression of PRDM1 (Blimp-1).  
(8) In pcBcl6∆ETO-FLAG, the fourth zinc finger of Bcl6 (aa residues 602-624) is 
deleted which abolishes the interaction of Bcl6 with its co-repressor ETO (see 
section 1.6.3 p.36) (Chevallier et al., 2004). The 23 aa deletion causes a size 
decrease of approximately 3 kD and seems to not affect overall stability or 
phosphorylation of Bcl6, as a banding pattern similar to that of the control (Bcl6-
FLAG) was observed by Western blotting (Figure 8.1). It would certainly be 
interesting to see which effect the disruption of the interaction between Bcl6 and 
ETO has on the BCL6-/- phenotype.  
In summary, 5 out of 8 complementation constructs appear to be functional 
when expressed in 293T cells (Figure 8.1) and are available for in-depth 
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analysis of the functional significance of some of the interaction sites between 
Bcl6 and its co-repressors. 
8.5 Conclusion and clinical implications 
This project and the conditional BCL6-/-;tetBCL6-HA cell line generated make 
an important contribution to the field of Bcl6 research and its future 
development. Through complementation analysis, the conditional BCL6 cell line 
will facilitate the precise genetic dissection of the interactions that Bcl6 makes 
with its co-repressors. To date, we are able to disrupt the co-repressor 
interactions of Bcl6 with SMRT/NCoR, MTA3 and ETO. In addition, as more 
information on the sites within the Bcl6 molecule that function in co-repressor 
interactions becomes available, the panel of complementation constructs can 
be easily expanded. Such analyses will greatly contribute towards our 
understanding of the importance of these interactions and possibly identify 
alternative sites (other than the BTB/POZ domain) within the Bcl6 molecule that 
are worth targeting therapy against. 
In addition to its use in complementation studies, the BCL6-/-;tetBCL6-HA cell 
line will serve as a valuable tool for translational research. Several Bcl6 
inhibitors are currently being developed and vigorous testing of these small 
molecules has been performed in cell culture systems, primary patient cells and 
mouse models (see section 1.10 p.41). However, a pitfall of this technology is 
that specific effects mediated through inhibition of Bcl6 cannot be distinguished 
from off-target side effects. The data generated from my cell line represents a 
unique resource to be able to overcome this problem for two reasons. Firstly, a 
potential Bcl6 antagonist tested on DG75 cells or Bcl6-expressing BCL6-/-
;tetBCL6-HAcells would be expected to reproduce the growth phenotype that I 
documented but not further stress or kill these cells. Secondly, I have identified 
a panel of genes that are strongly regulated by Bcl6 deficiency. These genes 
can be developed from a panel of PCR assays to give a semiquantitative 
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measure of how closely a potential Bcl6 antagonist mimics the effects of Bcl6 
deficiency in the DG75 cell line.  
I demonstrated that loss of Bcl6 protein is not sufficient to kill Bcl6-expressing 
BL cells (CHAPTER 6). This is contrary to the current belief that Bcl6 is 
necessary for survival of Bcl6-expressing GC representative B cell lines such as 
Raji (Polo et al., 2004), Ramos (Chattopadhyay et al., 2006), SUDHL4, 
SUDHL6 (Cerchietti et al., 2009), Farage, OCI-Ly1, OCI-Ly7 or OCI-Ly10 
(Cerchietti et al., 2010). A possible explanation for this finding is that the Bcl6 
inhibitors studied to date have off target side effects, which can now be easily 
tested in DG75 or Bcl6-expressing BCL6-/-;tetBCL6-HA cells. When adding 
Bcl6-inhibitors to these cells,if the inhibitors were specific, this should precisely 
reproduce the tet/dox-induced Bcl6-depletion phenotype. Furthermore, these 
inhibitors should have no effect on the already existing BCL6-/-phenotype in 
Bcl6-depleted BCL6-/-;tetBCL6-HA cells. However, if Bcl6-depleted BCL6-/-
;tetBCL6-HA cells showed any phenotype alteration or died when treated with 
Bcl6 inhibitors, this would demonstrate that these inhibitors do not kill cells only 
through specific inhibitionof Bcl6.  
A similar approach has been followed in the development of inhibitors targeting 
pro-survival members of the Bcl-2-family. The Bcl-2 protein family regulates 
apoptosis and its pro-survival members are hence attractive targets in cancer 
therapy (Adams and Cory, 2007). Induction of apoptosis by Bcl-2 family 
proteins strictly depends on Bax/Bak (Zong et al., 2001) hence the inhibitors of 
Bcl-2 pro-survival proteins were expected to not kill BAX/BAK knockout cells. 
However, when BAX/BAK knockout cells where treated with potential inhibitors 
(‘BH3 mimetics’), six out of seven compounds killed Bax/Bak-deficient cells due 
to off-target side effects, while only one proved specific (van Delft et al., 2006). 
Just as Bax/Bak deficient cells could screen for the most specific ‘BH3 mimetic’ 
drugs, Bcl6-depleted BCL6-/-;tetBCL6-HA cells can now be used to evaluate 
the specificity of Bcl6 inhibitors. 
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A further important implication of this project, other than studying the functional 
significance of the interactions between Bcl6 and its co-repressors and its use 
in the evaluation of Bcl6 inhibitors, is that the findings presented in this project 
may also translate into the clinical setting, i.e. the management of Burkitt’s 
lymphoma. The current treatment regime of BL involves intensive 
chemotherapy and although the disease is curable, it is difficult to manage and 
associated with many toxicities (Levine, 2002). Treatment of BL patients with 
aggressive chemotherapy is associated with two major complications. Firstly, 
BL occurs in immunodeficient individuals (i.e. patients suffering from human 
immounodeficiency virus (HIV) or EBV infection), hence these patients may not 
be stable enough to receive intensive chemotherapy. Secondly, the extremely 
high proliferative index of BL (~ 100 %) puts patients at elevated risk of 
potentially fatal tumour lysis syndrome (TLS) in response to intensive 
chemotherapy (Schiffer, 2001). For these reasons, any intervention that allowed 
for reduction of the chemotherapeutic dose administered would be of great 
benefit for treatment of BL patients. Much attention has been paid to the 
importance of the c-Myc translocation in BL, however, as depletion of Bcl6 in 
BCL6-/-;tetBCL6-HA cells greatly reduces cell proliferation (CHAPTER 6), my 
results argue strongly for a considerable contribution of Bcl6 to the malignant 
phenotype of BL. Thus, the administration of Bcl6 inhibitors in combination with 
reduced intensity chemotherapy to BL patients comprises promising potential 
for the future.  
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Appendix A
 
Figure A: Overview of clones
Bold clones were further analysed or used in subsequent genetic modification steps.
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